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UNIVERSITY OF LONDON 
ABSTRACT 
Doctor of Medicine
A QUANTITATIVE ANGIOGRAPHIC STUDY OF CORONARY ARTERIAL 
DISEASE IN THE TRANSPLANTED HUMAN HEART.
Islam Abbas Bolad
This study examined the early phase transplant coronary artery disease (TxCAD), as 
measured by the quantitative coronary angiography (QCA) mean lumen diameter loss 
(MLDL). A comparison was made between the large primary versus the smaller branch 
vessels. The relationship of different non-immunological and immunological factors to 
the development of TxCAD was examined, and we correlated the QCA data to that 
obtained from intracoronary ultrasound (ICUS). 121 patients who were transplanted 
between September 1994 and June 1999 were studied and followed up for a period of 
one to five years. 103 patients were males (85%) and the mean age was 48.5±10 years.
We found that TxCAD was predominantly a disease of the large vessels, as evidenced 
by greater MLDL in the first years after transplant. The MLDL increased with time in 
both the large and small vessels and the greatest loss occurred in the first year. The first 
year MLDL was a predictor of long-term MLDL. The relative changes in lumen 
diameter measured by QCA and ICUS were similar. A low early left ventricular 
echocardiographic ejection fraction was related to greater MLDL in the large vessels as 
was donor male sex. Domino and non-domino hearts did not differ in the long-term 
MLDL. Total ischaemic time, RATG induction of immunosuppression, baseline vessel 
tone, acute rejection, CMV infection, total number of HLA mismatches and the first 
year mean antivimentin antibodies level, were not related to MLDL, nor was the 
baseline right and left heart catheter haemodynamic data.
In conclusion, TxCAD as measured by QCA-MLDL was predominantly a disease of 
the large epicardial vessels and was predicted by a low early echocardiographic ejection 
fraction. Both QCA and ICUS could be used to assess TxCAD and their measurements 
were well correlated.
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ABBREVIATIONS
AECA: Anti endothelial cells antibodies.
AMI: Acute myocardial infarction.
ANOVA: Analysis of variance.
BP: Blood pressure.
CF: Calibration factor.
CMV: Cytomegalovirus.
CO: Cardiac output.
CT: Computed tomography.
Cx: Circumflex artery.
Dl: First diagonal artery.
D2: Second diagonal artery.
DSE: Dobutamine stress echo
EF: Ejection fraction.
FS: Fractional shortening.
HDL: HDL cholesterol.
HLA: Human leucocyte antigen.
IA: Intimal area.
ICUS: Intracoronary ultrasound.
B: Intimal index.
ISHLT: International society for heart and lung transplantation.
LAD: Left anterior descending artery.
LCSA: Lumen cross-sectional area.
LDL: LDL cholesterol.
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LV: Large vessels.
LVEDP: Left ventricular end diastolic pressure.
LVEF: Left ventricular ejection fraction.
MHC: Histocompatibility gene complex.
MIT: Maximal intimal thickening.
MLD: Mean lumen diameter.
MLDL: Mean lumen diameter loss.
MM: Mismatch / mismatches.
NS: Not significant.
OM1: First obtuse marginal artery.
OM2: Second obtuse marginal artery.
PAMP: Pulmonary artery mean pressure.
PAWP: Pulmonary artery wedge pressure.
PBS: Phosphate buffer saline.
PDA: Posterior descending artery.
PET: Positron emission tomography.
PRA: Panel reactive antibodies.
QCA: Quantitative coronary angiography.
QCU: Quantitative coronary ultrasound.
RAP: Right atrial pressure.
RATG: Rabbit antithymocyte globulin.
RCA: Right coronary artery.
RI: Remodelling index.
RVBr: Right ventricular branch of right coronary artery.
SD: Standard deviation.
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SIP: Scion image programme.
SV: Small vessels.
TA: Total area.
TC: Total cholesterol.
TG: Triglycerides.
TIT: Total ischaemic time
TxCAD: Transplant coronary artery disease.
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1.1 Background.
Heart transplantation has become established as the treatment of choice for selected 
patients with advanced heart failure, as the survival rates achieved with transplantation1 
greatly exceeds that achieved with optimum medical therapy2,3. Nevertheless, the long­
term results of heart transplantation are far from perfect. The Registry of the 
International Society of Heart and Lung Transplantation (ISHLT)1 indicates that the 
overall patient half-life (time to 50% survival) is only 9.3 years and the conditional 
half-life (time to 50% survival for patients who survive > 1 year) is only 11.8 years. 
After the first year, there is a constant mortality rate of 4% a year. The leading causes 
of death more than one year after transplantation are coronary artery disease, infection 
and malignancy1, 4, with transplant coronary artery disease being the most common 
cause of death and re-transplantation5,6.
Transplant coronary artery disease (TxCAD) was first reported in animal heart 
transplant models. After their successful orthotopic transplant in a dog in 19617 , Lower 
et al8 in 1968 drew attention to the proliferative and obliterative intimal changes of 
chronic vascular rejection in the epicardial coronary arteries of long surviving canine 
transplants.
Following the first human heart allograft by Christiaan Barnard9 in December 1967, 
Thomson10 in 1968 gave the first description of the pathologic findings in a 
transplanted human heart, that of Barnard’s patient, who had survived the operation for 
18 days. The first description of a human heart with the obliterative vascular changes 
that characterize chronic rejection appeared in 1969, when Thomson described the 
donor heart of a transplanted patient who had survived for 19 Vi months in the first
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long-term survivor reported from South Africa11. That patient died with extensive 
coronary artery disease after transplantation for ischaemic cardiomyopathy. Thereafter, 
detailed reports appeared on the cardiac findings and complications in a series of 
orthotopic transplants in the early 1970s12'18.
A number of important questions about transplants, including protocols for 
immunosuppression19, correlation of the surface electrocardiogram with allograft 
rejection20, and reversal of these changes with augmented immunosuppression, were 
subjects of the early laboratory study. The first heart transplant initiated a great amount 
of interest in other centres around the world. However, the one-year survival was only 
15 percent, and as a result, the enthusiasm for heart transplantation had waned by the 
end of 1971. Through the decade of the 1970s, investigators refined recipient selection 
criteria21, developed transvenous endomyocardial biopsy for diagnosing rejection22, 
developed rabbit antithymocyte globulin as an effective treatment of acute rejection , 
and defined many of the late post operative complications and management 
principles24. Application of heart transplantation depended on the development of better 
immunosuppressive therapy; this was achieved with the discovery that ciclosporin A 
(formerly Cyclosporin A), a peptide of fungal origin, which selectively blocks the early 
phase of T-cell activation and the expression of interleukin 2 25'28.
With improved outcomes in terms of both quality of life and patient survival, cardiac 
transplantation became the accepted therapy for many patients with end stage heart 
failure. Survival of 79% after transplantation at one year1 compares favourably with 
survival from heart failure at one year of 57% in men and 64% in women . 
Nevertheless, heart transplant long-term results are still far from perfect.
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Transplant coronary artery disease assumes greater importance as the numbers of long­
term survivors after transplantation increases. This chapter provides an overview of this 
clinical problem as a framework for the clinical, pathological and diagnostic aspects of 
TxCAD.
1.2 Incidence.
The reported incidence of TxCAD varies with the sensitivity of the method used for 
diagnosis. Using conventional qualitative coronary angiography, the incidence was 
found to be 11 % at one year and 40% at 5 years in the Canadian Study of Cardiac 
Transplantation Atherosclerosis . In a multiinstitutional study using qualitative 
angiography, Constanzo et al30 found the incidence to be 42% at 5 years.
Using more sensitive technique of intracoronary ultrasound (ICUS), the incidence was 
generally found to be higher than that of conventional qualitative angiography. Yeung 
et al found in a multicentre trial the incidence to be 40% within the first 4 weeks post 
transplantation, and 75% at one and 2 years. Julius et al32 found the incidence to be 43, 
64 and 58% at 3 months, 1 and 2 years respectively.
Examination of the coronary arteries at autopsy shows that TxCAD is much higher than 
that detected by either of these methods. In one series, Johnson et al found coronary 
lesions in 100% of patients who died more than 1 year after transplantation, even when 
death was not directly related to a cardiac event. In another series34, he found the 
incidence to be 89% in a study of 61 cardiac allografts examined 1 day to 11.9 years 
after transplantation.
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13 Pathology.
The pathologic findings in the coronary arteries of the human cardiac allografts show a 
wide spectrum of disease features which are not typical of conventional coronary 
atherosclerosis 34,35. On the basis of both light microscopic appearance and distribution 
of the coronary lesions in 61 human cardiac allografts of short and long-term survival, 
Johnson et al34 showed that TxCAD is a heterogeneous phenomenon with variable 
distribution, morphologic features and severity. Allografts were divided into two broad 
groups: those with fibrous or atherosclerotic lesions confined to the proximal region of 
epicardial arteries and those with diffuse necrotizing vasculitis or atherosclerosis of the 
entire coronary arterial system. Within the two groups, coronary artery morphologic 
features varied in a time-dependent fashion. Disease in the proximal region began as 
concentric fibrous intimal thickening, with atheromatous lesions observed after 1 year 
of transplantation. The earliest form of diffuse disease was a necrotizing vasculitis, 
which was invariably associated with acute myocardial rejection. Long-term survivors 
with diffuse disease showed severe fibrous or fibrofatty intimal lesions of the large and 
small epicardial and intramyocardial arteries. In some, diffuse disease may have 
resulted from healing of necrotizing vasculitis.
Arbustini et al36 investigated at autopsy or at re-transplantation the frequency of 
coronary thrombosis in 76 cardiac allografts: 37 in place < 2 months (early) and 39 in 
place 2 to 99 months (late). They found that coronary thrombosis was common in 
epicardial coronary arteries > 2 months after cardiac transplantation, as it was found 
only in one allograft in the early group and 24 (62%) of the late allografts (32±30 
months), all of the late allografts had TxCAD.
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1.4 Angiography.
The angiographic features of coronary disease in the transplanted heart are variable and 
include features that are unusual in the arterial disease within the native heart. Gao et 
al37 in an angiographic study in 81 transplant patients exhibiting coronary vascular 
disease, had classified the lesions into three categories: type A, discrete or tubular 
stenoses; type B, diffuse concentric narrowing; and type C, narrowed irregular vessels 
with occluded branches. The 81 arteriograms showing transplant coronary vascular 
disease were contrasted with 32 from non transplant patients with coronary artery 
disease analysed in a similar fashion. The results are shown in Table 1.1 below.
Table 1.1: Angiographic features of non-transplant vs. transplant 
coronary artery disease.
Parameter Non-TxCAD 
(32 arteriograms, 
178 lesions)
TxCAD
(81 arteriograms, 
461 lesions)
p-value
Lesion type A -100% A- 76% 
B- 24%
Vessels involved Primary-75 % 
Secondary-25 %
Type A:
Primary- 57% 
Secondary- 42% 
Tertiary-1.4% 
Type B: 
Primary- 25% 
Secondary- 44% 
Tertiary- 31%
0.05
Total occluded 
vessel segment
Proximal & Middle- 96% 
Distally 4%
Proximal & Middle- 
51%
Distally- 49%
<0.002
Poor collaterals in 
presence of total 
vessel occlusion
7% 92% <0.002
Quantitatively, TxCAD presents as progressive coronary luminal narrowing after 
cardiac transplantation. Gao et al38 assessed 25 patients after a mean of 5.1 weeks post­
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transplantation and annually thereafter. Five hundred and fifteen coronary segments in 
the 25 patients having 1-year follow-up and 353 segments in 18 patients reaching 2- 
years follow-up were compared with baseline angiograms. Significant change was 
defined as ± 0.10 mm, equal to 3.8% change in mean lumen diameter (MLD) based on 
three standard deviations obtained from estimation of measurement error. Coronary 
MLD fell from 2.44 ± 0.26 mm at baseline to 2.21 ± 0.34 mm (p<0.001) at 1-year 
follow-up. This rate of mean lumen diameter loss (MLDL) was 20 fold more rapid 
during the initial post-transplantation year than the rate of change of visually normal 
segments in non-transplant patients with coronary atherosclerosis elsewhere. There was 
no significant MLDL between the first and second year in those patients who had 
second year studies. Absolute MLDL for vessels greater than 2.9 mm significantly 
exceeded that for smaller vessels but did not differ when considered as a ratio of vessel 
diameter. In 21 of the 25 patients MLDL exceeded the three standard deviation 
threshold at their last angiogram, but only two of these patients had visually detectable 
TxCAD.
1.5 Clinical Features.
The clinical presentation of TxCAD is different from coronary disease in the general 
population. It is often clinically silent because the allograft is denervated and transplant 
patients, lacking afferent pain fibres, do not appear able to experience angina pectoris. 
However, reinnervation starts to occur within the first year, and increases with time39, 
and some patients experience chest pain characteristic of angina pectoris40.
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The presentation of acute myocardial infarction (AMI) is also different from that in the 
general population. Gao et al41 examined the clinical presentation of 25 episodes of 
AMI in 22 transplant patients. AMI occurred at a mean of 3.86 years post transplant. 
The commonest symptom was fatigue and weakness (64%), followed by dyspnoea 
(44%), palpitations (32%), dizziness (28%), diaphoresis (24%), nausea and vomiting 
(20%), syncope (16%), chest or arm pain (12%) and paresthesia (8%). The infarct was 
clinically silent in three episodes (12%). The commonest sign was a new S3 (32%), 
followed by cyanosis, confusion and pulmonary oedema (each accounting for 12%), 
liver enlargement (8%) and new S4 (4%). ECG changes typical of Q wave AMI was 
present in 7 of the 18 patients hospitalised for symptoms (39%). Five patients had non­
specific ST segment changes (28%) and 2 had no documented changes (11%). Two had 
old Q waves (11%).
Myocardial damage and fibrosis lead to deteriorating cardiac function and present non- 
specifically as effort intolerance, exertional dyspnoea and fatigue. Overt congestive 
cardiac failure may occur due to systolic or diastolic ventricular dysfunction42, 43. 
Arrhythmia, bradycardia and sudden death can occur from damage and fibrosis to the 
conducting system and / or the myocardium44,45.
Coronary artery spasm is known to occur in transplanted hearts. It commonly occurs 
during catheterisation of the coronaries4648. It has also been reported to occur 
spontaneously46,49and during exercise testing46. Clinically, coronary spasm can present 
with syncope50 46, hypotension or chest pain. The latter might not occur due to cardiac 
denervation.
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1.6 Prognosis.
The development of epicardial coronary disease in the transplanted heart conveys a 
poor prognosis42,51,52. The relative risk of cardiac events is 3 times higher and the 
relative risk of cardiac death is 4.6 times higher in recipients with angiographic 
evidence of TxCAD than in those without42. Keogh et al51found that the actuarial 
survival 5 years after the detection of moderate or severe angiographic disease was only 
17%. Disease that develops early after transplantation appears to be more aggressive 
and to be linked to a worse prognosis53,54.
1.7 Diagnosis of Transplant Coronary Artery Disease.
As early TxCAD is asymptomatic due to denervation, and as the late presentation is 
usually by a catastrophic event such as myocardial infarction or sudden death41, it is 
essential to screen patients regularly for TxCAD. The ultimate clinical goal of any test 
is to detect TxCAD and to provide prognostic information to identify those patients 
who might benefit from any available intervention. Specifically, the test should be able 
to identify both the anatomic, and more importantly, the physiologic consequences of 
the disease process in both the large epicardial arteries and the microcirculation. For 
convenience, these tests can be divided into non-invasive and invasive tests, and each 
has its merits and limitations.
1.7.1 Non-invasive tests.
Non-invasive tests are attractive because of their low morbidity and potential ability to 
supply physiologic information. Many of the non-invasive techniques to assess 
atherosclerotic coronary artery disease in the non-transplant patient have been applied
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to the cardiac transplant population, including exercise ECG, stress echocardiography, 
stress myocardial scintigraphy, positron emission tomography and ultrafast computed 
tomography.
1.7.1.1 Exercise electrocardiography.
Interpretation of exercise electrocardiographs in transplant patients is difficult. This is 
because the baseline ECGs are abnormal in the majority of transplant patients and that 
make the interpretation of stress-induced changes less sensitive and specific55; in a 
study of non-invasive means to diagnose TxCAD, Mairesse et al56 found that only 59% 
of the exercise electrocardiograms are interpretable for ischaemia. Absence of angina in 
the great majority of transplant patients further reduces the sensitivity, as does the 
inability to achieve the desired target heart rates required for adequate exercise stress 
testing57,58. However, development of hypotension during stress testing was found to 
be quite specific for focal grafts coronary artery disease and predicts future cardiac 
events
1.7.1.2 Radionuclide scintigraphy.
Thallium-201 and technetium-99 are well established in the diagnosis of coronary 
artery disease in non-transplant patients55, 61. This allows imaging of the regional 
distribution of myocardial perfusion, as these radiopharmaceuticals accumulate 
proportional to regional myocardial blood flow. Single photon emission computed 
tomography (SPECT) has improved the diagnostic accuracy. These perfusion tracers 
have also been coupled to vasodilatory (i.e. dipyridamole) and inotropic (i.e. 
dobutamine) pharmacologic stress agents.
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Smart et al63 and Redonnet et al64 studied the role of dipyridamole scintigraphy, which 
is not dependent on heart rate response for effect, in cardiac transplant recipients. This 
had moderate specificity (64-84%) for TxCAD when both fixed and reversible defects 
were considered. However, it lacked the sensitivity (21-58%) when rather more 
conservative angiographic criteria were used as the gold standard (i.e. epicardial 
coronary narrowing >50%). Exercise protocols, and the inclusion of angiographically 
diffuse distal stenosis into the definition of TxCAD, appears to improve both the 
sensitivity (67-77%) and specificity (100%) of myocardial perfusion imaging65, 66. 
However, inadequate heart rate response in these patients limit the sensitivity58. Thus, 
myocardial scintigraphy has good specificity but low sensitivity in non invasive 
detection of TxCAD.
1.7.13 Stress echocardiography.
Stress echocardiography has been shown to have good sensitivity and specificity in 
diagnosing TxCAD55,67'69, especially when dobutamine is used as the stressing agent. 
Dobutamine has been a particularly useful stressing agent because it increases 
contractility, heart rate and wall stress in a graded dose-dependant fashion and likely 
reflects the cumulative effects of both epicardial and small vessel TxCAD in a 
physiological manner. In addition, dobutamine improves the poor sensitivity of exercise 
protocols because the heart rate response is augmented and the transplant heart is more 
sensitive to catecholamine stimulation than the non-transplanted hearts70.
Compared to the sensitivity of scintigraphy, that of dobutamine echo of 79-95% is
ro  <7i
better ’ , even when the definition of TxCAD is more liberal and expanded to include 
angiographic stenosis of <50%, diffuse distal tapering or intimal thickening by
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intracoronary ultrasound. However, there appears to be some loss of specificity (55- 
91%) with this increase in sensitivity in studies using qualitative angiography as the
fn  A9reference method ’ . This loss may be due to the insensitivity of conventional
(qualitative) angiography in the detection of coronary disease55. If significant 
ultrasound intimal thickening (Stanford grade HI or IV; see table 1.2) is used as the 
standard, dobutamine stress echocardiography is quite specific71. Angina when it occurs 
during this test is also quite specific for TxCAD and probably reflects re-innervation of 
the transplanted heart72.
Dobutamine echocardiography also has prognostic value in this population. Akosah et 
al found that a positive test (new or worsening regional wall motion abnormality or 
failure of augmentation) was associated with 33% chance of a cardiac event 
(myocardial infarction, angina or heart failure) over a 2 year period. The most severe 
abnormalities were associated with a risk ratio of six (confidence interval 2.3 to 14.4) 
for a cardiac event.
In summary, because stress echocardiography, especially with dobutamine, has good 
sensitivity and specificity, it can be used as both a screening test and as an adjunct to 
angiography in the management of TxCAD.
1.7.1.4 Positron emission tomography.
Positron emission tomography (PET) represents an advanced form of nuclear imaging 
technology74. It has become established as the most accurate non-invasive means for 
the diagnosis of coronary artery disease in non-transplant patients using myocardial 
perfusion radiotracers, which include rubidium-82, N-13-ammonia, and 0-15-water.
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Studies in cardiac transplant recipients have demonstrated that resting myocardial blood 
flow does indeed decrease with time and this decrease is more profound when 
angiographic coronary artery disease is present75. However, studies with oxygen-15 
water as the perfusion tracer suggest that maximal hyperaemic blood flow may remain 
normal and the loss in coronary blood flow reserve (defined as the hyperaemic to 
baseline blood flow) may actually be due to elevated baseline coronary blood flow 
rather than microvascular coronary disease76. Allen-Auerbach et al77 in a study of 19 
patients found that the degree of abnormalities in endothelial independent myocardial 
flow as detected by PET one to two years after transplantation is associated with 
morphological indices of disease progression by ICUS.
Unfortunately, the limited published experience with this technology in transplanted 
patients has generally excluded patients with significant TxCAD. In addition, the high 
cost and limited availability of PET limits its use. More research is needed in this field 
before the sensitivity and specificity of PET in transplant patients can be accurately 
ascertained.
1.7.1.5 Ultrafast computed tomography scanning.
Ultrafast computed tomography (CT) scanning has been shown to be useful to detect or 
rule out high-grade coronary-artery stenosis and occlusions in the non-transplant 
population . The use of ultrafast CT scanning in detecting TxCAD has been studied by 
Babir et al79"81. In a study of 102 cardiac transplant recipients, they found that ultrafast 
CT scanning had a sensitivity of 83% and a specificity of 80% in detection of coronary 
calcification, and hence TxCAD, when an angiographic stenosis of >24% was taken as
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significant. The positive predictive value was 74% and the negative predictive value 
was 88%. Raising the threshold for the diagnosis of coronary artery disease to >49% 
stenosis increased the negative predictive value to 97%.
Detection of coronary calcification by ultrafast CT scanning has a prognostic 
significance. Lazem et al81 has demonstrated that absence of coronary calcification by 
ultrafast CT scanning is a significant predictor of event-free survival.
However, ultrafast CT scanning is not widely available. In addition, the sensitivity and 
specificity is lower than that of stress echocardiography.
1.7.1.6 Limitations of non-invasive testing.
Although the use of non-invasive testing for TxCAD is appealing, their routine clinical 
use is limited for several reasons:
1- Most of the studies of non-invasive testing have used the presence or absence of 
at least one angiographically focal epicardial coronary stenosis greater than 50% 
to define the sensitivity and specificity. This is a poor gold standard and is 
unreliable, as it has been documented before, that qualitative angiography is 
insensitive means to detect TxCAD82.
2- Most studies have not correlated ischaemic territories by non-invasive testing 
with angiographic anatomy.
3- Few studies, with limited numbers of patients, have studied the sensitivity and 
specificity of these tests. In addition, frequency of clinical events has generally 
been low
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4- Few studies have directly compared the sensitivity and specificity of various 
non-invasive testing methods.
5- Cardiac transplant recipients cannot achieve heart rates that are adequate for a 
meaningful interpretation of exercise stress testing.
6- When the test is dependant on an assessment of the relative coronary flow 
reserve between myocardial vascular territories, the interpretation of ischaemia 
may be difficult if there is diffuse arteriosclerotic involvement of the 
microcirculation and a concomitant reduction in coronary blood flow.
7- Although the potential prognostic use of thallium scintigraphy, dobutamine 
echocardiography and ultrafast CT scanning is encouraging, only small single 
centre experiences with limited numbers of patients over short periods of time 
have demonstrated this use.
1.7.2 Invasive tests.
The invasive tests used to assess atherosclerotic coronary artery disease in non­
transplanted patients are also used for the cardiac transplant population. These include 
qualitative coronary angiography, quantitative coronary angiography (QCA) and 
intracoronary ultrasound (ICUS). In addition, myocardial biopsies have also been used.
1.7.2.1 Qualitative coronary angiography.
Although coronary angiography was one of the most important cardiological advances 
in the 20th century, it has too often been placed inappropriately on a pedestal of 
infallibility. The role of conventional coronary angiography in diagnosing TxCAD is 
subject to considerable misunderstanding and the limitations are many.
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TxCAD is a diffuse disease that involves both the epicardial vessels and the 
microcirculation83. There is usually no “reference” unaffected segment, and thus 
although there might be a considerable loss of lumen diameter, the angiograms may 
appear normal, unless there is a focal narrowing. This insensitivity has been 
demonstrated by Mills et al84 and O’Neill et al82, when they compared qualitative 
coronary angiography with the quantified loss of lumen diameter demonstrated by 
QCA.
Luminal irregularities are often present which give a clue to the presence of disease. In 
an attempt to compensate for the insensitivity of qualitative angiography, most 
cardiologists report the presence of even minor irregularities. Despite this approach, 
considerable amount of disease is missed. In addition, there is always a risk of over 
reporting disease in the small tortuous vessels.
The angle of view is also a potential source of misinterpretation of qualitative 
angiography. The angiograms provides a two-dimensional silhouette of a three 
dimensional structure. In the presence of focal stenosis, many different luminal sizes
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and shapes can yield the same silhouette on angiography . Moreover, the angle of the 
angiographic view can misrepresent the degree of stenosis.
The spatial resolution of coronary angiography is limited38,85,86. Most coronary arteries 
are between 2 and 3 mm in diameter, but angiography can resolve only approximately 
0.1 mm85-87. This degree of resolution is not sufficient to allow for the precise diagnosis 
of all lesions. Angiography cannot detect structures smaller than 0.1 mm, and so can 
miss small but important lesions.
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Another reason why angiography can fail to identify coronary artery disease is that a 
vessel can actually adapt its structure to accommodate, and thereby conceal 
atherosclerosis within the vessel wall. The mechanism of the vessel remodelling was
OQ
first described in 1987 by Glagov et al , who found that when an atheroma first 
develops on the wall of a normal artery, the adventitia sometimes responds by 
remodelling outward, while the lumen maintains its original size. Because angiography 
shows only the lumen, a remodelled vessel will appear normal when, in fact, it is 
harbouring an atheroma. This can occur in patients whose level of coronary disease is 
severe. Angiography cannot identify the diseased lesion until the adventitia reaches a 
point of maximum expansion and the lumen is finally reduced in size. Of interest, there 
is also a “reverse Glagov phenomenon”. Just as atherosclerotic material will induce the 
adventitia to remodel outwards, regression of a lesion will cause the same adventitia to 
remodel back inwards again, while the size of the lumen remains constant. Because 
angiography cannot detect the reverse Glagov phenomenon, it cannot demonstrate 
whether drug therapy is proving successful in promoting lesion regression.
Atheromas have a predilection for arterial bifurcations. However, plaques at a vessel 
bifurcation are difficult to detect by angiography because the conjoining of two vessels 
often shields the lesion from view. All bifurcations have some degree of overlap 
between the “parent” and “child” vessel and this overlap prevents the angiograms from 
accurately depicting the lumen. As a result, lesions in the sites that are most likely to 
become diseased are also the most difficult to detect on angiography.
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In summary, conventional qualitative angiography is insensitive in diagnosing TxCAD. 
In addition to the conventional limitations of angiography in diagnosing coronary 
disease in non-transplanted hearts, such as angle misinterpretation, remodelling and 
bifurcation disease, it cannot diagnose loss of lumen diameter as there is no “normal” 
reference segment for comparison.
1.7.2.2 Quantitative coronary angiography.
In quantitative coronary angiography, computer assisted quantitative image analysis is 
applied to a series of coronary angiograms to measure change in lumen diameter89, 90. 
Edge-detection algorithms remove the subjective element from the measurement. High 
quality angiographic images are required and the radiographic techniques used are 
standardized to provide comparable images for measurement from each study. 
Intracoronary nitrates are given to eliminate any variation due to changing vascular 
tone. Figure 1.1 shows an example of such measurement.
Figure 1.1: QCA analysis of the proximal LAD.
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QCA does not provide an absolute measurement of lumen diameter. This is because 
each image is calibrated against the diameter of the angiography catheter used for the 
study. The catheter does not lie in the same plane as the artery and a magnification 
error will occur. Nevertheless, provided the technique is standardised the magnification 
ratio will remain constant between examinations, allowing valid comparisons to be 
made. QCA is much more sensitive than qualitative angiography for detecting vascular 
narrowing after transplantation82, 84,90. The method has been used to evaluate therapy 
aimed at preventing TxCAD91.
Apart from quantification of lumen diameter size, QCA suffers from the other 
limitations of qualitative angiography. Unlike intracoronary ultrasound (ICUS), early
QOdisease and disease in remodelling vessels that does not affect the lumen size can be 
missed.
However, QCA has got important advantages over ICUS. It is less invasive, and 
requires only minor modifications to the conventional angiographic technique, making 
it more acceptable to patients and ideal for incorporation into a routine follow up 
protocol. Patients do not need systemic anticoagulation, which is required for ICUS, 
and there is no concern about performing a cardiac biopsy during the same procedure. 
The cost is much less than ICUS, as the ultrasound probe is relatively expensive. Most 
importantly, the distal branch vessels, which are often involved in transplant disease 
can be easily examined angiographically; these are inaccessible to the currently 
available ICUS probes.
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In summary, QCA is much more sensitive than conventional qualitative coronary 
angiography in diagnosing TxCAD. It is less sensitive to ICUS; however, it is less 
invasive, less expensive and unlike ICUS, can be used to assess the coronary branch 
vessels.
1.7.2.3 Intracoronary ultrasound.
The images produced by introduction of an ICUS probe into the coronary arteries have 
been compared to those produced by histology . ICUS has several inherent 
characteristics, which are of value in the precise quantification of TxCAD. The 
tomographic orientation of ultrasound enables visualization of the full 360 degrees 
circumference of the vessel wall, rather than a 2-dimensional projection of the lumen. 
Accordingly, measurement of the lumen area by direct planimetry is performed on a 
cross sectional image, which unlike angiography, is not dependant on an angle of 
projection. Unlike QCA in which vessel sizing depends on careful calibration of the 
analysis system, ultrasound devices rely on an electronic distance scale which is 
internally generated and overlaid on the image. Because the velocity of the sound 
within soft tissues is nearly constant, ultrasound measurements are inherently accurate 
and require no special calibration method94.
The tomographic perspective of ultrasound enables characterization of the extent of 
atherosclerotic disease in vessels that are typically difficult to assess by conventional 
angiographic techniques. These include the diffusely diseased transplant coronary 
arteries, bifurcation lesions, ostial stenoses and eccentric plaques94. In each of these 
circumstances, the need for an unaffected reference segment, overlapping structures or
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foreshortening can preclude accurate angiographic imaging. However, ICUS is 
unaffected by these factors, enabling accurate imaging.
As the transducer is placed in close proximity to the vessel wall, high ultrasound 
frequencies are used for intravascular imaging, typically 20 to 50 MHz94. The use of 
high frequencies provides excellent theoretical resolution because the ultrasound 
wavelength, which determines the maximum resolution, is inversely proportional to the 
frequency. At 30 MHz, the wavelength is approximately 50pm, which permits axial 
resolution of approximately 100pm. Determinants of lateral resolution are more 
complicated and dependent on imaging depth and beam shape. Typically, lateral 
resolution for a 30 MHz device averages approximately 250pm at typical distances 
most prevalent in coronary imaging94.
Currently available ultrasound catheters for intracoronary application have an outer 
diameter between 2.9 and 3.5 F (diameter of 0.96 10 1.17 mm). These smaller diameter 
probes are suitable for examination of more distal locations within the coronary 
vessels94. However, examination of the most distal and branch vessels is not possible 
because of the size factor. Putting an ICUS probe into too small a vessel may cause 
coronary spasm.
In a normal healthy young adult, the thickness of the intima is below the level of 
ultrasound resolution and the artery wall has a uniformed single layered appearance. In 
older adults, and in disease, thickening of the intima allows it to be imaged as a 
separate structure from the media and adventia, giving the artery wall a characteristic 3 
layered appearance. The intima area can be planimetered to measure the plaque burden
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as a proportion of the vessel area or area inside the external elastic lamina95. The degree 
of intimal thickening has been quantitatively divided into four groups according to 
severity in the Stanford Clssification96, as shown below in table 1.2.
Table 1.2: Stanford ultrasound classification of coronary artery disease 
in cardiac transplant recipients.
Class
I II m IV
Severity Minimal Mild Moderate Severe
Intimal
thickness
<0.3mm
<180°
<0.3mm
>180°
0.3-0.5mm 
or
>0.5mm, <180°
>lmm
or
>0.5 mm, >180°
Using ICUS, Tuzcu et al97 in a study of 132 patients 1 to 9 years after transplantation, 
demonstrated that TxCAD is detected in more than 80% of patients, with proximal 
segments most frequently focally affected. Diffuse and circumferential atherosclerosis 
was more common in mid and distal segments. They also demonstrated in a separate 
study unequivocal atherosclerosis in 56% of patients studied within 1 month after 
transplantation, indicating pre-existing abnormality or donor related disease98. These 
studies suggest that TxCAD has a dual aetiology with many donor transmitted, early, 
focal, non circumferential plaques in proximal segments and more diffuse, concentric 
pattern in distal segments. Botas et al" noted that pre-existent donor coronary disease 
does not accelerate the progression of TxCAD within the first few years. However, 
Yeung et al31 found that the progression of intimal thickening occurs during the first 
year, followed by slow but inexorable progression over time.
i noPrognostically, Rickenbacher et al demonstrated that the finding of moderate to 
severe intimal thickening by ICUS predicts the development of angiographically
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apparent TxCAD. Moreover, Mehra et al101 demonstrated that recipients with severe 
intimal thickening were ten times more likely to suffer cardiac events than those 
without severe hyperplasia.
The safety of ICUS has been questioned. Pinto et al102 had demonstrated that the use of 
ICUS in transplant recipients is not associated with serious immediate complications, 
increased mortality, myocardial infarction or acceleration of atherosclerosis in the 
imaged segment.
In summary, ICUS is more sensitive than QCA in detecting TxCAD, and provides 
information about the vessel wall in addition to the diameter and area. However, it is 
highly invasive, requires anticoagulation, and prolongs the cardiac catheterisation 
procedure and radiation exposure. It cannot be applied to the smaller branch vessels of 
the coronary tree. The cost of the single use ultrasound catheters is relatively high and 
adds appreciably to the cost of cardiac catheterisation.
1.7.3 Molecular analysis of myocardial biopsy specimens.
The standard morphological features of endomyocardial biopsy specimens do not
1 mcorrelate well with graft vascular disease . However, immunohistochemical analysis 
provides a potentially valuable tool for the evaluation of TxCAD. About 80% of biopsy 
procedures locate vessels suitable for analysis103,104. Endomyocardial biopsy specimens 
taken in the first 3 months after transplantation reveal arteriolar / arterial endothelial 
changes (i.e. the expression of HLA-DR or ICAM-1 and the depletion of tissue 
plasminogen activator) that are strongly associated with the development of TxCAD 
and outcome105*108. Weis at al109 detected an association between early enhanced
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myocardial endothelin mRNA expression (but not endothelial nitric oxide synthase 
mRNA expression) and the development of new intimal thickening and epicardial 
endothelial dysfunction during follow up. Thus, microvascular markers of increased 
immunologic activity that are present soon after transplantation may predict later 
development of TxCAD in larger vessels. Whether the presence of early microvascular 
endothelial activation is merely a warning signal for TxCAD or is fundamentally 
involved in its pathogenesis remains unknown.
1.7.4 Problems of a gold standard for the diagnosis of transplant coronary artery 
disease.
The evaluation of any medical test is based on its ability to identify the presence or 
absence of disease accurately. For this accuracy to be established, a gold standard test is 
usually used to evaluate all other tests. Unfortunately, due to the diffuse nature of 
TxCAD and the involvement of both the epicardial vessels and the microcirculation, 
this does not exist.
Qualitative coronary angiography is very insensitive to TxCAD, as for interpretation, it 
needs an unaffected segment for comparison. Sensitivity can be improved by the use of 
QCA. However, QCA is a pure measure of the lumen diameter, and does not give 
information about TxCAD until the lumen diameter starts to change. ICUS has proved 
to be a more suitable gold standard in detecting early TxCAD, and it gives information 
about the lumen diameter and arterial wall. However, due to the time and cost involved, 
it is usually performed only as part of research studies in one coronary artery and is 
rarely a part of a routine catheterisation.
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Neither QCA nor ICUS give us information about the microcirculation. The 
microcirculation can be assessed indirectly by coronary blood flow studies. However 
such studies are not easily performed and are rarely available for comparison with non- 
invasive techniques.
In summary, information from both QCA and ICUS is needed to evaluate epicardial 
TxCAD. There is no direct test as yet to evaluate the microcirculation; the development 
of such a test is needed for the better understanding of TxCAD at the microvascular 
level.
1.8 Non-immunological factors associated with transplant coronary artery 
disease.
1.8.1 Cytomegalovirus infection.
1.8.1.1 Definition.
Cytomegalovirus (CMV) is a member of the beta herpesvirus group and has double- 
stranded DNA, a protein capsid, and a lipoprotein envelope. Like other members of the 
herpesvirus group, CMV demonstrates icosahedral symmetry, replicates in the cell 
nucleus, and can cause either a lytic and productive or a latent infection. Viral 
replication is associated with the production of large intranuclear inclusions and smaller 
cytoplasmic inclusions.
CMV which was initially isolated from patients with congenital cytomegalic inclusion 
disease, is now recognized as an important pathogen in all age groups110. In addition to 
inducing severe birth defects, CMV causes a wide spectrum of disorders in older
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children and adults, ranging from an asymptomatic, sub-clinical infection to a 
mononucleosis syndrome in healthy individuals to disseminated disease in immuno­
compromised patients111.
1.8.1.2 Epidemiology.
CMV has a worldwide distribution. Approximately 1 percent of newborns are infected 
with CMV, and the percentage is higher in many less developed countries110, m . 
Perinatal and early childhood infections are common. Virus may be present in milk, 
saliva, faeces, and urine. The virus is not readily spread by casual contact but requires 
repeated or prolonged intimate exposure for transmission112. In late adolescence and 
young adulthood, CMV is often transmitted sexually, and asymptomatic viral carriage 
in semen or cervical secretions is common. Transfusion of whole blood or certain blood 
products containing viable leukocytes also may transmit CMV.
Once infected, an individual probably carries the virus for life. The infection usually 
remains latent110. However, CMV reactivation syndromes develop frequently when T 
lymphocyte-mediated immunity is compromised, for example, after organ 
transplantation112. Most primary CMV infections in organ transplant recipients result 
from transmission of the virus in the graft itself.
1.8.1.3 Pathogensis.
Once acquired, CMV persists indefinitely in tissues of the host112, 113. The sites of 
persistent or latent infection are unclear but probably include multiple cell types and 
various organs. Autopsy studies suggest that salivary glands and bowel also may be 
areas of latent infection.
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When the host's T cell responses become compromised by immunosuppression, latent 
virus can be reactivated to cause a variety of syndromes111. Chronic antigenic 
stimulation in the presence of immunosuppression, following tissue transplantation, 
appears to be an ideal setting for CMV activation and CMV induced disease. Certain 
particularly potent suppressants of T cell immunity, such as antithymocyte globulin, are 
associated with a high rate of clinical CMV syndromes, which may follow either 
primary or reactivation infection. CMV may itself contribute to further T lymphocyte 
hypo-responsiveness, which often precedes super-infection with other opportunistic 
pathogens, such as Pneumocystis carinii.
The pathology of CMV associated vasculitis ranges from local involvement of the virus 
to widespread CMV disease114. Although the pathogenesis is not entirely clear, it 
probably concerns active infection of the virus in endothelial cells, as shown by 
Persoons et al115. An interesting observation in this field is the detection of CMV 
infected endothelial cells in the blood of acutely infected patients116,117.
1.8.1.4 Clinical Features.
In organ transplant recipients, CMV induces a variety of syndromes, including fever 
and leucopenia, myocarditis, hepatitis, pneumonitis, oesophagitis, gastritis, colitis, and 
retinitis111. The period of maximal risk is between 1 and 4 months after transplantation 
Clinical disease is related to various factors, such as the degree of immunosuppression; 
patients receiving certain immunosuppressive agents, such as antithymocyte globulin, 
appear to be more likely to have severe infections than those receiving other agents, 
such as ciclosporin.
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1.8.1.5 Clinical studies correlating Cytomegalovirus and transplant coronary 
artery disease.
The association between CMV and TxCAD has been suggested in several clinical 
studies118. This was initially suggested by Grattan et al119 in 1989, who in a study of 
301 patients, found that 28% of CMV infected patients developed severe coronary 
obstructive lesions, whereas only in 10% of patients not infected, did the same degree
190of TxCAD develop. Koskinen et al reported a cohort of 53 heart transplantation 
recipients and the correlation of coronary angiograms and capillary and arteriolar 
changes in endomyocardial biopsy specimens and their CMV status. They documented 
that biopsy specimens showed significant change after cytomegalovirus infection that 
was diagnosed on the basis of specific immunoglobulin M, a positive viral culture from 
blood, urine or bronchial alveolar lavage fluid together with a four fold 
immunoglobulin G rise or positive CMV antigenaemia test. The significant changes in 
coronary angiograms followed in two years after transplantation. In a different study, 
Wu et al121 demonstrated that allograft explantations with TxCAD had a much higher 
incidence of positive in situ hybridization for CMV nucleic acid in the vascular intima 
compared with explantations without TxCAD. A similar positive association between 
CMV and TxCAD has also been by others122,123.
However, not all investigators agree with the above mentioned positive association.
Balk et al124 failed to find such a relationship in their study of 100 patients who
survived at least 1 year after transplantation. There was no significant difference in the
incidence of TxCAD between CMV seropositive and CMV seronegative patients,
between patients with and without CMV infection (culture positivity), or between
1
patients with and those without clinical CMV syndrome. Weimar et al studied the
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clinical course of 87 cardiac transplants and found no association between acute or 
chronic rejection and patient pre-transplant CMV serostatus or post-transplant 
seroconversion. Stovin et al in a more limited study of 43 heart transplant recipients 
(22 of whom seroconverted), found no evidence of CMV associated inflammation in 
endomyocardial biopsies taken up to the time of CMV seroconversion (approximately 
57 days post-transplant), and no difference in rejection frequency between these 
patients and those who remained CMV-seronegative. In a retrospective analysis of 210 
cardiac transplant recipients, Radovancevic et al127 found no correlation between 
TxCAD with CMV infection.
Thus, the role of CMV in the pathogensis of TxCAD is not clear, and studies have 
shown contradicting results. The issue is complicated by the fact that the diagnosis of 
TxCAD and CMV have been made by various methods, which have different 
sensitivities and specificities for the diagnosis of TxCAD. Therefore it is difficult to 
draw a clear conclusion from these studies due to the variety of methods used to 
determine CMV infection and detect TxCAD.
1.8.2 Hyperlipidaemia.
Hyperlipidaemia is a potentially important risk factor for heart graft recipients. Many 
individuals awaiting cardiac transplantation have pre-morbid hyperlipidaemia . This 
hyperlipidaemia tends to normalize by the time end stage heart failure has developed.
Hyperlipidaemia with hypercholesterolaemia, hypertriglyceridaemia, and increased low 
density lipoproteins often develop in the months following transplantation. Farmer et
190al studied the pattern of change of lipid profile in 41 cardiac allograft recipients,
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before and after transplant. Post-transplant, patients received triple immunosuppression 
in the form of prednisolone, azathioprine and ciclosporin. Comparing the baseline 
levels to that obtained 3 months post-transplantation, the mean (± SEM) values 
increased for total plasma cholesterol (from 4.68±0.21 to 5.93±0.21 mmol/L, p < 
0.001), triglycerides (from 1.39±0.12 to 2.28±0.15 mmol/L, p < 0.001), HDL 
cholesterol (from 1.01±0.05 to 1.27±0.08 mmol/L, p < 0.002) and LDL cholesterol 
(from 3.09±0.18 to 3.59±0.18 mmol/L, p < 0.02). Apolipoprotein A-l and B-100 also 
increased, but lipoprotein(a) decreased from 11.7±1.7 to 6.8±1.1 mg/dl; p <0.0001) 
after transplantation. Although total cholesterol, triglycerides, LDL cholesterol, 
apolipoprotein A-l and B-100 increased dramatically after cardiac transplantation, so 
did HDL cholesterol, thereby keeping the LDL/HDL cholesterol ratio constant. The 
decrease in lipoprotein(a) after cardiac transplantation suggests that metabolism of 
lipoprotein(a) is independent of LDL cholesterol and that immunosuppressive drugs 
either decreased the synthesis or increased catabolism of lipoprotein (a).
The cause of these lipid abnormalities is unclear, although immunosuppressive agents,
particularly steroids, are probably important. Renlund et al130 have demonstrated that
the total cholesterol level was significantly higher in recipients receiving chronic
corticosteroid treatment compared to those who were not. Insulin resistance induced by
1-11
corticosteroids is also an important pathway leading to hyperlipidaemia . This will 
enhance VLDL secretion and impede the removal of triglycerides from VLDL in the 
circulation. This will result in hypertriglyceridaemia. The expanded VLDL pool 
increases the transfer of cholesterol out of HDL and probably out of LDL to VLDL. 
This in turn leads to low levels of HDL cholesterol and the formation of small 
cholesterol depleted LDL. Barbir et al132 also demonstrated that patients who received
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immunosuppression by means of prednisolone and azathioprine developed coronary 
arterial disease compared to patients who were treated with ciclosporin and 
azathioprine without routine oral prednisolone. Ciclosporin may also be responsible 
because it inhibits prednisolone clearance by the liver133. Its interaction with 
cytochrome P 450 system may also increase steroid induced effects. It also increases 
hepatic lipase activity, with impairment of very low density and low density lipoprotein 
clearance. This may lead to hypertriglyceridaemia and increased endothelial contact 
with small low density lipoprotein particles.
Rickenbacher et al134 studied 116 adult heart transplant recipients with a mean age of 
44.7±2.0 years (89 men and 27 women) undergoing annual coronary angiography and 
ICUS 3.4±2.7 (range, 1.0-14.6) years after transplantation. Prevalence of any transplant 
coronary artery disease (TxCAD) was 85% by ICUS and 15% by angiography. By 
multiple regression analysis, average fasting plasma triglyceride level (P < 0.006) was 
significantly correlated with severity of intimal thickening (R = 0.54, P < 0.0001). 
Average fasting plasma triglyceride level (P < 0.009) was significantly correlated with 
stenosis by angiography. Furthermore, hypertriglyceridaemia predicted intimal 
thickening as early as 1 year.
Hypercholesterolaemia has also been implicated in the pathogenesis of TxCAD. Eich et 
al135 reviewed 38 heart transplant recipients who survived more than 3 years after 
surgery and looked at the development of hypercholesterolemia for a possible 
correlative or predictive value to the development of early coronary artery disease after 
heart transplantation. Eleven patients were identified as having coronary disease by the 
third year after transplantation. They found that high cholesterol value at 6 months after
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transplantation was a strong predictor for development of accelerated coronary artery
1 'XOdisease and early graft failure. Barbir et al investigated the relationship of levels of 
serum lipids to the subsequent development of coronary arterial disease in 95 patients 
with angiographically normal coronary arteries one year after cardiac transplantation. 
The cumulative probability of coronary arterial disease in those with total cholesterol 
greater than 5.8 mmol/1 was at 2, 3 and 4 years was significantly higher than those with 
a total cholesterol less than 5.8 mmol/1. Similar results were also found by Sharpies et 
al136. However, other investigators found no association between lipid levels and 
TxCAD137,138.
Lowering cholesterol and triglycerides by lipid lowering agents has been associated
1 IQwith a reduction in TxCAD. Wenke et al in a 4-year prospective randomized study 
with heart transplant recipients, the efficacy of primary anti-hypercholesterolaemic 
therapy with simvastatin was compared with that of general dietary therapy. The aim of 
the treatment was to maintain post-transplantation LDL-cholesterol levels at <3.12 
mmol/L. Seventy-two heart transplant recipients receiving standard triple 
immunosuppression were randomly assigned to an active treatment group (low- 
cholesterol diet and simvastatin, n=35) or a control group (general dietary measures, 
n=37). In the course of 4 years after transplantation, the simvastatin group had 
significantly lower LDL-cholesterol concentrations than the control group (mean±SD, 
2.99±0.36 versus 4.06±0.44 mmol/L, p=0.002), a significantly lower incidence of 
TxCAD in the coronary angiographic findings (16.6% versus 42.3%, p=0.045). In a 
separate study, Stapleton et al140 used gemfibrozil to lower the triglycerides level in a 
prospective study of 56 of 137 heart transplant recipients with > 1 year post-transplant 
survival, and assessed the morbidity and mortality associated with the development of
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TxCAD following transplantation. At baseline, patients on the treatment arm had 
higher total cholesterol (6.97±0.94 vs. 5.8±1.33 mmol/L), LDL cholesterol (4.34±1 vs. 
3.54±1.1 mmol/L), and triglycerides (3±0.36 vs. 1.96±1.18 mmol/L) compared to the 
untreated patients. Levels of HDL cholesterol were statistically similar in both groups 
(1.1 ±0.29 vs. 1.17±0.1 mmol/L). In the treated group, there was a 3% decrease in total 
cholesterol (6.73±0.83 mmol/L) and an 8% decrease in LDL cholesterol (3.98±0.88 
mmol/L) following intervention with gemfibrozil (p=NS). In addition, an 11% increase 
in HDL cholesterol (1.22±0.31 mg/dl) and a 19% decrease in serum triglycerides 
(2.41±1.19 mg/dl) were observed (both p<0.01). The death rate was 5.4 % in the treated 
group compared to 14.8 % in the untreated group, in a mean cohort survival time of 
4.3±2.1 years. There was a significant difference in mortality (p=0.01) between those 
patients with high lipids who were treated (5.4%) compared to those patients with high 
lipids who were untreated (27.3%).
1.8.3 Hypertension.
According to the registry of the ISHLT1, hypertension develops in 72% of heart 
transplant recipients by 1 year and 95% by 5 years. The use of ciclosporin has been 
shown to be associated with its development141, 142. Several mechanisms, including 
endothelin mediated systemic vasoconstriction143, impaired vasodilation secondary to 
reduction in nitric oxide144, and altered cytosolic calcium translocation145, have been 
proposed to underlie ciclosporin induced hypertension. In addition, other studies have 
shown activation of the sympathetic nervous system146 and the renin angiotensin 
system147, as well as abnormalities in prostaglandin metabolism, as culpable 
mechanisms. Haemodynamic features of ciclosporin induced hypertension consist of
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elevated peripheral vascular resistance148, ventricular vascular uncoupling contributing 
to left ventricular hypertrophy149, 146and abnormalities in the diastolic function of the 
allograft.
Studies investigating the role of recipient blood pressure in the incidence of TxCAD 
have generally been negative. Hauptman et al150 in a study of 204 patients using ICUS, 
found no significant difference in the progression of intimal thickening and the 
presence of hypertension. Rickenbacher et al134 found no significance in post-transplant 
blood pressure in the incidence of TxCAD as measured by conventional angiography or 
ICUS. Interestingly, Costanzo et al30 in a multiinstitutional study of donor and recipient 
risk factors, found that donor hypertension is a risk factor for TxCAD as measured by 
angiography (p=0.07).
The pulse pressure has recently come to light as an important predictor of 
cardiovascular mortality in both the hypertensive and normotensive non-transplant 
populations. Fang et al151 initially showed in a retrospective study of a population of 
5730 participants in a follow-up of 5.43 years of follow-up that a large pulse pressure 
difference was the most powerful measure available of initial blood pressure to 
identify, in advance, those hypertensive patients at greatest risk for a subsequent
1 ^ 7myocardial infarction. The same group subsequently showed in a retrospective study 
of 7346 normotensive participants, aged 25-74 years, in a follow-up period of 17.4 
years, that that among young subjects with a very low risk of cardiovascular disease, a 
wide pulse pressure was associated with increased cardiovascular mortality. Similar 
results relating pulse pressure to increased incidence of cardiovascular mortality and 
myocardial infarction has been shown by other investigators153,154.
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Although the effect of systolic and diastolic blood pressure post-transplant on the 
incidence of TxCAD has generally been negative in previous studies, the effect of the 
pulse pressure has not been investigated before. Thus our study provided an 
opportunity to do so.
1.8.4 Diabetes.
Induction of diabetes in rat models is associated with increase incidence of TxCAD in 
the allografts compared to non-diabetic allografts155. In addition, treatment of diabetes 
in heterotopic heart transplant rat models is associated with decreased diabetes-induced 
TxCAD156.
The effect of diabetes on TxCAD in humans has also been investigated. Ladowski et al
1 S7 investigated whether non-insulin and insulin diabetic patients who received a heart 
transplant had higher incidence of TxCAD, as diagnosed be qualitative angiography, 
compared to non-diabetics 4 years after transplant. They found that they did not have a 
higher incidence of graft atherosclerosis. Valentine et al investigated insulin 
resistance in 66 patients without overt diabetes, in the development of TxCAD, 2 to 4 
years after transplant using ICUS and measuring the plasma glucose and insulin after 
oral glucose. Coronary artery intimal thickness (IT) and subsequent outcome were 
compared in patients stratified as having "high" versus "low" plasma glucose (>8.9 
mmol/L) and insulin (>760 pmol/L) 2 hours after glucose challenge. Patients with high 
glucose or insulin concentrations had greater IT: 0.38±0.05 versus 0.22±0.02 mm, 
P<0.05, and 0.39±0.05 versus 0.20±0.02 mm, P<0.01, respectively. Thus insulin 
resistance plays a role in TxCAD as diagnosed by ICUS. In our study, we investigated 
serum glucose level to the incidence of TxCAD, as diagnosed by QCA.
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1.8.5 Smoking.
The literature is deficient in studies relating post-transplant smoking and the 
development of TxCAD. Radovancevic et al127 found that smoking after transplantation 
was related significantly to the occurrence of TxCAD as diagnosed by coronary 
angiography, postmortem examination or examination of the transplanted heart at the 
time of re-transplantation. Kapadia et al159 found that conventional atherosclerosis risk 
factors, including smoking, do not predict development of TxCAD, as diagnosed by 
ICUS. In our study, none of the transplant recipients smoked after transplantation.
1.8.6 Donor risk factors.
Donor risk factors had been implicated in the pathogenesis of TxCAD30,134,15°. These 
risk factors include brain death, donor age and sex. Total ischaemic time, although not 
found in previous studies to affect survival and cardiac function160"162, might have an 
effect on the development of TxCAD.
1.8.6.1 Brain death.
Organs for heart transplantation are usually obtained from brain dead patients163, 164 
who are on ventilators, after appropriate consent has been verified. Less commonly, 
hearts from the heart-lung blocks obtained from patients undergoing heart-lung 
transplantation is used (domino hearts)165. Whether the hearts from brain dead patients 
are more likely to develop TxCAD compared to domino hearts remains to be 
investigated adequately.
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Brain death has been suggested to have an impact, although not clearly defined, on the 
quality of peripheral organs166. The influence of brain death on outcome of kidney 
transplantation has been suggested by clinical observation that the behaviour of grafts 
from living donors is consistently superior from those from cadavers167. These 
intriguing results suggest that events surrounding brain death may alter the donor organ 
so that it is more prone to recipient alloimmunity.
Several animal experiments had been performed to assess the effects of brain death on 
the heart168,169. Bittner et al169 designed a study to establish a validated canine brain 
death model. Ten consecutive dogs were studied to investigate the effects of brain death 
on hemodynamic, metabolic, and hormonal function. Brain death was induced by 
inflation of a subdurally placed balloon and was validated neuropathologically. 
Functional data and blood samples were collected before and 15, 45, 90, 240, 360, and 
420 minutes after the induction of brain death. No inotropic or vasoactive support was 
given. The results were expressed as mean ± standard error of the mean. The Cushing 
reflex occurred in all animals and lasted 13.3±1.5 minutes. Raised catecholamine levels 
were documented at 15 minutes, whereas the pituitary gland hormones vasopressin and 
adrenocorticotrophic hormone decreased significantly after 15 and 45 minutes, 
respectively. Triiodothyronine, thyroxine, and glucagon decreased significantly from 
0.58±0.05 ng/ml, 2.20±0.15 pg/dl, and 49.7±9.1 pg/ml to 0.34±0.03 ng/ml (p < 0.05), 
1.14±1.14 pg/dl (p < 0.05), and 6.9±1.4 pg/ml (p < 0.05) respectively. Insulin and 
lactate dehydrogenase showed a moderate increase after brain death. Diabetes insipidus 
occurred after 45 minutes in nine animals (urine output 13.5±1.8 ml/kg/hour). Left and 
right ventricular end-diastolic pressure increased significantly toward the end of all
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experiments. Cardiac output increased and systemic and pulmonary vascular resistance 
decreased, but heart rate remained unchanged.
Smith et al165 studied the outcome of 72 cardiac transplants using domino hearts, as 
regards to outcome and the development of TxCAD. There were four deaths (5.6%) at 
less than 30 days (2 from multiple organ failure, 1 from primary allograft failure and 1 
from acute rejection). Actuarial survival estimates at 1 and 5-year were 77±5.2% and 
69±6.3%, respectively. This compared favourably with survival data obtained in 234 
non-domino cardiac recipients. There was no difference in the incidence of freedom 
from graft atherosclerosis (74±3% versus 70±3% at 5-years) as diagnosed by 
conventional angiography between the domino and non-domino groups.
The incidence of TxCAD in domino heart transplants hasn’t been investigated in detail. 
Our study thus provided an excellent opportunity to study this relationship, as TxCAD 
was measured by QCA rather than qualitative angiography. In addition, the incidence 
of TxCAD in the primary versus the small coronary arteries will be assessed.
1.8.6.2 Donor age.
The relationship between donor age and the incidence of TxCAD has been investigated 
before; the results have been contradictory.
One of the large studies was conducted by Costanzo et al30. In this multi-institutional 
study, 2609 patients one to five years post cardiac transplant were studied by coronary 
angiography to diagnose coronary artery disease. They found that angiographic TxCAD 
was very common after heart transplantation, occurring in approximately 42% of the
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patients by 5 years. By multivariate analysis, older donor age was found to be a risk 
factor for development of TxCAD (p <0.0001). Recipient’s age was not found to be a 
significant risk factor.
In a multicentre ICUS study, Hauptman et al150 studied 204 post-transplant patients. 
ICUS was performed at baseline and 1 year post transplant in 70 patients, at year-1 and 
year-2 in 46 patients, year-2 and year-3 post transplant in 49 patients and 39 patients 
had ICUS at different times. The maximal intimal thickening (MIT) and Intimal Index 
(II) were measured. For patients studied at baseline and year-1, both MIT and II 
correlated significantly with donor age (p=0.013 and p=0.025 respectively). However, 
with the use of cut off point of 500 pm for critical MIT at baseline, there was no 
significant difference in donor age. There was also no significant relation to recipient’s 
age.
In a study using both qualitative angiography and ICUS to detect TxCAD, 
Rickenbacher et al134 studied 116 heart transplant recipients. The patients were 1 to
14.6 years (mean 3.4±2.7) after transplantation. Prevalence of any TxCAD was 85% by 
ICUS and 15% by angiography. Donor age (P < 0.006) was significantly correlated 
with stenosis by angiography but using ICUS, donor age was not significantly 
correlated with intimal thickening (p < 0.8).
The above studies showed that by using qualitative angiography a relationship can be 
shown to exist between increasing donor age and TxCAD, while by using ICUS, this 
relationship doesn’t exist. Whether this relationship exists when TxCAD is diagnosed 
by using QCA is not known.
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1.8.63 Donor gender.
The role of donor gender in the development of TxCAD has also been questioned, and
o n
again the results are inconclusive. Costanzo et al in their multi-institutional study 
using coronary angiography to diagnose TxCAD, found that donor male sex predict the 
development of TxCAD (p=0.006). In addition, they found that recipient male sex was 
also a risk factor in TxCAD (p=0.02).
However, using conventional angiography and ICUS, Rickenbacher et al134 found no 
relationship between donor gender and TxCAD (p<0.2 and pel respectively). In 
addition, Hauptman et al150 in the multi-institutional study using ICUS, found no 
significant difference in intimal thickening, as measured by MIT and n, as regards 
donor or recipient gender in the incidence of TxCAD. The role of donor gender in the 
pathogenesis of TxCAD thus needs further evaluation.
1.8.6.4 Total ischaemic time.
198Physiologic and metabolic changes develop in organs lacking circulation . Whether 
these changes have any effect on the subsequent development of TxCAD when the 
heart is transplanted has been questioned.
Rickenbacher et al134 investigated the development of TxCAD and its relation to total 
ischaemic time (111) in cardiac transplant patients using conventional coronary 
angiography and ICUS. They found that increased TIT has no significance in the 
development of TxCAD (p =0.3 by both methods). Similar results were found by 
Costanzo et al30 using conventional angiography, and by Hauptman et al150 using ICUS.
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The relationship between TIT and TxCAD hasn’t been studied using QCA. Our 
research thus provides an opportunity for that.
1.8.7 Coronary artery tone.
The endothelium plays a critical role in the control of vasomotor tone by the release of 
vasoactive substances170. It releases a number of mediators that regulate tone and 
growth in response to changes in shear stress and other haemodynamic and metabolic
171factors . An important product is nitric oxide, which is formed from L-arginine by the 
enzyme nitric oxide synthase. Damage to the endothelium may result in reduced 
production of nitric oxide and/or other vasoactive substances such as prostacyclin172. 
Functional endothelial disturbances are clinically detectable as abnormal vasomotor 
responses to endothelium dependent vasodilators such as acetylcholine or substance P. 
Reduced coronary vasodilation or vasoconstriction in response to these agents has been
11 'X  177observed in a substantial proportion of cardiac transplant recipients * . In contrast, 
endothelium independent vasodilators such as nitroglycerine and adenosine usually 
elicit normal vasodilator responses173,178,179.
The predictive value of endothelial dysfunction in the later development of TxCAD is 
not clear. Different studies have shown different results. Angiographic studies have 
shown that acetylcholine induced coronary vasodilation 2 months after transplantation 
may be impaired to the same extent in patients with and without angiographic evidence 
of TxCAD at 1 year follow up180. However, in an ICUS study, Davis et al181 showed 
that coronary segments with endothelial dysfunction, compared to normally dilating 
segments, early after transplant has a greater increase in intimal thickness at 1 year.
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This suggests that endothelial dysfunction has a predictive value for the subsequent 
development of TxCAD.
As the endothelium plays a critical role in regulating the coronary tone, and as 
endothelial dysfunction has been shown by ICUS studies to predict later development 
of TxCAD, the question arises whether early change in vascular tone is a predictor of 
later development TxCAD. On review of the literature, such study hasn’t been 
undertaken as yet. We have thus investigated this question in our current study.
1.8.8 Change in cardiac haemodynamics secondary to transplant coronary 
artery disease.
Review of literature shows that very little information is available on the impact of 
TxCAD on cardiac function. Grocott-Mason et al182 studied such relationship in the 
decade following cardiac transplantation. They performed a retrospective analysis on 
137 patients who survived at least 1 year and returned for annual assessment. Any 
irregularity on conventional angiography was interpreted as indicative of TxCAD. The 
incidence of TxCAD was 8.8% (12 of 137) at one year. Only 34 of 137 patients (25%) 
were alive and free from TxCAD at 10 years. The mean time post-transplant to 
diagnose TxCAD was 4.4±2.4 years for single vessel disease and 5.8±2.6 years for 
triple vessel disease. Cardiac function was impaired if TxCAD was present, with higher 
filling pressures and lower left ventricular ejection fraction (LVEF); five years post­
transplant, the left ventricular end diastolic pressure (LVEDP) was 11.5±3.6 vs. 
13.8±5.7 mmHg, mean right atrial pressure (RAP) was 4.9±2.3 vs. 6.9±3.2 mmHg, 
LVEF was 66.2±11.3% vs. 59.4±13.9%.
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They also analysed the one-year haemodynamic data of all recipients with normal 
coronary arteries. These were grouped into 2 groups. Group 1, those documented not to 
have developed TxCAD during the first decade (n=34); Group 2, those who were 
documented to have developed TxCAD between 1 to 10 years (n=81). Those who died 
before 10 years were excluded, unless they were shown to have developed TxCAD, as it 
was unknown whether they would have developed TxCAD if they had survived 10 
years. Patients in Group 1 (who never developed TxCAD) had significantly better 
cardiac function than those in Group 2 (i.e. prior to the diagnosis of TxCAD): LVEF of 
70.3±0.4% vs. 63.3±13.4%, mean RAP of 3.7±1.8 vs. 6.1±4 mmHg, respectively, both 
P < 0.05. Similar differences in cardiac function were found comparing 1 and 5 years 
haemodynamic data for patients with or without TxCAD at 5 or 10 years, respectively.
The data above confirms that even with normal coronary arteries on conventional 
angiography, differences in cardiac function are detectable in those who develop 
TxCAD at a later date. Whether these data can be reproduced when TxCAD is 
measured by the more sensitive QCA is not known. Our study thus provided an 
opportunity to do that.
1.9 Immunological factors associated with transplant coronary artery disease.
Although the pathogensis of TxCAD is thought to be multifactorial, immunological 
factors probably play a major role in its development, as the vascular endothelium is 
known to be immunologically active, and as it is highly responsive to cytokines and 
express numerous molecules which interact with ligands on lymphocytes183. This 
section will deal with the different immunological aspects that are thought to be 
implicated in the pathogenesis of TxCAD.
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1.9.1 Acute rejection.
The immune system mounts a response to the allograft which may lead to hyperacute, 
acute or chronic rejection. Hyperacute rejection occurs within hours after 
transplantation, and is due to preformed circulating antibodies from prior transfusion, 
pregnancy or ABO incompatibility. In the immunosuppressed patient, acute rejection 
might occur from the second week onwards after transplantation, and is characterized 
by deterioration in cardiac function and cellular infiltration of the myocardium by 
mononuclear cells. Chronic rejection is the most important cause of death after the first 
year, due to the accelerated coronary vascular disease184. The process is a fibrointimal 
hyperplasia that can go undetected by conventional coronary arteriography as has been 
discussed previously; this then progress to diffuse atherosclerotic changes.
The “gold standard” for the diagnosis of acute cardiac allograft rejection is by 
histologic examination of an endomyocardial biopsy (EMB)185, 186. Noninvasive
187methods can be used in conjunction with histology to aid diagnosis . These include 
the use of electrophysiology (QRS summation voltage, fast-Fourier-transformed 
electrocardiography and intramyocardial electrocardiography188), echocardiography189 
(intramyocardial wall thickness, myocardial mass, fractional shortening), immunologic 
methods190,191 (cytoimmunological monitoring, transferring receptors, and interleukin 2 
receptors), radioisotopic techniques192, 193 (anti-myosin-monoclonal antibodies, 
thallium, technetium, and gallium scintigraphy and indium labelled cells), as well as 
resonance imaging194.
At the instigation of the International Society of Heart Transplantation (now known as 
the International Society for Heart and Lung Transplantation [ISHLT]), a standardized
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grading system for heart transplant biopsy specimens was published in the Journal of 
Heart Transplantation in November/December 1990195’196. The purpose of this grading 
is to provide a system into which other previously used systems could be translated for 
the purpose of multicentre clinical trials and for publications so that results from 
different centres could be compared effectively. The ISHLT has classified acute cardiac 
rejection into the following grades:
0- No rejection.
1- This is subdivided into:
1 A- Focal (perivascular or interstitial) infiltrate without necrosis.
IB- Diffuse but sparse infiltrate without necrosis.
2- One focus only with aggressive infiltration and / or focal myocyte damage.
3- This is subdivided into:
3A- multifocal aggressive infiltrates and / or myocyte damage.
3B- diffuse inflammatory process with necrosis.
4- Diffuse aggressive polymorphous infiltrate ± oedema ± haemorrhage ± 
vasculitis, with necrosis.
Early acute rejection has been considered the critical risk factor for chronic 
rejection (TxCAD)128. Subclinical host alloreactivity may persist despite putatively 
satisfactory maintenance immunosuppression; indirect presentation of donor MHC 
antigens may become increasingly important over time. In addition, noncompliance 
by the recipient may allow continuing low-grade host alloresponsiveness. As a 
result, several studies have been undertaken to investigate the relationship between 
acute rejection and subsequent development of TxCAD.
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One of the initial studies was by Uretsky et al137. They found that occurrence of two 
or more major rejection episodes were associated with the development of TxCAD 
(p < 0.005), as diagnosed by qualitative angiography. In a separate study, 
Radovancevic et al127 subsequently showed that the total number of rejection 
episodes correlated significantly with the occurrence of TxCAD (P < 0.05), 
showing that patients who experienced two or more rejection episodes had an 
incidence of TxCAD of 40%, as opposed to a 23% incidence in patients who 
experienced no rejection. A composite rejection score derived from multivariate 
regression analysis of the severity, frequency, and timing of acute cardiac rejection 
episodes was found to correlate with the development of CAD (P < 0.05). Narrod et 
al197 in a study of 173 heart transplant recipients found a significant relationship 
between acute rejection episodes after the first year of transplant and the subsequent 
development of TxCAD. Zerbe et al198 in a review of 146 allografts established a 
positive association between moderate rejection in the first 3 months after 
transplantation and development of TxCAD.
However, not all investigators agree about this relationship. Gao et al199 analysed 
126 consecutive heart transplant recipients and devised an arbitrary method to 
incorporate the number, duration, and severity of myocardial rejection episodes 
during the first postoperative year, resulting in a rejection score for each patient. 
They then correlated the later incidence (mean follow-up, 4 years) of angiographic 
accelerated graft coronary artery disease with this rejection score. They found no 
significant difference between patients with and without TxCAD in their rejection 
parameters. In a separate study, Stovin et al126 studied the grades of rejection seen at 
all biopsies performed in the first 6 months after heart transplantation in 108
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patients who survived more than 6 months. The development of TxCAD was 
assessed at routine follow-up coronary angiography in 101 patients and at necropsy 
in seven patients. No significant association was found between either moderate 
rejection or any level of rejection and the later development of TxCAD, nor did the 
absence of any rejection protect against its development.
All the above studies used qualitative angiography to assess the development of 
TxCAD. This is a subjective and insensitive method of diagnosing TxCAD; QCA 
or ICUS would be more appropriate methods. In a multicentre study using ICUS, 
Kobashigawa et al200 studied 68 heart transplant recipients from seven heart 
transplant programmes. All patients underwent baseline ICUS and again at 1 year 
after transplantation. Rejection episodes were recorded for each patient during the 
first year after transplantation, and was categorized into 3 groups; the Treated 
Endomyocardial Biopsy group (ISHLT >3 A requiring augmented 
immunosuppression), Treated Rejection group (any rejection, confirmed clinically 
or by biopsy, requiring treatment) and Average Biopsy Score (when a biopsy score 
was obtained by assigning a numerical score to each ISHLT grade). There was no 
significant difference in the development of TxCAD between patients in the 
Treated Endomyocardial Biopsy and the Treated Rejection groups and those who 
did not reject. However, there was a significant correlation between increased 
average biopsy score at 0 to 3 months after transplantation and increased intimal 
thickening. This suggests that recurrent mild rejection episodes may have an 
important role in the development of transplant coronary artery disease.
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901In an autopsy study, Winters et al compared the severity of rejection to the degree 
of luminal narrowing, as measured by means of digitization on a video image 
analysis system, in the coronaries of 15 allografts. Rejection episodes, considering 
all degrees of rejection, were strongly related to percent luminal narrowing (p = 
0.01).
In summary, the role of acute rejection in the development of TxCAD seems to 
vary depending on the method used to diagnose it. We thus investigated the role of 
acute rejection in the development of TxCAD in the main and secondary vessels 
when QCA is used.
1.9.2 Mismatches at the HLA locus.
1.9.2.1 Introduction.
Antigenic differences between members of a species are called alloantigens, and when 
these play a determining role in the rejection of allogeneic tissue grafts, they are called
9H9histocompatibility antigens . Evolution has conserved a single closely linked region 
of histocompatibility genes, the products of which are prominently displayed on cell 
surfaces and provide a strong barrier to allotransplantation. The terms major 
histocompatibility antigens and major histocompatibility gene complex (MHC) refer to 
the gene products and genes of this chromosomal region. The response to a given 
antigenic determinant is now known to require the binding of the appropriate peptide 
fragment to an MHC molecule. In humans, the MHC is called HLA (Human Leucocyte 
Antigen)202 and is located on the short arm of chromosome 6. The individual letters of 
HLA have various unofficial meanings, and by international agreement HLA is the 
logo for the human MHC.
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Three classes of gene products are encoded within the 4000-kilobase region of HLA202. 
Class I molecules, expressed on virtually all cell surfaces, consist of one heavy and one 
light polypeptide chain and are the products of three reduplicated loci: HLA-A, HLA- 
B, and HLA-C. Class II molecules are restricted in expression to B lymphocytes, 
dendritic cells, monocytes, antigen-activated T lymphocytes, and to epithelial and 
endothelial cells that have been activated by interferon. They consist of two 
noncovalently linked polypeptide chains (a and P) of unequal length. They are the 
products of several closely linked genes, collectively termed the HLA-DR (D related). 
The class II heterodimers form a structure similar to that of class I.
1.9.2.2 Clinical studies.
Clinical studies show that HLA histocompatibility between donor and recipient is an 
important determinant of allografts outcome in kidney transplantation203. In 
combination with pharmacological modification of the host immune response using 
immunosuppressive agents, HLA matching is effective at weakening the potency of 
host T cells to destroy donor tissue, reducing both the frequency and severity of 
rejection and graft loss204*206.
In contrast, in human heart transplantation, published clinical studies have produced 
conflicting results between histocompatibility and survival207, 208. In addition, only a 
few studies have examined the effect of HLA mismatch on the occurrence of TxCAD. 
Numerous complex reasons account for these inconsistencies.
1- Donor-recipient HLA matching is not done prospectively in heart 
transplantation, and the number of fortuitously well matched recipients is very 
small.
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2- Tissue typing has been performed with serologic rather than with DNA 
genotyping techniques. Although serologic methods for the recognition of 
distinct HLA types have improved, at present by no means are all MHC 
antigens distinguishable. Often when one antigen is reported for a given locus, it 
is assumed that the patient is homozygous when in fact the second allele is an as 
yet untypeable antigen.
3- Data on the relationship between HLA mismatch and heart allografts rejection 
may be affected by inter-institutional variability in the diagnosis, grading, and 
threshold for treatment of rejection.
4- Lack of sensitivity of invasive (coronary angiography) and non-invasive 
methods for detecting TxCAD makes it difficult to assess the impact of donor- 
recipient tissue matching on the occurrence and progression of this disease.
Cocanougher et al209 investigated the relationship between HLA matching and 
allografts failure and recipients death as a result of TxCAD. An HLA score was 
obtained by assigning two points for each completely mismatched A, B, and DR 
antigen, one point for tolerated cross reactive antigens, and no points for completely 
matched antigens. Total and B-DR HLA scores were higher in patients who died 
because of TxCAD than in long term survivors with angiographic evidence of TxCAD 
(10.2±1.4 vs. 8.8±2.2, p = 0.02 respectively). This intriguing finding suggests that 
patients with greater degree of HLA mismatch have greater mortality when TxCAD 
develops.
Some investigators found no relationship between HLA mismatch and the development
o i nof TxCAD. Homick et al studied 550 heart transplant recipients with postmortem data
78
or yearly angiograms, donor: recipient serological HLA typing, and biopsy data. They 
did not find any significant association between the mean number of mismatches for 
Class I or Class II antigens that exerted a protective or deleterious effect. In a different 
study, Zerbe et al198 studied 146 allografts obtained either at re-transplantation or 
autopsy. Epicardial coronary vessels were measured by planimetry of photographs of 
coronary artery sections with use of a digitizing tablet. Only rejection rate in the first 3 
post-operative months, but not the degree of HLA mismatch, were associated with 
severity of coronary artery luminal narrowing.
Interestingly, an inverse relationship between HLA mismatch and development of and 
outcome from TxCAD has been suggested. Kerman et al211 in a review of 448 
ciclosporin treated heart transplant recipients examined the relationship of donor- 
recipient HLA compatibility to survival, rejection and death from TxCAD. An inverse 
relationship was found between HLA A and B mismatch, but not HLA DR mismatch, 
and death from coronary artery disease in that 17% (19/111) of well matched (<2 A and
B mismatches) vs. 9% (32/327) of poorly matched patients (>2 A and B mismatches)
212died from TxCAD (p = <0.01). Similar results had been found by Radovancevic et al 
in a separate study of 167 patients who underwent cardiac transplantation. They found 
that at the HLA-A locus, there was significantly higher incidence of TxCAD (p<0.01) 
in the group of patients with zero mismatches (10 of 17, 58%). At the HLA-B locus, 
there were no statistically significant differences between the number of mismatches 
and the development of TxCAD. At the HLA-DR locus, there was no correlation at all. 
Generally, the group of patients with four to six mismatches had a significantly lower 
incidence of TxCAD (p <0.05) than the patients with three or fewer mismatches. One 
can only speculate that that these well matched patients experienced fewer acute
rejection episodes and consequently received less immunosuppression which allowed a 
greater degree of alloreactivity to proceed undisturbed leading to TxCAD.
1.9.23 Animal studies.
Evidence from animal models militates against the hypothesis that antigens of the MHC 
are the sole targets of the recipient’s immune responses, which eventually lead to the 
occurrence and progression of TxCAD. Adams et al have developed a heterotopic 
heart transplant model in which Lewis rats serve as heart donors and Fisher 344 rats 
serve as recipients. These rat strains differed only at minor histocompatibility loci. 
Despite the absence of MHC antigenic differences, allografts blood vessels developed 
intimal proliferative lesions, which by light microscopy, were very similar to the 
histopathologic changes typical of human TxCAD. Grusby et al214 generated mice 
lacking major histocompatibility complex (MHC) antigens and demonstrated that they 
reject allogeneic skin grafts with little delay. Thus allografts rejection might be 
mediated by alternative immune responses.
1.9.2.4 Conclusion.
The role of MHC donor/ recipient differences in the pathogenesis of TxCAD has not 
yet been completely elucidated. Clinical studies have been inconclusive in defining the 
relationship, together with the associated morbidity and mortality. Animal studies do 
not support the role of MHC alloimmune mechanisms in the development of TxCAD.
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1.9.3 Anti-HLA antibodies and the relationship of the lymphocytic cross-match 
and panel reactive antibodies in the development of transplant coronary 
artery disease.
The presence of preformed lymphocytotoxic antibodies reactive against donor 
lymphocytes in recipient serum, detected in a routine crossmatch, is considered a 
contraindication to solid organ transplantation because of the high incidence of humoral 
allografts rejection, early graft failure and poorer patient survival215*217. In addition, the 
development of TxCAD in transplant recipients has been linked with the development
< 7 1 0  o o nof anti-HLA antibodies after transplantation * . These antibodies are directed 
primarily against donor major histocompatability complex (MHC) class I HLA antigens 
constitutively expressed by the allografts endothelium, since non-activated endothelium 
does not express MHC class II HLA antigens215.
Lymphocytotoxic crossmatch is usually performed by mixing donor spleen 
lymphocytes with recipients serum, which has been pre-treated with Dithiothreitol 
(DTT) to digest IgM autoantibodies. Rabbit compliment is then added. The donor 
lymphocytes, both T and B, are isolated from donor spleen lymphocytes by antibody 
coated magnetic beads. Positive crossmatch is usually defined as a greater than 10% 
killing of donor lymphocytes above background levels216. Lymphocytotoxic antibodies 
can also be tested against lymphocytes from a donor panel representative of all 
established HLA specificities of class I and II MHC, collectively referred to as 
measurements of panel reactive antibodies (PRA) . Recipient sera is incubated with 
the lymphocytes, in addition to rabbit complement (complement dependent 
cytotoxicity-CDC). The PRA test is usually considered positive if the panel reactivity 
was greater than 5% and the strength of the reaction was greater than 10% above 
background levels216.
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A positive cross match does not always lead to hyperacute or accelerated graft 
rejection221. Investigators thus started to characterise the antibodies responsible for 
positive crossmatches. Experience in renal transplant patients suggested that a positive 
crossmatch due to IgM antibodies may be irrelevant and may not affect primary 
allografts survival222. These IgM antibodies may be either non-HLA lymphocytotoxic 
autoantibodies or non deleterious anti-HLA class I antibodies223. Scheinin et al221 in a 
retrospective study of 125 heart transplant patients, demonstrated that an IgM positive 
crossmatch did not have a deleterious effect on survival. There was no statistically 
significant difference in the development of TxCAD in those with a positive 
crossmatch.
Rose et al219 studied serial serum specimens from 118 heart transplant recipients and 
tested them against a reference panel of 70 cells for anti-HLA lymphocytotoxic 
antibodies. Patients with positive sera on at least three separate samplings at minimal 
intervals of 1 week were considered to be antibody producers (Ab+), and those with 
less than three positive sera samplings were considered non-producers (Ab-). Graft 
atherosclerosis confirmed by coronary angiography or autopsy developed in 12 Ab+ 
patients (16%), compared with 1 of 42 Ab- patients (2.3%) (p < 0.05).
Reed et al224 have investigated the role of various demographic and immunologic 
parameters as prognostic indicators of TxCAD in a population of 274 heart allograft 
recipients. Using HLA-A2 as a marker for the release of soluble HLA antigens from the 
donor, they established that recipients displaying circulating donor alloantigens for 
more than 26 weeks following transplantation are at increased risk of developing
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TxCAD (P=0.008). This association suggests that the release of alloantigens from the 
allograft is indicative of chronic injury and/or that it stimulates chronic rejection via the 
indirect allorecognition pathway.
The role of a positive lymphocytotoxic crossmatch or PRA before transplantation on 
subsequent development of TxCAD as diagnosed by QCA has not been studied before. 
We have thus investigated their role in relationship to the development of large and 
small vessel TxCAD.
1.9.4 Non HLA antiendothelial cell antibodies.
Non HLA, antiendothelial cell antibodies (AECA) have been detected initially in
kidney transplant recipients225, 226. This was followed by a similar detection of these
antibodies in heart transplant recipients227'229. Western blotting studies230, 231 have
shown that the patients can make antibodies against many different endothelial
peptides; two-dimensional gel electrophoresis has shown in excess of 40 different
protein spots which react with IgM in sera from patients with TxCAD183,232. Many of
these were identified as normal cytosolic proteins / enzymes including triose phosphate
isomerase and 75 Kd glucose regulated protein which belongs to the head shock 70 
181family of proteins . The most frequent response was against a doublet of peptides at 
56/58 kDa shown by N-terminal analysis and absorption studies to be the intermediate 
filament protein vimentin.
Vimentin is the intermediate filament protein characteristic to endothelial cells and 
fibroblasts. However, it is not restricted to these cells only. Proliferating and migrating 
smooth muscle cells also express vimentin, in addition to the desmin that they also
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express at rest. Staining normal heart sections with antibodies to vimentin provides a 
picture similar to that obtained with antibody against CD31 (a marker of endothelial 
cells). Vimentin is diffusely expressed in the intima and media of normal coronary 
arteries and is upregulated in diseased coronary arteries . Antibodies against vimentin 
reflect disease activity in the coronary arteries, but to date an effector function hasn’t 
been ascribed. It is not known how vimentin, a cytosolic protein, is exposed to the 
immune system. It may be that nonomeric peptides of vimentin are normally present on 
the cell surface, presented within endothelial MHC molecules. Alternatively, damage to 
endothelial cells leads to novel or further exposure or release of vimentin peptides.
Dunn et al230 in our institution investigated the frequency of AECA against human 
umbilical vein endothelial cells by one-dimensional sodium dodecyl sulphate 
polyacrylamide gel electrophoresis and western blotting. Peptide-specific AECA were 
found in 15/21 heart transplant recipients with accelerated coronary artery disease, and
2331/20 transplant patients who had not developed the disease. Jurcevic et al m 
retrospective study of 109 up to 5 years post-transplant patients, using 880 samples, 
found that the mean titres of antivimentin antibodies, calculated up to 1, 2, and 5 years, 
were significantly higher in patients who developed TxCAD than those who remained 
disease free (P<0.0001, P<0.0038, and P<0.0001, respectively). A predictive test based 
on the first-year mean vimentin titre alone (> or = 120) produced a test with 63% 
sensitivity and 76% specificity.
However, Hosenpud et al234 found no relationship between AECA and TxCAD. 
Recipient serum obtained between 6 and 8 weeks (early) and 1 year (late) after 
transplantation were reacted with recombinant human interferon (rhlFN)-gamma pre­
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treated donor-specific human aortic endothelial cells (HAECs) in 10 recipients with and 
10 recipients without TxCAD at 1 year after transplantation. HAEC IgM binding was 
assessed by flow cytometry and complement fixation and HAEC lysis was measured 
using standard chromium release assays. Seven of 10 and 5 of 10 patients with TxCAD 
had IgM detected by flow cytometry at early and late time points, respectively (14±2 
and 16±5 mean channel shift), whereas 5 of 10 and 6 of 10 patients without TxCAD 
had IgM detected by flow at early and late time points, respectively (15±4 and 14±3 
mean channel shift). This finding was not different between groups. Despite between 
50% and 70% of all patients having detectable IgM binding to endothelial cells, no 
patient's serum was cytotoxic to its donor-specific HAECs. They concluded that IgM 
antibody to endothelial cells is common (at low titers) after transplantation and that it is 
not cytotoxic and in their study provided no discrimination between those with and 
without chronic rejection.
It is thus obvious that the opinion is divided about the relationship of AECA and 
TxCAD. No study has been performed to date to relate the presence of these antibodies 
to the development of TxCAD in a large population of patients over time, using QCA 
to diagnose TxCAD. Our study thus provided an excellent opportunity to explore this.
1.9.5 Induction of immunosuppression with rabbit antithymocyte globulin.
Immediately after transplantation, immunosuppression has to be instituted in order to 
prevent rejection of the transplanted heart. This will have to be continued throughout 
the patient’s life. Numerous protocols are being used by different transplant centres for 
maintenance of immunosuppression, and they are continually changing. Currently, the 
most common protocol involves triple drug therapy of ciclosporin, azathioprine and
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prednisolone. These are usually given in higher doses in the early post-transplant 
period, with weaning to lower doses and less toxic levels for chronic administration.
Rabbit antithymocyte globulin (RATG), a "custom-made" polyclonal antibody 
produced in rabbits, is the immunosuppressive medication of choice for severe 
rejection, not usually responsive to conventional therapy; it is also associated with a 
lower incidence of subsequent acute rejection235. It is also used initially after 
transplantation when the renal function is poor, in place of ciclosporin. Some centres 
have adopted giving RATG to induce immunosuppression in the first 3 days post 
transplant. The effect of this on the subsequent development of TxCAD has been 
looked into before.
Carrier et al235 conducted a retrospective study to evaluate the cardiac transplant 
outcome, in their 10 year experience of induction of immunosuppression with RATG. 
163 patients who had a 3-day course of intravenous RATG immediately following heart 
transplantation (Group 1), were compared to 48 patients who had intravenous and oral 
ciclosporin immediately following heart transplantation (Group 2). One, 5- and 10-year 
actuarial survival rate averaged 85±3%, 77±4% and 67±5% in Group 1 compared with 
88±5%, 81±6% and 76± 6%in Group 2 (p = 0.5). At 1, 5 and 10 years, the freedom rate 
from TxCAD as diagnosed by conventional coronary angiography averaged 93±2%, 
68±5 %and 50±7% in Group 1 compared with 93±4, % 58±8% and 30±8 %in Group 2 
(p = 0.1). Thus there was a trend towards a lower incidence of coronary atherosclerosis 
5 and 10 years after transplantation in the RATG induction group, but this did not reach 
statistical significance. At 1 year, the freedom rate from an episode of acute rejection 
averaged 43±4% in Group 1 and 30±7% in Group 2 (p = 0.03). Using Minnesota
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Antilymphocyte Globulin (ALG), Dresdale et al236 found that ALG might reduce the 
occurrence of TxCAD as diagnosed by conventional coronary angiography in their 
follow up of cardiac transplant recipients up to a median duration of 34 months.
Thus the relationship of RATG induction of immunosuppression and subsequent 
development of TxCAD is not clear. Our study thus provided an opportunity to further 
investigate this issue.
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2.1 Study objectives.
We investigated coronary arterial disease in the transplanted heart using quantitative 
coronary angiography (QCA) up to 5 years after transplantation. Our aim was to 
determine the relationship of disease in the larger vessels (LV) compared to that in the 
smaller vessels (SV). QCA unlike ICUS, has the advantage of examining the small 
vessels (SV). We also investigated the pathogenic risk factors associated with TxCAD, 
and the effect of disease on the haemodynamics of the transplanted heart.
2.1.1 Specific research questions.
The study was designed to determine:
1- The reliability and validity of our QCA data.
2- The rate of change in coronary lumen diameter segments from immediately 
after transplant (baseline), to years 1, 3, and 5 years.
3- The changes in the large and the smaller epicardial vessels. The large vessels 
(LV) category included the proximal and mid left anterior descending artery, 
proximal circumflex artery, proximal and mid right coronary artery. The smaller 
vessels (SV) category included the distal segments of the three main coronary 
arteries, the first and second diagonal arteries, first and second obtuse marginal 
arteries, right ventricular branch of the right coronary artery and the posterior 
descending artery. Table 2.1 shows the abbreviations of these segments that will 
be used throughout this study.
4- The effects of the LV and SV TxCAD on the haemodynamic parameters of the 
heart.
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5- The relationship of different immunological and non-immunological factors to 
the development of SV and LV TxCAD. These factors are shown in the table 
2.2.
Table 2.1: Abbreviations of the main coronary arteries 
and their measured segments.
Artery/ Arterial Segment Abbreviation
Left Anterior Descending Artery LAD
Cirumflex Artery Cx
Right Coronary Artery RCA
Proximal Prox.
Middle Mid.
Distal DisL
First Diagonal D1
Second Diagonal D2
First Obtuse Marginal OM1
Second Obtuse Marginal OM2
Right Ventricular Branch RVBr.
Posterior Descending Artery PDA
Table 2.2: Factors investigated for their role in the development of TxCAD.
Pattern of early change in vessel diameter.___________________
Donor and recipient age and sex.__________________________
Vessel tone___________________________________________
Domino and non-domino transplants._______________________
Cause of donor death.___________________________________
Total ischaemic time.___________________________________
RATG induction of immunosuppression.____________________
Prednisolone treatment during the first year.__________________
Conventional cardiovascular risk factors.____________________
Immunological factors, including acute rejection, and antivimentin
antibodies.____________________________________________
Pre-transplant CMV serology and post-transplant CMV count.
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2.1.2 Main outcome measure.
The main outcome measure was mean lumen diameter loss (MLDL) in the large and 
small sized vessels as determined by QCA.
2.2 Study population.
The study population consisted of patients who have undergone heart transplantation at 
Harefield Hospital between September 1994 and June 1999, and were consented for the 
angiographic follow-up. In total, 121 patients were enrolled in this study. These 
patients were followed up for a period ranging from one to five years. The study was 
approved by the Hillingdon Ethics Committee, which at the time of the start of the 
study was responsible for ethical approval of our research studies.
One hundred and three patients were males (85%) and 18 were females (15%). The 
mean age was 48.5±10 years. Out of 121 patients, 114 (94%) were Caucasians, 5 (4%) 
were Asians, 1 (1%) was Afro-Caribbean and 1 (1%) was Middle Eastern. The cause of 
the heart failure, which necessitated transplantation, was ischaemic in 74 (61%) 
patients, idiopathic dilated cardiomyopathy in 29 (24%), congenital in 6 (5%) and other 
causes in 12 (10%) patients. The mean organ ischaemia time was 155±57 minutes.
23  Angiographic method.
Quantitative coronary angiography (QCA) was performed initially within the first 
month after transplant, and subsequently at 1-year, 3-years and 5-years. The 
angiograms were performed through the femoral approach by the standard
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percutaneous Judkins technique237, 238. To allow for the quantitative analysis of the 
angiograms, specific modifications of the angiographic technique were made:
1- 8-Fr Cordis catheters239 were used in all the angiographic procedures, in order 
to standardise QCA calibration for analysis.
2- 200 pg of intracoronary glycerine trinitrate (GTN)240 was injected into the LCA 
after an initial angiographic run in the shallow RAO projection, and a repeat run 
taken 30 seconds after the GTN injection in the same projection, to assess the 
vessel tone. Subsequently, different runs were taken of the LCA after contrast 
injection. All runs for the RCA were taken 30 seconds after 200pg of GTN was 
injected into it.
3- Standardised projections were taken for the left and right coronary arteries 
following the 200pg GTN injection into these vessels. The X-ray tube and the 
image intensifier were moved to different positions, to acquire cinefilm runs of 
these vessels in different projections when contrast was injected. These 
positions were documented to establish the exact angle, table height, image 
intensifier and magnification used, so that the exact positions and projections 
were used in the following years for each particular patient. In some cases a 
repeat of the angiogram obtained in the first projection was obtained following 
the other angiographic projections to help assess the reproducibility of the 
method.
4- The same catheterisation laboratory was used for all the angiographic 
procedures (figure 2.1). All angiograms were recorded on cine films.
Right heart catheterisation was performed through the femoral vein using the 
standardised Seldinger approach237. A 7 Fr multipurpose catheter was used to document
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the right-sided cardiac pressures241, and the cardiac output calculated using the Fick 
principle242.
Figure 2.1: The cardiac catheter laboratory.
2.4 QCA analysis.
2.4.1 Instruments.
The Cardiovascular Measurement System (QCA-CMS) workstation (figure 2.2) 
distributed by MEDIS Medical Imaging Systems BV, Nuenen-the Netherlands, was 
used for analysis o f the cine films. This has been shown to provide more precise 
measurements in quantitative analysis o f coronary lumen diameters than other 
systems243. The basic hardware configuration consisted of:
1- A Pentium Processor.
2- High quality frame grabber for digitisation o f images.
3- High-resolution monitor.
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4- A laser printer.
5- A mouse.
This system was used in conjunction with a high quality cine-projector (CAP-35E) with 
built-in optical zoom lens.
Figure 2.2: QCA “Cardiovascular Measurement System” workstation.
QCA analysis software, V 2.3S, was used. This system provided an automated 
calibration procedure based on the angiographic catheter and computer assisted edge 
detection to allow measurement o f the lumen diameter o f individual coronary segments.
2.4.2 Analysis method.
2.4.2.1 Calibration.
Each film was put onto the cine-projector. An initial reference frame was marked and 
the counter zeroed. The cine was then forwarded to the desired view for analysis and 
the system calibrated choosing a frame that showed the angiographic catheter filled
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with contrast. The frame had to show a non-tapering segment of the catheter in a stable 
position. If there was any doubt about the accuracy of the detected catheter contour, the 
procedure was repeated. The zoom and brightness were adjusted such as the calibration 
factor (CF) was around 0.09 mm/pixel prior to making the measurements in adherence 
with the operational procedure recommended by the manufacturer. For a particular 
view, when comparing different cines of the same patient, the variability of the CF was 
always kept to be less than 0.005244.
2A.2.2 Measurement of coronary lumen.
A frame that showed clearly the segment to be studied with its start and end points 
(bifurcation points) was selected for the segment analysis. The frame number, CF, 
brightness and zoom were documented. The second or third cardiac cycle following 
contrast injection was usually chosen, making sure that the segment of interest was 
fully opacified244. The frame had to be at end-diastole or in the diastasis period so that 
the effect of motion blur was minimal.
The analysis of each coronary segment was done in a standardized manner according to 
the guidelines of the Bypass Angioplasty Revascularization Investigation (BARI) 
investigators. These guidelines were approved by the American College of Cardiology 
and American Heart Association for analysis of coronary angiograms245. BARI 
investigators used angiographic definitions used in formats of prior revascularisation 
trials, particularly the Coronary Artery Surgery Study (CASS). These guidelines 
endorse the system developed by the BARI investigators and published by Alderman 
and Stadius in Coronary Artery Disease246. This system provided for nomenclature of
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the most frequently encountered coronary arterial segments as shown in figure 2.3. 
Table 2.1 shows the abbreviations of the main arteries and their measured segments.
Figure 2.3: The coronary artery map used by the BARI investigators.
27 —  26 25'*'"
Reproduced with permission from Alderman et al246.
The arterial segments measured in our analysis are as follows:
1- LAD segments; proximal (segment 12), middle (segment 13 between segments 
15 and 16) and distal (segment 14).
2- LAD branch vessels; first (segment 15) and second (segment 16) diagonal.
3- Circumflex; proximal (segment 18) and distal (segment 23 / 19a).
4- Circumflex branch vessels; first (segment 20) and second (segment 21) obtuse 
marginal vessels.
5- RCA segments; proximal (segment 1), middle (segment 2) and distal (segment 
3) segments.
6- RCA branch vessels; right ventricular branch (segment 10) and posterior 
descending artery (segment 4).
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These segments were measured in all the cases, except when there was an anatomical 
variation, overlap of vessel segment in all the views or poor opacification of the 
segment by contrast. The bifurcation points were manually set inside the corresponding 
bifurcations. When these points were approved, the automated edge detection algorithm 
of the CMS outlined the luminal borders of that segment. Whenever possible, no 
manual corrections were made; the exception to that was when a branch occurred 
within the measured segment, in which case the branch point was edited by visual 
inspection. When the outlined segment was approved, the computer automatically 
calculated the mean lumen diameter (MLD) of the segment, which was documented for 
our study.
When the view was changed to assess a different vessel, or a different segment of the 
same vessel, the calibration process was repeated. In analysing yearly consecutive cines 
of the same patient, exactly the same projection for each segment was used on each 
occasion, with the same magnification, view and skew, together with the same table 
and image intensifier height. Figures 2.4 and 2.5 show the images from the same 
patient at baseline and at Year-1.
Figure 2.4: An example of QCA analysis of the proximal LAD at baseline.
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Figure 2.5: QCA analysis of the proximal LAD at Year-1 in the same patient 
analysed in figure 2.4.
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2.5 Intracoronary ultrasound.
2.5.1 Ultrasound catheters.
The equipment used to perform intracoronary ultrasound (ICUS) consisted of 2 major 
components, a catheter incorporating a miniaturized ultrasound transducer and a 
console containing the electronics necessary to reconstruct the image94. Transducers 
with ultrasound frequencies of 30MHz were used; these had a wavelength of 50pm, and 
permitted an axial resolution of approximately 100pm, and lateral resolution of 
250pm94. The transducers used were of the mechanical type, which used a drive cable 
running the length of the catheter that rotates a single piezoelectric transducer element 
mounted near the distal catheter tip.
The outer diameters of the catheters used varied from 3Fr to 4Fr. Catheters with two 
different delivery devices had been used. In the first (Sonicath catheter, Boston
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Scientific Cooperation, Watertown MA, USA), the distal catheter contained a short 
monorail segment (5 to 10mm in length). With the transducer positioned just proximal 
to the monorail portion of the catheter, the vessel was selectively cannulated with the 
guide-wire, and the device was then advanced and retracted to interrogate the vessel. 
The second type (Spycath, Boston Scientific Cooperation), a sheath was advanced to a 
distal location in the artery. The transducer was then advanced within the sheath to 
image the vessel. Both devices with or without the sheath, worked well, although with 
the catheter without a sheath, some difficulty was experienced tracking tortuous 
vessels.
2.5.2 Examination technique.
Standard interventional techniques for intracoronary catheter delivery were used for 
intraluminal coronary ultrasound examination. After the QCA had been performed, 
intravenous heparin (to maintain activated clotting time between 200 to 250 seconds) 
was administered before imaging. An 8 Fr guiding catheter was used to subselectively 
cannulate the vessel of interest to be studied using a steerable 0.014-in angioplasty 
guidewire. A stable guiding catheter position with good support was essential, because 
the ultrasound catheters have less trackability and larger profile than modem balloon 
angioplasty catheters. The imaging catheter was carefully advanced and positioned at 
an obvious landmark on the vessel, usually a branching point as shown in figure 2.6. 
The imaging catheter was then withdrawn slowly using a motorized pullback device at 
a constant speed (between 0.25 and 1 mm/s). The images were recorded on a super 
VHS tape for subsequent quantitative analysis.
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Figure 2.6: Tip of the ICUS catheter positioned at a landmark, the OM1 on this 
patient
2.5.3 Intracoronary ultrasound data analysis.
The recorded super VHS images were digitised using a Pinnacle Systems Studio DC 10 
Plus capture card. This allowed image capture at a resolution of 720 x 540 Pixel in 8 
bits matrix at a rate of 25 frames per second. The images were stored in a computer 
hard disc.
There are two general methods of using ICUS to quantitate TxCAD247. In the first, 
measurements can be taken at several selected sites in a coronary artery and followed 
up serially over time. The site may be chosen because of certain TxCAD 
characteristics, such as the presence of heavy calcium or severe narrowing; 
alternatively, it can be any site that is easily known and reproduced in subsequent 
studies (usually close to branch points). In the second method, the average TxCAD 
severity can be determined and followed up serially. The average severity of intimal
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thickening, lumen diameter, and intimal volume density can be accurately determined 
with the use of the principles of morphometry. With this method, the sites are chosen 
randomly without regard to severity of the disease or proximity to vessel branches. As 
TxCAD is a diffuse disease morphometric analysis was used. Morphometry is a 
mathematical science in which three-dimensional information can be obtained from 
data collected in one or two dimensions. This principle was demonstrated in 1847 by 
the French geologist Delesse, and states that the ratio of two cross sectional surface
94ftareas are equal to the ratio of the two corresponding volumes . A similar relationship 
is true for surface densities (the ratio of surface area to volume). In the case of coronary 
arteries, the volume density of the intima (volume of intima/volume of intima + lumen) 
is equal to the intimal index (cross-sectional area of intima/cross-sectional area of 
intima + lumen).
In the artery studied, during pullback, 10 frames at equal intervals of time, were
A4A AfA
obtained for morphometric analysis. Johnson et al ’ have shown that no more than 
10 random sites on the coronary segments studied are necessary to precisely determine 
the mean severity of TxCAD. The frames were taken at end-diastole from the digitised 
cardiac cycles, at a time of maximal dilatation of the vessel. The frames were then 
imported for analysis by the Scion Image Programme (SIP) version 4.02, the PC 
version of NIH Image, distributed by Scion Corporation. The cross hairs recorded with 
the ICUS images were used for calibration. The following parameters of quantitative 
coronary ultrasound (QCU) were derived94, and their abbreviations are shown in table 
2.3:
1- Lumen cross-sectional area (LCSA): the lumen-vessel wall interface was 
traced by planimetry, and the area was automatically calculated by the SIP.
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When a three-layer appearance o f the vessel was present, but the intima 
consisted only o f  a thin line (< 100pm), this line was considered the lumen 
boundary; this is shown as the inner line in figure 2.7. In the absence o f a three 
layer appearance, the innermost interface (presumably the adventitia) was 
considered the border.
2- Total Area (TA), also known as the external elastic membrane cross sectional 
area (EEM-CSA): the leading edge o f the adventitia was traced by planimetry, 
when the three-layer appearance was present. This is shown as the area within 
the outer red boundry in figure 2.7. When the three-layer appearance was 
absent, the TA was considered to be equal to the LCSA.
Figure 2.7: LCSA (area within inner white boundary) and TA (area within outer 
red boundary) in a vessel with the three layer appearance, with the IA being the
area between the two boundaries.
IA f LCSA
I
\\
3- Intimal area (IA), also referred to as the intimal cross-sectional area (IT-CSA): 
this was used to describe the severity o f TxCAD when the three-layer
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appearance was present, and was calculated from the difference between TA 
(EEM-CSA) and the LCSA. This method includes the media in the 
measurement of the intima (or plaque) 94 as the media is not always 
distinguished as a clear layer because its thickness is slightly greater than the 
axial resolution of the imaging systems. When the three-layer appearance was 
absent, the IA was considered to be zero.
4- Intimal Index (II): this was calculated by dividing the IA by TA. It has been 
used by some investigators to describe the severity of the lesion. It is a more 
sensitive measurement of disease severity than IA, which has a disadvantage 
that it is directly proportional to the TA.
5- Remodelling Index (RI): this was calculated by dividing the change in total 
area by the change in intimal area (RI=ATA/ALA) 251. The coronary segments 
were divided into the following categories:
i-RI >1, the ATA>AIA, reflecting adequate compensation or 
overcompensation.
ii-RI >0 and <1, ATA < AIA, reflecting partial compensation.
iii-RI<0, no increase in TA, representing no compensation or even a 
decrease in TA, reflecting shrinkage o f the vessel.
Table 2.3: Table of abbreviations of the Quantitative Coronary Ultrasound 
parameters and their meaning.
Abbreviation Meaning
LCSA Lumen cross sectional area.
TA Total area
EEM-CSA External elastic membrane cross sectional area
IA Intimal area
IT-CSA Intimal cross sectional area
n Intimal index
RI Remodelling index
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2.6 Haemodynamic measurements.
Right and left heart pressure data were obtained during angiography using fluid filled 
catheters. These were recorded on hard copies and interpreted in conjunction with the 
QCA data. The right atrial, pulmonary artery, pulmonary wedge and left ventricular end 
diastolic pressures data were documented, and the data obtained by the standard 
methods252.
2.7 CMV antigen measurement.
Over the past few years, the direct detection of pp65 antigen, which is a matrix protein 
between the viral capsid and envelope, in blood leucocytes has been successfully 
applied to permit early diagnosis of CMV infection253*255. The method allows early 
diagnosis, usually before the onset of clinical symptoms, and is used by our 
immunology laboratory. The pp65 antigen is detected in cytospin preparations made 
from blood leucocytes using immunological methods. It is found primarily in the cell 
nucleus of granulocytes. Sensitivity and specificity is approximately 90%. The assay is 
usually completed 6hrs from receipt of sample of 7ml of heparinised blood or blood in 
EDTA. The results were reported as the number of positive cells per 200,000 white 
cells.
2.8 Analysis of the immunological parameters.
2.8.1 Cardiac biopsies.
Right ventricular (RV) cardiac biopsies were taken for histological evidence of 
rejection starting from the first week post-transplant. They were done at regular time 
schedule during the first year, according to the Harefield Hospital protocol. This 
protocol requests that regular biopsies are to be taken weekly for the first six weeks
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post transplant, then fortnightly for the subsequent 6 weeks, then monthly for the 
subsequent 3 months, then every 2 months for the subsequent 6 months. Additional 
biopsies were done during the first year, regardless o f the protocol, if  there was a 
clinical indication or to monitor the response o f a rejection episode to 
immunosuppressive treatment. After the first year, cardiac biopsies were only done if  
there was a clinical indication.
The procedure was normally performed through the right internal jugular (RIJ) vein 
using the percutaneous transvenous approach256 using Yacoub’s bioptome (figure 2.8). 
At least four good myocardial biopsies were taken from each patient in each biopsy 
session and the specimens put into a formalin filled pot for subsequent histological 
analysis.
Figure 2.8: Yacoub’s bioptome.
Endomyocardial biopsies were then fixed in 10% formol saline and processed 
routinely. Histopathological changes o f rejection are graded according to the 
International Society for Heart and Lung Transplantation Working Formulation for 
Heart Rejection195.
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2.8.2 HLA typing.
HLA typing was performed by PCR-SSP (Sequence Specific Primers) developed by 
Olerup et al257 using 20 ml of blood anticoagulated with sodium citrate which was 
collected from recipients and/ or donors. The kits used were purchased from Protrans 
(Heidelberg, Germany) and incorporated primers for the typing of HLA-A, -B, -Cw, - 
DR and -DQ alleles. This method incorporated the polymerase chain reaction and 
sequence specific primers (PCR-SSP) for the rapid determination of HLA alleles and 
was used for HLA typing of both the recipient and donor. The oligonucleotide primers 
were designed to obtain amplification of specific alleles. The discrimination between 
alleles took place during the in vitro amplification. This reduced the post-amplification
. . 257processmg to a minimum .
2.8.3 HLA mismatching.
An HLA mismatch is defined as the presence of a particular HLA A, B or DR 
specificity on the donor HLA phenotype that is not present on the recipient HLA type. 
The minimum HLA mismatch for a given locus is 0 with a maximum mismatch of 2 
disparate HLA specificities.
2.8.4 Panel reactive antibody screening.
Panel reactive lymphocytotoxic antibody status was determined using an HLA class I 
(A, B, C) and class II (DR and DQ) typed panel of lymphocytes from 40 healthy 
volunteers and 10 patients with chronic lymphocytic leukaemia in a modified NIH 
microcytotoxicity technique258. The panel was selected to include the majority of class 
I and class II specificities. All sera were screened by a modified microcytotoxicity 
technique. Blood samples were collected from patients into plain tubes.
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2.8.5 Cross-matching.
Donor spleen samples approximately 1.5 cm cubed in size were used for cross- 
matching. These were pushed through a metal sieve into RPMI medium to form a 
suspension. This suspension was then treated with an equal volume of Dextran 110 
solution (6% in 0.9% NaCl) and a small amount of carbonyl iron (Sigma, Poole, UK) 
for 30 minutes at 37°C with occasional mixing. T and B lymphocytes were then 
purified and were then incubated with recipient sera for 60 mins at 22°C followed by a 
further 60 minutes after the addition of 5|il rabbit complement (Cedarlane, Ontario, 
Canada). Cell viability was assessed after staining with a mixture of ethidium bromide 
and acridine orange using a fluorescent microscope (Carl Zeiss, Welwyn Garden City, 
UK) with a X20 objective lens. A positive reaction was defined as greater than 10% 
killing of donor cells above background levels of cell death seen in the wells of donor 
spleen cells incubated with a negative control serum (Pooled Human Male AB serum).
2.8.6 Antivimentin antibodies ELISA.
Recombinant human Vimentin (Cymbus, Chandlers Ford, UK) was diluted to lOpg/ml 
in PBS and lOOpl coated overnight at 4°C onto 96 well polystyrene plates to give a 
concentration of 1 pg/well. After washing the wells of the plate five times with 200pl 
of PBS-Tween, 100 pi of serum at 1/50 was added and left for 1 hour at room 
temperature, and subsequently washed. lOOpl of a monoclonal rabbit anti-human IgM- 
HRP (horse radish peroxidase) conjugated antibody was added for a further 45 minutes. 
After a further 5 washes with PBS-Tween, the presence of antivimentin IgM antibody 
was determined colorimetrically using tetramethyl benzidine (TMB) as a substrate. The 
colour reaction was allowed to develop for 4 minutes before the addition of 1M 
sulphuric acid to stop the reaction. The absorbance was measured at 450 nm with a
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reference at 620 nm in the Labsystems Multiskan plate reader. Using a standard curve 
generated from the dilutions of a well characterised positive serum which was tested in 
each assay and expressed in titre units, the relative amount of antivimentin antibodies 
present in the test sera was determined259.
2.9 Statistical analysis.
Standard statistical methods for medical research were adopted for data analysis. The 
data were originally stored on Microsoft Excel spreadsheets and transferred onto the 
Minitab software package (Release 12; Minitab Inc., State College, Pennsylvania) for 
statistical analysis. Continuous variables were expressed as mean ± standard deviation 
and categorical variables as proportions. The Normality of continuous variables was 
checked using a Normal probability plot and assessed using the Anderson-Darling test. 
Non-parametric tests or transformations were used when variables did not appear to be 
normally distributed. Table 2.4 (below) shows the continuous and categorical clinical 
variables that were analysed.
Table 2.4: The continuous and categorical clinical variables that were analysed.
Continuous Variables Categorical Variables
Mean lumen diameter Gender (males versus females)
Age Race (Caucasians versus non-Caucasians)
Blood pressure variables Donor and recipient CMV immunological 
status (positive versus negative)
Lipid profiles Pre-transplant Lymphocytic crossmatch 
(positive versus negative)
Total ischaemic time Pre-transplant PRA (positive versus 
negative).
Haemodynamic variables Acute rejection score
ECG summation voltage Number of mismatches
CMV count
Antivimentin antibodies titre
ICUS variables
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Initially, univariate analysis was performed on all our data for the LV and SV groups. 
Subsequently, multivariate analysis was performed to derive the multivariate models 
for the respective groups.
2.9.1 Univariate analysis.
2.9.1.1 Demographics.
The age was expressed as mean ± SD, and gender and race as percentages.
2.9.1.2 Change in segment diameter using QCA.
The decrease in individual segment diameter from baseline was calculated both in 
terms of absolute and proportional (percentage) mean lumen diameter loss (MLDL). 
The percentage decrease from baseline to, for example, Year-1 was calculated as 100 x 
(“Year-0” value -  “Year-1” value)/ “Year-0” value.
Subsequently, the vessels were grouped into LV and SV and the MLDL for each group 
was calculated for each patient. The significance of the difference in MLDL between 
the LV and SV was evaluated using a paired t-test, pairing by patient
When more than two group means were compared, analysis of variance (ANOVA) was 
used.
2.9.13 Increase in vessel segment diameter after GTN.
The paired t-test was used to compare the increase in mean lumen diameter (MLD) 
between the LV and SV, after intracoronary GTN was given.
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2.9.1.4 Change in ICUS measurements.
Again, paired t-test was used to assess the significance of change in intimal area, lumen 
cross-sectional area, total area and intimal index between successive measurements.
2.9.1.5 Change in vessel diameter related to clinical parameters.
The correlations of donor and recipient ages and subsequent MLDL were evaluated and 
their significance evaluated using a t-test. The two-sample t-test was used to assess 
whether MLDL differed between the sexes. ANOVA was used to assess whether 
MLDL differed between the races. To test for the significance of the correlation 
between the blood pressure and lipid profile parameters and MLDL, the t-test was used. 
ANOVA was used to assess whether donor cause of death was associated with different 
mean lumen diameter loss. To test for a difference in MLDL between domino and non­
domino donors, the two-sample t-test was used and the same test was used for the 
RATG induction therapy and first year prednisolone treatment. The significance of the 
relationship between ischaemic time, glucose and creatinine levels and the MLDL were 
investigated using the t-test.
2.9.1.6 Endomyocardial biopsies.
A biopsy score was initially derived for each patient. The relation of the biopsy score 
and MLDL was tested using the t-test. Using the same test, the relation of the MLDL 
and summation ECG voltage and the echocardiographic fractional shortening/ ejection 
fraction were tested.
I l l
2.9.1.7 Cytomegalovirus count.
The CMV count was not normally distributed as tested by the Anderson-Darling test. 
The Mann-Whitney test was used to test for any significant relation between the count 
and pre-transplant CMV serological status. In order to obtain a more “normal” 
distribution, the transformation ln(l + CMV count) was used; the relation of this 
transformed variable and MLDL was tested using a t-test.
2.9.1.8 Immunological factors.
Patients were grouped by their total number of mismatches; the MLDL for the different 
groups were compared using the ANOVA test. The significance of the pre-transplant 
lymphocytic crossmatch, Pre-transplant PRA and antivimentin antibody titre (positive 
or negative) to MLDL was tested using the two-sample t-test.
2.9.1.9 Haemodynamic data.
The correlation of the different haemodynamic data and MLDL was tested using the t- 
test.
2.9.2 Multivariate analysis.
After performiong univariate analysis on the relationship between the different 
potential predictor variables and MLDL, all variables with p-value < 0.2 and more than 
80% of values present (i.e. not missing) were used. The multivariate model was 
obtained using standard linear regression with MLDL as the response variable, starting 
with the candidate regressor variables and eliminating non-significant variables using 
the backward elimination procedure, using a nominal 5% significance level.
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CHAPTER 3
QCA RELIABILITY & VALIDATION.
3.1. Terminology and previous studies.
3.2. Method.
3.3. Reliability.
3.4. Validation of QCA data using intracoronary ultrasound.
3.5. Discussion.
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To determine the reliability and validity of the QCA measurements of coronary lumen 
diameter obtained in our laboratory, we carried out a preliminary study comparing 
QCA with ICUS and also examined the variation between repeated QCA measurements 
within the same subject.
3.1 Terminology and previous studies.
Four important terms used in mensuration260’ 261 are defined in table 3.1. Validation 
refers to the process of establishing that a technique provides a suitable method for 
measuring the quantity of interest, whilst accuracy is the determination of how far the 
measured value, derived from repeated observations, deviates from the ‘true value’ 
obtained from a reference method i.e. the size of any ‘systematic error’ in the 
measurement. The reliability of a measurement determines how far a single 
observation may be expected to deviate from the true value and this is often expressed 
as the precision of the measurement or the 95% confidence interval for repeated 
measurements; these are derived from repeated observations of the same object and are 
a measure of the size of the ‘random error’. The effect of a random measurement error 
may be reduced by making repeated observations (or by increasing the sample size 
from a study population) where systematic errors cannot be eliminated in this way.
In practice, accuracy is either determined from repeated measurements made with the 
same apparatus under different conditions or by comparison with another (reference) 
measurement system. In the first case, it is an indicator of how robust the results of the 
measurement process are against changes in the conditions under which the 
observations were made; in the second case, accuracy is an assessment of the validity 
of the measurement in relation to the reference method.
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Table 3.1: Terminology.
Term Definition
Validation Determining whether the instrument is actually measuring what it purports to 
be measuring260.
Accuracy The mean, signed, difference between the true and measured values or between 
the values from measurements repeated under different conditions261.
Reliability The test that demonstrates whether the instrument will produce the same result 
when administered repeatedly to an individual260.
Precision The standard deviation of the differences between the true and measured 
values or between the values from repeated measurements261.
Reiber et al assessed the accuracy and precision of measurements of coronary lumen 
diameter derived from computer-assisted quantitation of 35 mm coronary 
cineangiograms. A computer-assisted technique was developed to assess absolute 
coronary arterial dimensions to reduce the subjective aspect of vessel edge detection. 
The boundaries of optically magnified and video-digitised coronary segments and the 
intracardiac catheter were defined by automated edge-detection techniques. The 
accuracy and precision of the edge detection procedure as assessed from cinefilms of 
contrast-filled acrylate (Perspex) models (phantoms) were -30 pm and 90 pm 
respectively. Short-, medium-, and long-term variability measurements were assessed 
from repeated coronary angiographic examinations performed 5 min (with unchanged 
geometry of X-ray system and patient position), 1 hr (the X-ray system and geometry 
and patient position were changed between the acquisitions), and 90 days apart, 
respectively. For all studies the mean differences in absolute diameters were less than 
0.13 mm. The variability in obstruction-diameter ranged from 0.22 mm for the best 
controlled study (medium-term) to 0.36 mm for the least-controlled study (long-term); 
the variability in reference-diameter ranged from 0.15 to 0.66 mm, respectively.
Lowry et al compared lumen diameter measurements obtained from transplanted 
hearts by QCA to that of ICUS. Twenty-five patients underwent both procedures
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following cardiac transplantation (20 < 1 year, 5 > 1 year). Lumen diameter and area 
measurements of proximal coronary artery segments were compared using both 
techniques. Overall, lumen diameter and area measurements correlated closely between 
the two procedures, both for the early and late follow-up patients.
3.2 Method.
In order to assess the variation of our QCA results, a repeat angiogram of the first 
angiographic projection in the RAO projection was taken at the end of the left coronary 
artery catheterisation, and the proximal segments of the LAD and Cx measured 
quantitatively. This was done as follows. One minute after intracoronary GTN (200jig) 
was administered as described in chapter 2, a cineangiographic aquisition was obtained. 
The X-Ray settings (angle, skew, table height and image intensifier height) were all 
documented. The X-ray system was then adjusted to acquire further angiograms of the 
left coronary artery. At the end of the sequence of left coronary views, the X-ray 
system was positioned in the same settings of the initial angiogram and a repeat 
angiogram was then obtained. Subsequently, the proximal segments of the LAD and Cx 
in these repeat angiograms were analysed quantitatively to determine the variation in 
measurements obtained under these conditions.
3.3 Reliability.
The diameter of 99 proximal LAD segments (LAD1) with their corresponding proximal 
segments from the repeat angiogram (LAD2) was measured quantitatively. The 
corresponding proximal segments of the Cx artery in the initial (Cxi) and repeat (Cx2) 
angiograms were also measured; however due to technical factors such as poor 
opacification of the vessel and wire overlap, 5 proximal Cx segments could not be
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measured and we were able to measure 94 pairs of segments. Table 3.2 shows the mean 
lumen diameter (MLD) of the segments and their standard deviation, and Table 3.3 
shows the differences between the first and repeat measurements together with the 
means for the total LAD and Cx segments. Figure 3.1 and Figure 3.2 show the scatter 
plot of the measured LAD and Cx segments respectively. The repeat measurements 
were very closely related to the initial ones and the accuracy (mean difference) between 
the initial and repeat measurements was 19pm (p<0.004) for the LAD and 
10pm(p=0.24) for the circumflex artery.
Table 3.2: Mean diameter of the segments and their standard deviation.
Segment Number 
of segments
Mean lumen diameter 
(mm)
Standard deviation 
(mm)
LAD1 99 4.441 0.687
LAD2 99 4.461 0.688
Cxi 94 3.735 0.882
Cx2 94 3.745 0.879
Table 33: Difference between initial and repeat measurements of the mean lumen 
diameters of the LAD and Cx proximal coronary segments.
Variable Number of 
segments
Mean lumen diameter 
in mm
Standard deviation 
in mm
LAD Difference 99 -0.019 (accuracy) 0.065 (precision)
LAD Mean 99 4.451 0.687
Cx Difference 94 -0.010 (accuracy) 0.082 (precision)
Cx Mean 94 3.740 0.880
117
Figure 3.1: Scatter plot of LAD replicate 1 against replicate 2.
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Figure 3.2: Scatter plot of Cx replicate 1 against replicate 2.
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We used the probability plot to assess whether the difference between the initial and 
repeat measurements of the LAD and Cx arteries follow a normal distribution. The 
probability plot is a graphic technique for assessing whether or not a data set follows a 
given distribution such as the normal distribution264. The data were plotted against a 
theoretical normal distribution in such a way that the points should form or 
approximate a straight line. Deviation from the line indicates deviation from
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normality264. Figures 3.3 and 3.4 show that the LAD and Cx difference between the 
initial and repeat measurements were normally distributed.
Figure 3.3: Difference between LAD replicates.
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Figure 3.4: Difference between Cx replicates.
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We used the repeated measurements to assess the degree of variation that might be 
expected to occur between a pair of QCA measurements of the same vessel segment 
obtained from a pair of cineangiograms using the same projection in the same patient. 
If the variance of the measurement is o2, the variance of the difference between a pair
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of replicate measurements will be 2 a2 and hence an estimate of &  is given by half the 
sample variance of the differences265. So, for the LAD, our estimate of &  was 0.0652/2 
(see table 3.3) and the estimate of the standard deviation was 0.065/V2 i.e. 0.046. For a 
“normal distribution”, there is approximately a 95% chance of the second of a pair of 
measurements falling within 2 standard deviations of first. So, there was 95% 
probability range for a repeated LAD measurement lying within approximately ± 
0.10mm of the first measurement.
Similarly, for the circumflex, the sample variance of the 94 differences was 0.0822 and 
standard deviation = 0.082/V2 i.e. 0.058. So, there was 95% probability range for a 
repeated Cx measurement lying within approximately ±0.12mm of the first 
measurement.
3.4 Validation of QCA data using intracoronary ultrasound.
We assessed the validity of our QCA data by comparing it to data obtained from ICUS 
in 18 transplant patients. Direct comparisons between the 2 techniques are limited by 
several factors. First, QCA measures the lumen diameter from a single angiographic 
projection of the vessel segment. Lumen area can only be calculated by assuming the 
vessel cross sectional to be approximately circular so the area is approximately IId2/4. 
This assumption appears justified in transplant patients without gross coronary disease. 
Second QCA cannot measure an absolute vessel diameter because of the magnification 
error created because the catheter located in the aortic root which is used to calibrate 
the image does not lie in the same plane as the vessel segment to be measured. This, 
systematic, magnification error will however be constant when further measurements of
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the same vessel segment are made in the same angiographic projection. We have 
therefore not only compared absolute QCA and ICUS measurements but also compared 
the relative change in vessel diameter over time measured by the two techniques.
Figure 3.5 shows the plot graph of the correlation between the ICUS lumen cross 
sectional area and QCA mean area in all the vessels. There was a strong evidence of a 
correlation between the two, correlation factor being 0.641 (p<0.001).
Figure 3.5: Plot of ICUS lumen cross-sectional area against QCA mean 
lumen area in all vessels in pm2.
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We also tested the hypothesis that the decrease in ICUS lumen cross-sectional area 
from baseline to Year-1 was similar to the decrease in QCA mean area over the same 
period. The plot graph in figure 3.6 shows the result that the measured losses were 
correlated, but can sometimes vary from each other by a large margin. The sign was 
nearly always the same for both measurements i.e. when ICUS indicated a decrease, 
then so did QCA and vice versa.
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Figure 3.6: Plot of the loss in ICUS luminal cross-sectional area against loss
in QCA mean area in um2.
D ecrease in mean area, Year 0 to 1; QCA versus IVUS
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We then assessed whether the relative (percent) diameter change from baseline to Year- 
1 as measured by one modality is reflected by the other. Figure 3.7 shows the scatter 
plot of QCA ratio (QCA at Year-1/QCA at Year-0) to that of the ICUS ratio. The 
dashed line represents the line of identity (QCA-ratio = LCSA-ratio) and the solid line 
represents the regression line obtained from our data. The two ratios were very well 
correlated (R = 0.682). The F-test , which tests whether the standard deviations of 
two populations are equal, showed the p-value to be 0.42 implying no significant 
evidence of a poor fit.
Figure 3.7: plot of QCA-ratio versus LCSA-ratio.
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3.5 Discussion.
We have assessed both the reliability and the validity of QCA measurements in our 
laboratory. The 95% confidence intervals for a single repeat measurement of the LAD 
or Cx were ±0.10mm and ±0.12mm respectively. This was similar to that found by Gao 
et al38 in their QCA study (± 0.1mm). Under ideal circumstances, modem radiographic 
imaging techniques provide spatial resolution of 5 line pairs per millimetre87 (5 black 
lines alternating with 5 white lines at intervals of 100pm). Thus this 100pm error 
reflects the inherent error of the radiographic technique and X-Ray image rather than an 
error in QCA system.
Although only the proximal LAD and Cx coronary artery segments have been studied 
here, we have no reason to suspect that the right coronary artery (RCA) will behave 
differently. The systematic error identified in the repeat LAD measurement is 
unexplained. It is unlikely to reflect a general error in the method since there was no 
significant change in the circumflex measurements. It may reflect some change in LAD 
vessel tone between the first and second measurements. However, its magnitude is 
small in comparison to both the long term changes observed in the rest of this project 
and to the ‘random’ errors observed in the reliability study.
Direct comparison between QCA and ICUS data is flawed because of the magnification 
error inherent in the QCA method. Nevertheless, our QCA data correlated with the 
ICUS data. Changes in vessel lumen diameter with time measured by QCA were very 
closely related to those observed by ICUS. These findings were in agreement with 
those of Lowry et al .
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These observations support the use of QCA in the rest of this study. Although QCA has 
some limitations including the failure to image the vessel wall, we have demonstrated 
that it can provide valid and reliable measurements of vessel lumen diameter. In 
addition QCA has many advantages over ICUS including its less invasive nature, the 
ability to avoid anticoagulation, the ability to study smaller branch vessels, its lower 
cost and the ease with which it can be incorporated into a routine angiographic follow 
up protocol.
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CHAPTER 4
RESULTS I
CHANGE IN VESSEL MEAN LUMEN DIAMETER 
AND TONE WITH TIME.
4.1 Mean lumen segment diameter at each year.
4.2 Loss in the individual segment mean lumen diameter from baseline.
43  Mean lumen diameter of the “large” and “small” vessel segments.
4.4 Change in mean lumen diameter from baseline & between 
successive years in the “large” and “small” vessels.
4.5 Relationship of change in the vessel diameter in the first year to 
long-term changes.
4.6 Increase in vessel segment diameter after GTN with time: 
basic statistics.
4.7 Correlation between increase in segment mean lumen diameter 
after GTN at baseline and subsequent loss of diameter.
4.8 Change in intracoronary ultrasound parameters.
4.8.1 Intimal area, lumen cross-sectional area and the 
total area as determined by ICUS.
4.8.2 Intimal and remodelling indices.
4.9 Discussion.
4.9.1 QCA results.
4.9.2 ICUS results.
4.9.3 Conclusion.
125
This chapter describes the changes that were observed in vessel diameter and tone with 
time. The methods used were described in chapter 2. We also compared changes in the 
larger coronary vessels (LV) with those in the smaller vessels (SV) which, in life, can 
only be studied by QCA because they are usually too small to admit an ICUS probe.
<3 i  A M  |  QA
Although histological studies ’ ’ have emphasised the importance of these SV in 
coronary disease within the transplanted heart, these vessels have not been analysed in 
detail in previous clinical studies. Our study population consisted of 121 patients.
We noticed that the vessels tone, as detected by the difference in vessel diameter before 
and after GTN, was different at the baseline angiogram compared to that at year-1. As
767  768the endothelium plays a critical role in regulating the coronary tone ’ we also 
investigated whether early change in vascular tone was a predictor of later mean lumen 
diameter loss (MLDL).
We also performed ICUS in a subgroup of 22 patients who also underwent QCA 
examination and investigated the changes that occur in the vessel segment areas and 
indices over the first three years after transplant. The implications of the ICUS findings 
for the QCA study will be discussed.
4.1 Mean lumen segment diameter at each year.
The diameter of individual coronary segments at Year-0 (baseline), 1, 3 and 5 are 
shown in table 4.1 A and 4. IB for the LV and SV respectively. The segments measured 
at baseline were slightly less than the number of patients in the study as a few segments 
could not be measured due for technical reasons (e.g. inadequate opacification of the 
segment or problems caused by overlapping structures). With time, there was a 
decrease in the number of patients analysed because of those who had not reached their
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3 or 5 year follow up before the end of the study. There was a continuous loss in the 
diameter of vessel segments with time in both the LV and SV; the small increase in 
mean diameter seen at Year-5 in some segments was probably due to the small sample 
size.
Table 4.1A: Mean lumen diameter of the “large” vessel segments.
Vessel Year n Mean
(mm)
Standard
deviation
Median
Proximal 0 116 4.50 0.72 4.51
LAD 1 117 4.21 0.72 4.28
3 48 4.11 0.67 4.01
5 8 3.81 0.55 3.98
Mid 0 115 3.12 0.74 3.00
LAD 1 110 2.92 0.69 2.80
3 44 2.76 0.67 2.78
5 6 2.73 0.6 2.65
Proximal 0 118 3.86 0.82 3.84
Cx 1 115 3.65 0.76 3.71
3 47 3.68 0.80 3.70
5 8 3.19 1.09 3.06
Proximal 0 118 4.40 0.70 4.41
RCA 1 115 4.14 0.67 4.14
3 46 4.05 0.70 4.13
5 7 4.00 1.08 4.52
Mid 0 116 3.84 0.75 3.90
RCA 1 112 3.67 0.69 3.75
3 46 3.50 0.70 3.54
5 7 3.85 0.54 3.99
For meaning of abbreviations, please see table 2.1
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Table 4.1B: Mean Lumen diameter of the “small” vessel segments.
Vessel Year n Mean
(mm)
Standard
deviation
Median
Distal 0 112 1.77 0.44 1.65
LAD 1 106 1,71 0.41 1.59
3 46 1.62 0.37 1.54
5 7 1.62 0.30 1.56
D1 0 113 1.89 0.50 1.89
1 110 1.83 0.46 1.83
3 43 1.84 0.42 1.84
5 6 1.59 0.49 1.59
D2 0 89 1.46 0.40 1.34
1 87 1.45 0.39 1.41
3 36 1.43 0.39 1.47
5 3 1.51 0.22 1.44
Distal Cx 0 113 1.97 0.75 1.79
1 107 1.91 0.68 1.65
3 45 1.92 0.78 1.76
5 8 1.82 0.39 1.77
OM1 0 109 1.90 0.55 1.82
1 109 1.83 0.49 1.74
3 46 1.77 0.47 1.70
5 6 1.70 0.29 1.76
OM2 0 84 1.43 0.38 1.36
1 82 1.40 0.36 1.35
3 40 1.45 0.30 1.37
5 5 1.58 0.21 1.61
Distal 0 117 3.56 0.87 3.57
RCA 1 113 3.33 0.86 3.44
3 46 3.22 0.86 3.42
5 8 3.02 1.07 3.41
RVBr. 0 113 1.70 0.35 1.76
1 110 1.67 0.35 1.69
3 47 1.57 0.32 1.61
5 8 1.49 0.18 1.42
PDA 0 109 1.78 0.41 1.74
1 105 1.72 0.39 1.70
3 42 1.71 0.35 1.70
5 6 1.83 0.56 1.72
For meaning of abbreviations, please see table 2.1
4.2 Loss 
We then 
3 and 5, 
absolute
in the individual segment mean lumen diameter from baseline.
calculated the loss in segment mean lumen diameter from baseline to Year-1, 
to assess its magnitude and time course. This was expressed both in terms of 
and proportional (percentage) change. The proportional decrease to a
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particular year, e.g. Year-1, was calculated as 100 x (“Year-0” value -  “Year-1” value)/ 
“Year-0” value. Tables A4.1A &B and tables A4.2A&B in the appendix detail the 
decrease in segment diameter from baseline in absolute and proportional terms. There 
was gradual MLDL with time in both the “large” and “small” vessels.
4.3 Mean lumen diameter of the “large” and “small” vessel segments.
Vessel segments were grouped into large (proximal and mid LAD, proximal Cx, and 
proximal and mid RCA) and small vessel (distal LAD, Cx and RCA, D1 and D2, OM1 
and OM2, RV branches and PDA) groups as described in chapter 2. A composite mean 
lumen diameter (MLD) for each category of vessels was then calculated as shown in 
tables 4.2 A&B. There was MLDL with time; the slight increase in diameter at Year-5 
in the small vessels is probably due to the small sample size.
Table 4.2 A: Mean lumen diameter of all the “large” vessel segments.
Year n Mean Standard
deviation
Median
0 120 3.9559 0.4938 3.9430
1 118 3.7307 0.4553 3.7540
3 48 3.6302 0.4645 3.5690
5 9 3.470 0.501 3.710
Table 4.2 B: Mean lumen diameter of all the “small” vessel segments.
Year n Mean Standard
deviation
Median
0 120 2.0076 0.3493 1.9428
1 118 1.9116 0.2697 1.8622
3 48 1.8448 0.2291 1.8344
5 9 1.8612 0.1820 1.8529
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4.4 Change in mean lumen diameter from baseline & between successive years in 
the “large” and “small” vessels.
We calculated the absolute MLDL from baseline, in both the LV and SV separately
(table 4.3) together with the proportional change (table 4.4). The absolute and
proportional MLDL progressed with time.
Table 4.3: Absolute mean lumen diameter loss from baseline in the “large” and
“small” vessels.
Large Vessels Small Vessels
Year n Mean Standard Mean Standard
(mm) deviation (mm) deviation
1 117 0.23 0.27 0.0812 0.1557
3 47 0.42 0.27 0.1615 0.2070
5 8 0.52 0.29 0.271 0.379
Table 4.4: Proportional mean lumen diameter loss from baseline in the “large”
and “small” vessels.
Large Vessels Small Vessels
Year n Mean Standard Mean Standard
(%) deviation (%) deviation
1 117 5.314 7.040 2.633 7.739
3 47 10.135 6.461 5.96 7.55
5 8 13.05 8.03 8.62 10.61
The difference between the MLDL in the LV and SV was then calculated, both in 
absolute and percentage values (table 4.5). Using the t-test, the p-value examined the 
hypothesis that the absolute (or percentage) LV-MLDL equals the absolute (or 
percentage) SV-MLDL. The absolute and proportional MLDL was significantly greater 
in the LV up to Year-3.
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Table 4.5: Absolute and proportional difference between the “large” and “small”
vessel mean lumen diameter loss.
Year n
Absolute difference Proportional difference
Mean
(mm)
Standard
Deviation
p value Mean
(%)
Standard
Deviation
p value
1 117 0.1475 0.2011 <0.0001 2.681 6.389 <0.0001
3 47 0.2619 0.2665 <0.0001 4.18 7.36 0.0003
5 8 0.245 0.388 0.12 4.42 11.90 0.33
We also calculated the LV and SV-MLDL between successive years. The results are 
shown in figure 4.1 and displayed in table A4.3; using the t-test, the p-value signifies 
whether the mean loss equals zero. There was significant MLDL from baseline to 
Year-1 and from Year-1 to Year-3, in both the LV and SV.
Figure 4.1
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Subsequently, we calculated the difference between LV-MLDL and SV-MLDL 
between successive years. The results are shown in figure 4.2, and displayed in table
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A4.4. There was evidence that the LV had significantly more MLDL than the SV from 
baseline to Year-1 and from Year-1 to Year-3.
Figure 4.2
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We investigated whether or not MLDL from baseline to Year-1 was similar to MLDL 
from Year-1 to Year-3 using the matched paired t-test. There was significant evidence 
that the first year MLDL was higher than MLDL from Year-1 to Year-3 for both LV 
and SV (p < 0.0001 for both cases).
4.5 Relationship of change in the vessel diameter in the first year to 
long-term changes.
We investigated whether diameter change in the first year was predictive o f subsequent 
loss o f  diameter. Table A4.5 A and A4.5 B show the summary statistics and a p-value 
for each group, investigating whether the mean long-term decrease was the same for the 
different groups. The long-term MLDL increased with group with greater loss during
132
the first year. Long-term reflects the maximum reductions in diameter from baseline to 
Year-3 or to Year-5. Using ANOVA (which is used to compare the means of more than 
two independent groups) there was significant difference in the long-term (from 
baseline up-to Year-5) MLDL between the groups (pcO.OOl).
Figure 4.3 shows the scatter plot of the long-term percentage MLDL against percent 
MLDL from baseline (Year-0) to Year-1 in the LV. Initial MLDL was a good predictor 
of long-term MLDL. A linear regression of long-term percent decrease gave the 
following formula:
long-term % MLDL = 6.92 + 0.614 x initial % MLDL (pcO.OOl)
For example, if there is no change in the first year, the long-term percent MLDL is 
predicted to be 6.9%; if there is a 10% MLDL in the first year, the long-term mean 
percent MLDL is predicted to be 13%.
Figure 4.3: Long-term “large” vessel percentage mean lumen diameter loss 
against percentage loss from baseline to Year-1
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Figure 4.4 shows the scatter plot of the long-term percent MLDL in the SV against 
percent MLDL from baseline to year-1. Although the relationship was not as strong as 
for the LV, initial MLDL was still a good predictor of long-term MLDL. A linear 
regression of long-term percent MLDL gave the following formula:
long-term % MLDL = 3.51 + 0.874 x initial % MLDL (pcO.OOl)
Figure 4.4: Long-term “small” vessel percentage mean lumen diameter loss 
against percentage loss from baseline to year-1
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4.6 Increase in vessel segment diameter after GTN with time: basic statistics.
We measured the MLD of the proximal LAD and Cx and the OM 1, before and after 
glycerine trinitrate (GTN) was given to assess whether a change in vessel diameter (a 
reflection of vessel tone) was related to long-term TxCAD, as measured by MLDL. 
Figure 4.5A and 4.5B shows QCA of the proximal Cx before and after GTN 
respectively. Tables 4.6 to 4.8 show the basic statistics for the increase in diameter (in 
mm), from before GTN to after GTN, for each year. The p-value tests the hypothesis of 
zero mean increase in diameter, using a paired t-test. There was a significant increase in 
diameter in all segments after GTN administration for all three vessels; however the
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least mean increase occurred at baseline (Year-0), indicating that the resting vessel tone 
was least at that time.
Figure 4.5A: QCA of the proximal Cx before GTN.
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Figure 4.5B: QCA of the proximal Cx after GTN.
Table 4.6: Proximal LAD absolute mean lumen diameter increase after GTN.
Year n Mean lumen 
diameter increase 
(mm)
Standard
deviation
(mm)
p-value
0 55 0.2882 0.2109 <0.0001
1 69 0.4191 0.4653 <0.0001
3 36 0.3625 0.2960 <0.0001
5 5 0.3700 0.0474 0.0001
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Table 4.7: Proximal Cx absolute mean lumen diameter increase after GTN.
Year n Mean lumen 
diameter increase 
(mm)
Standard
deviation
(mm)
p-value
0 59 0.3415 0.2326 <0.0001
1 69 0.5291 0.2232 <0.0001
3 35 0.4666 0.3133 <0.0001
5 6 0.3850 0.2224 0.0082
Table 4.8: OM1 absolute mean lumen diameter increase after GTN.
Year n Mean lumen 
diameter increase 
(mm)
Standard
deviation
p-value
0 58 0.1771 0.1745 <0.0001
1 68 0.2649 0.1412 <0.0001
3 32 0.2447 0.1488 <0.0001
5 4 0.2500 0.1140 0.022
4.7 Correlation between increase in segment mean lumen diameter 
after GTN at baseline and subsequent loss of lumen diameter.
Having demonstrated that the least diameter increase after GTN administration was at
baseline, we then investigated whether there was a correlation between the extent of
this increase in diameter after GTN at the baseline angiogram, and the subsequent
MLDL compared to baseline, thus reflecting TxCAD on the long-term. The
correlations could not be computed for MLDL between Year-0 to Year-5, due to small
data size at Year-5. Table 4.9 shows the results of these correlations and their p values
(for testing zero correlation). The negative correlations indicate that a larger increase in
diameter after GTN is associated with a smaller subsequent MLDL. For the proximal
LAD, there was marginal evidence that a higher diameter increase after GTN was
associated with a smaller MLDL between Year-0 and Year-1; there was little evidence
of a longer-term correlation. For the Proximal Cx, there was marginal evidence that a
higher increase after GTN was associated with a smaller MLDL between Year-0 and
Year-3; there was little evidence of other correlations. For the OM1, and contrary to
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what was found in the proximal LAD, there was evidence that a higher increase after 
GTN was associated with a higher MLDL between Year-0 and Year-1; there was no 
evidence of another correlation. Thus overall, there was no consistent evidence that 
response to GTN at baseline angiogram predicted subsequent change in mean lumen 
diameter.
Table 4.9: Correlation between baseline increase in proximal LAD, proximal Cx, 
and OM1 segment diameter after GTN and the long-term MLDL.
Period of diameter 
loss
Proximal LAD segments Proximal Cx. segments OM1 segments
Correlation p-value Correlation p-value Correlation p-value
Year-0 to Year-1 -0.263 0.052 0.027 0.84 0.323 0.013
Year-0 to Year-3 -0.245 0.50 -0.672 0.047 0.020 0.96
4.8 Change in intracoronary ultrasound parameters.
4.8.1 Intimal area, lumen cross-sectional area and the total area as determined 
by ICUS.
Table 4.10 shows the summary statistics of the intimal area (LA), lumen cross-sectional 
area (LCSA) and the total area (TA) of all the vessels as analysed using morphometric 
analysis (see sections 2.5.2 and 2.5.3). Twenty-two patients were studied in total, and 
the follow up ranged from 1 to 3 years. Note that only 18 patients had follow up at 
Year-1. The LAD was examined in 10 patients, the Cx in 6 and the RCA in another 6 
patients. Changes in these areas are shown in figures 4.6, 4.7 and 4.8 respectively from 
baseline to Year-1. Based on a matched paired t-test, the p-value evaluates the 
hypothesis of zero mean change. There was significant evidence in most cases that 
mean IA increased. The LCSA decreased, but the evidence was not significant, 
probably because of the small sample size. There was little evidence that mean TA 
changed.
Table 4.10: Summary statistics for all the vessels intimal area, 
lumen cross-sectional area and the total area.
Year n Intimal Area Lumen Cross-Sectional Area Total Area
Mean
(mm2)
Standard
deviation
(mm2)
Median
(mm2)
Mean
(mm2)
Standard
deviation
(mm2)
Median
(mm2)
n
Standard
deviation
(mm2)
Median
(mm2)
0 22 0.50 1.18 0.00 14.68 4.46 14.53 15.18 4.34 15.75
1 18 1.43 1.73 0.96 13.15 3.65 13.66 14.58 3.58 15.25
2 8 1.78 1.87 1.61 14.62 3.28 13.46 16.41 3.89 14.95
3 4 4.33 3.94 2.69 14.43 3.68 14.53 18.77 5.99 19.14
Figure 4.6
Increase In the intimal area from 
baseline to Year-1
p=0.12
3 .5 p=0.028
p=0.03p=0.008CM
|  2.5
c  2
S 1.5  
<  «
0 .5
□  All (n= 18) 
■  LAD (n=8)
□  Cx (n=5)
□  RCA (n=5)
V e sse l
Figure 4.7
Decrease in lumen cross-sectional 
area from baseline to Year-1
CM
E
E
c
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
p=0.33 p=0.61
p=0.13
p=0.38
V e ss e l
□  All (n=18) 
■ LAD (n=8)
□  Cx (n=5)
□  RCA (n=5)
138
Figure 4.8
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4.8.2 Intimal and remodeling indices.
Table 4.11 shows the summary statistics o f the intimal index (II) and remodelling index 
(RI); section 2.5.3 shows the definitions o f  II and RI. Change in II is shown in figure 
4.9. The II significantly increased when all the vessels were considered together. 
However, the increase was not always significant when the vessels were considered 
separately, probably because o f the small sample size.
Figure 4.10 shows the frequencies o f the different remodelling patterns over the first 
year and over the three years period. Remodelling indices were classified into the 3 
groups shown in section 2.5.3. During the first year, “overcompensation” and “absence 
o f compensation and vessels shrinkage” occurred with similar frequencies o f  39% and
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“partial compensation” occurred in 22% o f vessels. Overall during the 3 years o f the 
study, “absence o f  compensation and vessel shrinkage” was the commonest, accounting 
for 47% o f the RI, followed by “overcompensation” accounting for 33%, followed by 
“partial compensation” accounting for 20%.
Table 4.11: Summary statistics of the intimal and remodelling indices.
Year n Intimal Index Remodelling Index
Mean Standard
deviation
Median Mean Standard
deviation
Median
0 22 0.0305 0.0698 0.0000 _ _ .
1 18 0.0947 0.1093 0.0550 -1.29 8.64 0.39
2 8 0.0985 0.0917 0.0829 -3.89 13.72 0.11
3 4 0.2038 0.1308 0.1410 -0.265 0.933 -0.496
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Figure 4.10
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4.9 Discussion.
4.9.1 QCA results.
We have shown that there was a progressive MLDL in the LV and SV with time, the 
greatest loss o f diameter occurred in the first year. The absolute and proportional 
MLDL was significantly more in the LV compared with SV in the first 3 years after 
transplant. The degree o f initial MLDL in the first year was quite a good predictor o f 
long-term MLDL.
Our finding that a progressive MLDL occurred during the first 3 years after 
transplantation contrasts with the results reported by Gao et al38; although they found 
that there was significant loss in vessel diameter in the first year post-transplant, they 
did not demonstrate significant loss in mean diameter between the first and second 
year. In addition, they found that the loss in absolute diameter for vessels greater than
2.9 mm (large vessels according to their classification) significantly exceeded diameter 
loss for smaller vessels. However they found that the proportional (percentage) loss did 
not differ for the LV and SV. Their classification o f LV and SV was according to
absolute vessel size, rather that ours of proximal and mid primary coronary arteries 
versus distal primary and secondary coronary vessels, might have contributed to this 
difference. In addition, their study contained only 25 patients which would have 
reduced their ability to detect changes in the coronary lumen diameter.
Our finding that an initial MLDL in the first year was a predictor of long-term MLDL 
is in keeping with another study by Gao et al53. In their study of 139 consecutive 
patients who underwent transplantation, 45 patients progressed from a normal 
qualitative angiogram to the presence of 50% or greater stenosis in one or more major 
vessels within 1 year (fulminant group); 94 did not (indolent group). At 1, 3, and 5 
years after initial detection of TxCAD, 50%, 33%, and 16% of patients in the fulminant 
group and 89%, 70%, and 60% of patients in the indolent group were free of ischemic 
events (p < 0.0001).
An important implication of our finding that an initial MLDL was a predictor of long­
term MLDL is the need for tighter control of cardiovascular risk factors and 
immunosuppression, if a large initial MLDL was detected. In addition, the extent of 
initial MLDL will help determine the frequency of follow-up angiograms.
However, detecting early loss in vessel diameter can only be done by QCA. Most 
clinicians base their findings on qualitative angiography, which is an insensitive means 
of detecting change. Our findings can be applied in routine clinical practice if computer 
assisted techniques are used.
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Vessel tone was low immediately after transplant in both the LV and SV, but it tended 
to increase later. Review of literature showed that a similar study relating endothelium 
independent vasodilation to TxCAD was not undertaken before. Our study showed that 
in general endothelium independent vasodilation by GTN at baseline was not a 
predictor of MLDL on the long term. An exception to this was our finding that higher 
tone at baseline in the OM1 was associated with greater MLDL between baseline and 
Year-1; however, that association disappeared on longer-term follow-up and hence its 
significance is questionable.
Other studies have investigated whether endothelium dependant vasodilation is related 
to subsequent TxCAD. Aptecar et al180 compared the responses of epicardial coronary 
arteries to stepwise intracoronary infusion of acetylcholine (10'8M to 10'5M) in 18 
patients who had undergone transplants within 2 months after surgery, to that in 7 
control subjects. Follow-up at 1 year showed angiographically normal coronary arteries 
in 12 patients and coronary atherosclerosis in 6 patients. In patients who had undergone 
transplants, acetylcholine-induced endothelium-dependent coronary artery dilation was 
similarly impaired early after surgery (within 2 months) in patients with and without 
coronary atherosclerosis at 1-year follow-up. Thus, the response to acetylcholine was 
not a predictor of secondary atherosclerosis. Nitenberg et al174 showed that the 
acetylcholine response is persistently abnormal in transplant recipients compared with 
that in normal control subjects and that this abnormality may not be related simply to 
the presence of atherosclerosis.
However, Davis et al181 studied the endothelium-dependent vasomotion early post­
transplant in 20 patients by serial intracoronary acetylcholine infusion, and the percent
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change in diameter was measured by quantitative angiography. The development of 
arteriosclerosis was studied by use of ICUS in the same 20 patients by quantifying the 
changes in II and maximal intimal thickness of 46 matched coronary segments between 
initial and 1-year follow-up studies. They found that coronary segments with 
endothelial dysfunction demonstrated a significantly greater increase in mean II and 
maximal intimal thickness by 1-year post-transplant compared with segments with 
normal endothelial function.
4.9.2 ICUS results.
In our study, using ICUS, there was significant increase in both the mean IA and the II 
from baseline to Year-1. There was a decrease in the LCSA from baseline to Year-1; 
however the decrease was not significant in our study, possibly due to the small sample 
size. There was no change in the TA. During the 3 years of our study, “absence of 
compensation and vessel shrinkage” was the commonest remodelling pattern, followed 
by “overcompensation”, followed by “partial compensation”.
Our finding that that the mean IA and II increased from baseline to Year-1 is in keeping 
with the finding of Yeung et al31, who in their multicentre ICUS study found that in 92 
patients evaluated at 1 year, there was an increase the IA. This is further confirmed by 
the findings of Rickenbacher et al269 who found that the mean intimal thickness and II 
were significantly higher at Year-1 after transplantation.
We found that the commonest remodelling patterns early after transplantation (Year-1) 
are “overcompensation” and “absence of compensation and vessel shrinkage” (39% 
each), and the latter was the commonest pattern occurring later in transplant (47% at
144
9S1Year-3). This seems to be in keeping with the findings by Lim et al who studied 75 
heart transplant recipients with 151 matched coronary segments for the presence of 
intimal disease progression as detected by serial ICUS examinations 1 to 3 years apart. 
They found that early after cardiac transplantation, a large proportion of the coronary 
segments with progression of intimal thickening had “overcompensation” of the vessel 
wall; however, a substantial number of coronary segments (22%) showed “absence of 
compensation and vessels shrinkage”.
An important study correlating the different ICUS parameters in transplanted hearts 
was undertaken by Tsutsui et al270. In 38 transplant recipients, serial ICUS 
examinations were performed 3.7±2.2 weeks after transplantation and annually 
thereafter for 5 years. They found that most of the intimal thickening occurred during 
the first year after heart transplantation. Changes in the TA showed a biphasic response, 
consisting of early expansion and late constriction. Thus, different mechanisms of 
lumen loss were observed during 2 phases after transplantation: early lumen loss 
primarily caused by intimal thickening and late lumen loss caused by TA area 
constriction. Again, our study seems to be in keeping with these findings, although 
changes in our parameters were not always significant. This is probably due to the 
fewer number of patients in our study, and to the shorter follow-up.
Comparison of our QCA data to the ICUS data was made as mentioned in section 3.4. 
Assuming that the vessel is circular, ICUS lumen cross sectional area and QCA mean 
area were strongly correlated, correlation factor being 0.641 (pcO.OOl). Also the QCA 
ratio (QCA at Year-l/QCA at Year-0) was well correlated to the ICUS ratio (R2= 
0.682). Our ICUS findings, coupled with those of others indicate that progressive loss
145
of MLD observed by QCA may be the result of two processes- intimal thickening or 
vessel shrinkage. It is not possible to differentiate these by QCA.
4.9.3 Conclusion.
In conclusion, TxCAD is predominantly a disease of the large epicardial vessels, rather 
than the small distal and secondary branch vessels in the first year after transplantation. 
This finding contrasts the histological concept that TxCAD is mainly a disease of the 
SV34, 37, 184; although disease in the SV is readily recognizable on histological 
examination, it is the LV that tend to lose their luminal diameter more when assessed 
by QCA. Useful information about TxCAD progression can be gained by assessing the 
change in vessel diameter during the first year. Vessel tone cannot be used solely to 
predict the development of TxCAD. Many different factors affect endothelial 
function ’ , and thus the endothelial response to different agents is not a pure
reflection of atherosclerosis.
The ICUS study provided us with valuable information. Although intimal thickening, 
which is the first manifestation of TxCAD, can reduce lumen diameter, compensatory 
vessel expansion can mask the early phase of the disease. Thus, absence of lumen 
narrowing by angiography does not exclude intimal thickening.
As QCA, unlike ICUS, can be used to measure both LV and SV, and due to the good 
correlation between the QCA and ICUS results, QCA was used to study the factors 
underlying the early development of TxCAD in patients treated in our centre.
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This chapter examines the significance of the different non-immunological factors in 
the development of MLDL in the LV and SV, from baseline to Year-5. Both recipient 
and donor factors are considered. Only univariate analysis is considered in this chapter, 
with multivariate analysis discussed in chapter 7.
5.1 Donor and recipient age and sex.
The mean donor age was 34±12 years. Table A5.1 shows the correlation of donor age 
to the development of LV and SV disease, as measured by the yearly absolute MLDL 
compared to baseline diameters. There was no evidence of any correlation between 
change in vessel size and donor age.
Of 119 donors whose sex was known to us, 47 were women and 72 men (i.e. 39.5% 
and 60.5% respectively). Table 5.1 shows the result of the comparisons between 
female and male patients and the MLDL from baseline to Year-1, 3 and 5, in both the 
LV and SV groups. The p-values test the hypothesis of equal MLDL for men and 
women (two-sample t-test). In the LV group, there was evidence of greater MLDL for 
hearts from male donors between Year-0 and 1. In the SV group, there was significant 
evidence of a greater MLDL for men during the same time period, but otherwise the 
evidence was less compelling than for the LV.
Table 5.1: Comparison between donor sex and the mean lumen diameter loss in
“large” and “small” vessel groups.
Year Sex n Large Vessels Small Vessels
Mean loss Standarddeviation p-value Mean loss
Standard
deviation p-value
0 to 1 Female 46 0.129 0.253 0.0008 0.042
0.111
0.156
0.151
0.020
Male 69 0.297 0.258
0 to 3 Female 19 0.335 0.229 0.063 0.176
0.153
0.274
0.153
0.74
Male 27 0.481 0.290
0 to 5 Female 3 0.508 0.162 0.95 0.548
0.104
0.539
0.119
0.30
Male 5 0.520 0.364
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Table A5.2 shows the result of the correlation of the recipient age to the development 
of LV and SV disease, as measured by the yearly absolute MLDL compared to baseline 
diameters. Positive correlations indicate larger percentage diameter loss with increasing 
age. In the LV group, there was no evidence of a correlation between change in vessel 
diameter and recipients age at transplant. In the SV group, there was significant 
evidence of greater MLDL between Year-0 and Year-3 with increasing recipient age. 
However, the result is not sustained on follow-up.
Comparison was made between female and male recipients and the MLDL from 
baseline to Year-1, 3 and 5, in both the LV and SV groups as shown in table A5.3. 
There was no evidence of a difference in MLDL between the sex in both groups.
5.2 Recipient race.
We examined the MLDL from baseline (in mm) in the LV and SV in the Caucasians 
and non-Caucasians, and tested the significance of this diameter loss. Table 5.2 shows 
the result. Overall, there are indications of a smaller loss in mean lumen diameter of the 
SV for Caucasians, but with such a small sample of non-Caucasians, the results remain 
uncertain.
Table 5.2: Comparison of the loss in mean lumen diameter from baseline (in mm) for 
“large” and “small” vessels for Caucasians and non-Caucasians.
Year Race n Large Vessels Small Vessels
Mean loss Standard
deviation
p-value 
for the
Mean loss Standard
deviation
p-value 
for the
Oto 1 Non-
Caucasian
7 0.384 0.254 0.11 0.2685 0.2216 0.001
Caucasian 110 0.219 0.266 0.0693 0.1439
Oto 3 Non-
Caucasian
3 0.452 0.335 0.85 0.1411 0.0835 0.86
Caucasian 44 0.422 0.271 0.1629 0.2132
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5.3 Recipient aetiology of heart disease.
Figure 5.1 shows the aetiology of the underlying heart disease necessitating transplant.
Figure 5.1: Numbers and percentages 
of cardiac diseases necessitating 
transplant
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In order to obtain reasonable sample sizes, we formed three groups; ischaemic, 
idiopathic and others. The number of men and women in the three groups are shown in 
Figure 5.2.
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Table 5.3 summaries the mean age for the three groups. There was strong evidence that 
the mean age differs between the groups, with patients in the ischaemic group tending 
to be older. Table A5.4 compares the absolute MLDL from baseline in the LV and SV 
for the three aetiology groups. There was little evidence that MLDL differed between 
the aetiology groups, for either the LV or SV.
Table 53: Mean age for the different aetiological groups.
Group n Mean age Standard
deviation
p-value
Ischaemic 74 52.2 6.2 <0.001
Idiopathic 29 46.2 11.5
Other 18 37.1 10.6
5.4 Recipient post-transplant blood pressure.
Table A5.5A, A5.5B, A5.5C and A5.5D show the pattern of post-transplant systolic, 
diastolic, mean and pulse blood pressure (BP) respectively over the years. For all four 
measurements, the pattern was for quite a large increase in BP from pre-transplant to 1- 
month post-transplant, a smaller increase from 1 to 6 months post-transplant and then a 
steady level. Figure 5.3 shows a plot of mean BP against time. We have therefore taken 
three possible predictors of TxCAD: (i) increase in BP from pre- to 1 month post­
transplant; (ii) increase in BP from 1 month to 6 months post-transplant; (iii) value at 6- 
months post-transplant. We only analysed the mean BP.
Table 5.4 shows the basic statistics of the different mean BP parameters used in our 
analysis, and table 5.5 shows the correlation between these parameters and MLDL 
between year-0 and subsequent years, and p-values for testing zero correlation. 
Negative correlations indicate that a larger increase in BP was associated with a smaller
151
subsequent loss in diameter. There was no significant correlation between the 
parameters used and development of significant MLDL in either LV or SV. An 
exception to that was the significant negative correlation between increase in BP from 
baseline to one month, and SV-MLDL between baseline and 3 years. The significance 
of this isolated correlation is not clear.
Figure 5.3: Mean BP over time 
post-transplant
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Table 5.4: Basic statistics of the different mean blood pressure parameters
used for our analysis.
Blood Pressure Number of 
values, n
Mean
(mmHg)
SD Median
(mmHg)
Pre to 1-month 115 19.15 17.71 18.0
1-month to 6-months 120 6.56 16.98 5.33
At 6-months 120 107.24 14.44 107.00
Table 5.5: Correlation between the different mean blood pressure 
parameters and the “large” and “small” vessels mean lumen 
diameter loss from baseline to subsequent years.
Blood Pressure Period in years Large Vessels Small Vessels
Correlation p -value Correlation p-value
Pre to 1-month Year-0 to Year-1 0.157 0.10 -0.022 0.82
Year-0 to Year-3 0.032 0.84 -0.329 0.026
1-month to 6-months Year-0 to Year-1 -0.028 0.77 0.088 0.35
Year-0 to Year-3 0.140 0.35 0.136 0.36
At 6-months Year-0 to Year-1 0.048 0.61 0.065 0.49
Year-0 to Year-3 0.170 0.25 0.118 0.43
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5.5 Recipient post-transplant plasma lipids.
The patients were divided into those on statins (89, or 73.6%) and those not on statins 
(32, or 26.4%). Table A5.6 compares the two groups with respect to MLDL from 
baseline to Year-1, and the different lipid fractions at Year-1. Although patients on 
statins had significantly lower total cholesterol, total triglycerides and LDL cholesterol, 
there was no difference in MLDL in the LV or SV between those on and not-on statins.
Table A5.7 correlates MLDL from Year-0 to Year-1 for the LV and SV, and the 
various lipid fractions. There was no evidence of any correlation with the level of the 
different lipid fractions.
5.6 Donor Factors.
This section examines the correlation of three donor risk factors to the later MLDL. 
The three donor factors are the cause of donor death, brain death (domino and non­
domino hearts) and the total ischaemic time.
5.6.1 Cause of donor death.
Of the 121 donors, the transplanted hearts were obtained from living donors as part of 
domino transplants in 24 patients (20%), and the rest were obtained from brain dead 
donors. Table 5.6 shows the causes of donor death and the number of female donors 
and table A5.8 shows the underlying disease in the donor patients in domino 
transplants. We grouped the causes of donor death into 5 groups as shown in table 
A5.9, to allow statistical analysis. Note that the numbers used for the causes of death 
correspond to that used in Table 5.6. Table 5.7 shows that there was significant
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evidence that donors who died from intra-cranial haemorrhage had less MLDL in the 
first year for both the LV and SV.
Table 5.6: Causes of donor death and the number of female donors.
Cause Number % of total Number of 
women
% women
1= Intra-cranial haemorrhage 56 46.28 30 54.55
2= Head injury 24 19.83 4 17.39
3= Meningiococcal meningitis 2 1.65 0 0
4= Hypoxic arrest 4 3.31 3 75.00
5= Paracetmol overdose 1 0.83 1 100.00
6= Brain abscess 1 0.83 1 100.00
7= Brain tumour 5 4.13 1 20.00
8= Carbon monoxide poisoning 2 1.65 1 50.00
9= Hanging 2 1.65 1 50.00
10= Domino =XXXX 24 19.83 5 20.83
Total 121 100.00 47 39.50
Table 5.7: Comparison of mean lumen diameter loss in the five donor groups.
Year Cause of death n Large Vessels Small Vessels
Mean loss Standard
deviation
P-
value
Mean loss Standard
deviation
P-
value
Otol Intra-cranial
haemorrhage
55 0.1541 0.2980 0.041 0.0401 0.1512 0.022
Head injury 23 0.2503 0.2235 0.0767 0.1421
A = 3,4, 6, 7. 12 0.3643 0.2804 0.1718 0.2228
B = 5, 8, 9 4 0.2435 0.1376 0.0684 0.1593
Domino 23 0.3120 0.1858 0.1391 0.1047
0 to 3 Intra-cranial
haemorrhage
19 0.4220 0.2841 0.49 0.1248 0.1326 0.077
Head injury 7 0.3374 0.3954 0.1495 0.2073
A = 3, 4, 6,7. 6 0.3079 0.2559 0.2029 0.2719
B = 5, 8, 9 2 0.5733 0.0896 0.5547 0.7499
Domino 13 0.5021 0.1827 0.1421 0.0970
5.6.2 Non-domino versus domino hearts.
Table 5.8 shows the result of the comparison of MLDL in the dominos and non­
dominos in the LV and SV respectively. Between Year-0 and Year-1, the MLDL 
seemed to be greater for the domino patients, for both LV and SV. After that, though, 
the evidence ceased to be significant, the domino patients had slightly smaller SV- 
MLDL.
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Table 5.8: Comparison of the absolute mean lumen diameter loss from 
baseline to Year-1 in “large” and “small” vessels for non-domino 
and domino donors.
Year Domino status n Large Vessels Small Vessels
Mean loss Standard
deviation
p-value Mean loss Standard
deviation
p-value
0 to 1 Non-domino 94 0.208 0.280 0.037 0.067 0.163 0.012
Domino 23 0.312 0.186 0.139 0.105
0 to 3 Non-domino 34 0.393 0.295 0.14 0.169 0.237 0.58
Domino 13 0.502 0.183 0.1421 0.0970
5.6.3 Total ischaemic time.
The correlation between the total ischaemic time and vessel lumen diameter has also 
been investigated. Table A5.10 shows the summary statistics for the total ischaemic 
time in minutes. Table A5.ll shows the correlations of the ischaemic time and MLDL 
from Year-0 to subsequent years. There was no evidence that longer ischaemic time 
was associated with change in mean diameter for LV and SV.
5.7 Creatinine and glucose.
We correlated the recipients’ serum creatinine and glucose levels to MLDL. We used 
the immediate pre-transplant level, maximum level during the first year and the Year-1 
level for the correlation. Table A5.12 shows that there was marginal evidence of a non­
zero correlation of 0.231 between the maximum creatinine level during Year-1 and the 
SV-MLDL between Year-0 and Year-1. Although there was some evidence that the 
correlation was non-zero, it was not a very strong correlation between the two 
variables. Table A5.13 shows the glucose correlation. There was no evidence of any 
significant correlation.
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5.8 Echocardiographic ejection fraction and fractional shortening.
Echocardiographic ejection fraction (EF) was very highly correlated to the fractional 
shortening (FS) (correlation = 0.963, p < 0.0001), and thus their correlation with other 
variables yielded similar results. This was expected as echocardiographic EF and FS 
are mathematically coupled. Table 5.9 shows the correlations of minimum EF in first 
year and MLDL between baseline and subsequent years. There was significant 
evidence of negative correlations for the LV. The correlations were also negative for 
the SV, though there was no longer significant evidence of non-zero correlation. The 
minimum ejection fraction / fractional shortening tend to occur early after transplant as 
shown in figure 5.4.
Table 5.9: Correlation of the minimum echocardiogram ejection fraction 
in the first year and the mean lumen diameter loss between baseline and 
subsequent years for the “large” and “small” vessels.
Period of lumen 
diameter loss
Large vessels Small vessels
Correlation p- value Correlation p-value
Year-0 to Year-1 -0.267 0.004 -0.120 0.20
Year-0 to Year-3 -0.322 0.027 -0.135 0.37
Figure 5.4: Time of occurrence of minimum fractional shortening.
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The mean±SD of the first recorded FS after transplant was 35±6.5% and the median 
was 35%. Table 5.10 show the first fractional shortening above and below the median, 
and its relationship to MLDL for the LV and SV. There was strong evidence of smaller 
LV-MLDL in the early stages for patients with higher initial fractional shortening.
Table 5.10: The relationship of the first fractional shortening 
measured after transplant, to mean lumen diameter loss 
in the “large” and “small” vessels.
Year Initial FS n Large Vessels Small Vessels
Mean
loss
Standard
deviation
p-value Mean
loss
Standard
deviation
p-value
0 to 1 <35% 60 0.290 0.262 0.0098 0.106 0.143 0.076
>35% 57 0.164 0.259 0.055 0.165
0 to 3 <35% 28 0.428 0.272 0.89 0.147 0.151 0.61
>35% 19 0.416 0.277 0.183 0.273
5.9 Cytomegalovirus.
5.9.1 Basic statistics.
Of the 121 patients, the pre-transplant CMV serological status was positive in 70 
(57.8%) and negative in 51 (42.2%). The serological CMV status was known for only 
91 donors; of these 39 (42.9%) were positive and 52 (57.1%) negative. Table 5.11 
shows the two-way frequencies and table 5.12 shows the basic statistics of the post 
transplant CMV count.
Table 5.11: Pre-transplant CMV status of the donors and recipients.
Recipient Donor Negative Donor Positive All
Negative 24 14 38
Positive 28 25 53
All 52 39 91
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Table 5.12: Basic statistics of the CMV count.
Variable n Mean Standard
deviation
Median Minimum
value
Maximum
value
CMV count 1337 9.21 67.73 0 0 1475
5.9.2 Correlation of the CMV count to mean lumen diameter loss.
CMV count was extremely skewed to the right. In order to try to analyse it, we found 
that it was helpful to work with ln(l + CMV count) (where "In" stands for natural 
logarithm). Table A5.14 shows the correlation of the mean ln(CMV count + 1) in the 
first year to MLDL from baseline to subsequent years, for the LV and SV respectively. 
There was no significant evidence of any correlation.
We also compared the MLDL for patients with zero CMV count throughout the first 
year and patients with at least one non-zero count in the first year. Table A5.15 shows 
the result. Again, there was no significant evidence that MLDL was linked to positive 
CMV count.
5.9.3 Relationship of the pre-transplant CMV serological status to mean lumen 
diameter loss.
Table 5.13 shows the relationship of the pre-transplant CMV serological status to the 
development of LV and SV disease. The p-value was based on an ANOVA test. For 
both LV and SV there was significant evidence that hearts from CMV positive donors 
tend to have less MLDL over the first year.
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Table 5.13: Relationship of the pre-transplant serological status to the 
development of “large” and “small” vessel mean lumen diameter loss.
Year CMV status n Large Vessels Small Vessels
Mean
loss
Standard
deviation
p-value Mean
loss
Standard
deviation
p-value
Oto 1 Donor -ve, recipient -ve 24 0.2791 0.2319 0.022 0.0923 0.1019 0.037
Donor -ve, recipient +ve 27 0.3218 0.2343 0.1530 0.1745
Donor +ve, recipient -ve 13 0.1482 0.2563 0.0298 0.0918
Donor +ve, recipient +ve 23 0.1108 0.3202 0.0295 0.2218
0 to 3 Donor -ve, recipient -ve 8 0.5177 0.3116 0.59 0.1725 0.1805 0.84
Donor -ve, recipient +ve 12 0.4174 0.3457 0.1957 0.3187
Donor +ve, recipient -ve 6 0.4715 0.2623 0.1217 0.1572
Donor +ve, recipient +ve 4 0.2583 0.2668 0.0828 0.0987
We also examined serological CMV negative donors, and assessed LV and SV-MLDL 
in those who became CMV viraemia positive compared to those who remained CMV 
viraemia negative. Fifty-one patients had donor negative hearts; of these 37 had a zero 
CMV count throughout the first year, so that the median equals zero. The MLDL from 
baseline (in mm) for patients with zero and non-zero CMV counts in the first year is 
shown in table 5.14; the p-value was determined using a 2-sample t-test. There was no 
significant evidence of a difference in MLDL between the groups.
Table 5.14: Relationship of serologically negative CMV donor hearts to mean 
lumen diameter loss in those who developed CMV antigenaemia compared 
to those who did not develop CMV antigenaemia.
Year Any positive 
Year-1 
CMV 
count?
n Large Vessels Small Vessels
Mean loss Standard
deviation
p-value Mean loss Standard
deviation
p-value
0 to 1 No 37 0.296 0.222 0.78 0.124 0.134 1.0
Yes 14 0.318 0.263 0.125 0.183
0 to 3 No 15 0.416 0.335 0.33 0.217 0.291 0.27
Yes 5 0.583 0.303 0.095 0.166
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5.10 Haemodynamic data.
5.10.1 Cardiac output.
The basic statistics of the cardiac output (CO), as measured by right heart 
catheterization is shown in Table A5.16. This is illustrated in figure 5.5. Mean CO 
increased from baseline to Year-1 and then stayed fairly constant. Table 5.15 assessed 
the significance of the increase in CO from baseline to Year-1, which turned out to be 
significant.
Figure 5.5: Cardiac output pattern 
over time
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Table 5.15: Increase in cardiac output from baseline to Year-1.
n Mean
increase
Standard
deviation
Median Minimum
value
Maximum
value
p-value
107 0.362 1.299 0.27 -3.6 2.7 0.0048
In investigating any association between the cardiac output and MLDL, we used the 
cardiac output value at baseline and the increase in cardiac output from baseline to 
Year-1 as possible prognostic variables. Tables A5.17 and A5.18 show the correlation 
between cardiac output at baseline and the increase from baseline to Year-1, to 
subsequent MLDL. There was little evidence of an association with MLDL.
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5.10.2 Angiographic ejection fraction.
Figure 5.6 shows the angiographic ejection fraction (EF) pattern over time, and table 
A5.19 shows the basic statistics. Mean EF decreased from baseline to Year-1 and then 
stayed fairly constant. Table 5.16 shows the relationship of the decrease in EF from 
baseline to Year-1, which was significant. The correlation between the baseline 
angiographic EF and decrease in EF from baseline to Year-1, to MLDL was 
investigated, as shown in Tables A5.20 and Table A5.21 respectively. Although the 
correlation with the baseline EF was negative, the evidence of an association was not 
significant. There was no significant correlation between the decrease in EF from 
baseline to Year-1, to the MLDL.
Figure 5.6: Pattern of 
angiographic ejection fraction
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Table 5.16: Basic statistics of the decrease in angiographic ejection 
fraction from baseline to Year-1.
n Mean
decrease
Standard
deviation
Median Minimum
value
Maximum
value
p-value
101 3.12 12.54 4.0 -34 29 0.014
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5.10.3 Filling pressures.
The basic statistics of the mean right atrial pressure (RAP), mean pulmonary artery 
mean pressure (PAMP), mean pulmonary artery wedge pressure (PAWP) and the mean 
left ventricular end diastolic pressure (LVEDP) over time are shown in tablesA5.22, 
A5.23, A5.24 and A5.25 respectively. Figures 5.7, 5.8, 5.9 and 5.10 show the 
respective plot of the values. The mean RAP, PAMP and PAWP appeared to decrease 
from baseline to Year-1 and then stayed fairly constant; the values at Year-5 are likely 
not representative due to the small sample size. The LVEDP decreased from baseline to 
Year-1 and then started to rise again. The decrease in mean RAP, PAMP and LVEDP 
values from baseline to Year-1 was statistically significant as shown in tables A5.26, 
5.27 and A5.28; the values of the PAWP were closely related to that of the PAMP, and 
thus will not be discussed further. In investigating the correlation between the mean 
RAP, PAMP and LVEDP to MLDL, we used the values at baseline and the decrease 
from baseline to Year-1 as prognostic variables, and correlated them to the MLDL as 
shown in tables A5.29 to A5.34 respectively. There was no significant correlation of 
any of these parameters to MLDL.
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Figure 5.10: Behaviour of the left 
ventricular end diastolic pressure
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5.11 Discussion.
Donor and recipient age and sex.
In this univariate analysis, donor age was not a predictor of LV or SV-MLDL. Donor 
male sex was associated with greater MLDL from baseline to Year-1 in the LV and SV, 
although the evidence for the SV was not as compelling as for the LV. Increasing 
recipient age was associated with greater MLDL in the SV between baseline and Year- 
3; however, the result was not sustained on follow-up and thus its significance is 
questionable. Recipient sex was not related with MLDL.
Costanzo et al30 in their multicentre qualitative angiographic study found that donor age 
was a risk factor, while Hauptman et al150 in their multicentre ICUS study found no 
relationship between the two. Rickenbacher et al134 found that donor age was related to 
the development of TxCAD when qualitative angiography was used, but it was not 
related when ICUS was used. Thus it seems that when the insensitive qualitative 
angiography was used, donor age was found to be related with the development of 
TxCAD, and when the sensitivity of the diagnosis of TxCAD was increased by using
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ICUS, no relation was found. Our QCA results are in agreement with the ICUS studies 
that there is no relation between donor age and TxCAD as assessed by MLDL.
In a study based on qualitative angiography, Costanzo et al30 in a large multicentre 
study found that donor sex was related to the development of TxCAD. Hauptman et 
al150 and Rickenbacher et al134 in smaller studies using ICUS could not demonstrate 
such a relation. Thus it seems clear that the relation with TxCAD depends on the 
method used to diagnose TxCAD.
Recipient age was not a risk factor for MLDL in our study. This is consistent with the 
findings of Costanzo et al in their multicentre qualitative angiographic study, and of 
Hauptman et al150 in their multicentre ICUS study. We also found that recipient’s sex 
was not a risk factor for MLDL, and this was shown previously by Hauptman et al150;
in
however, Costanzo et al found that recipient’s male sex was a risk factor for TxCAD. 
Recipient Race.
Caucasians had a smaller initial SV-MLDL in our study. However with such a small 
sample of non-Caucasians (6%), and lack of this relationship on long-term follow up, 
the significance of this finding is questionable. Costanzo et al30 in their large 
multicentre qualitative angiographic study, found that recipient black race was a risk 
factor to the development of TxCAD. Differences in population size and means used to 
diagnose TxCAD prevents accurate comparison of our study with that of Costanzo et 
al30.
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Recipient aetiology of heart disease.
Recipient native heart disease was not related to MLDL in either the LV and SV. This 
is in agreement with the results of the multicentre study of Costanzo et al30, although 
they used qualitative angiography to diagnose TxCAD.
Recipient post-transplant blood pressure.
Increase in mean BP from pre-transplant to 1-month post-transplant, froml-month to 6 
months post-transplant and the mean value at 6 months post-transplant were not related 
to MLDL. This is in keeping with the findings of Rickenbacher et al134 and Hauptman 
et al150. A reasonable explanation for this is that the majority of heart transplant 
recipients (72%) develop hypertension by one year1. In addition, hypertension is always 
treated and the antihypertensive medications may have other beneficial effects on 
atherosclerosis, other than by lowering the BP273,274.
Recipient post-transplant plasma lipid level.
We found that post-transplant plasma lipid level was not associated with MLDL in 
either the LV and SV. Although patients on statins had significantly lower total 
cholesterol, LDL cholesterol and low triglycerides, there was no difference in MLDL. 
Rickenbacher et al134 found that increased triglycerides were related to the development 
of TxCAD, when the latter was diagnosed with either ICUS or conventional 
angiography. Eich et al135 found that high cholesterol level at 6 months was a good 
predictor for the development of TxCAD on the long term. The follow up in the first 
study was 3.4±2.7 years (range 1-14.6) and in the latter all the patients had at least 3 
years follow up. This might have contributed to the difference in their results compared
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to ours. In addition, other investigators found no relationship between lipid levels and 
TxCAD137’138.
Donor Factors.
Aetiology o f donor death
Although the aetiology of donor death relation to graft survival has been studied
<2'7C
before , the literature is quite deficient in research relating the aetiology of donor 
death to the development of TxCAD. We found that donors who died from intracranial 
haemorrhage had less MLDL in the first year in both the LV and SV. The reason for 
this is unclear.
Non-domino versus domino hearts.
We found an increase in MLDL in domino transplants in the first year after transplant. 
There are no previous studies with QCA or ICUS in the domino population. Smith et 
al165 showed that there was no difference in the incidence of freedom from graft 
atherosclerosis (74±3% versus 70±3% at 5 years) between the domino and non-domino 
groups, as diagnosed by conventional angiography. Similarly, Anyanwu et al in a 
study of 131 domino transplants found that the 1,5 and 10-year graft survival to be 
good, and that late death caused by coronary disease was uncommon. Other work has 
been done mainly on kidney transplants. Terasaki et al167 found that the behaviour of 
kidney grafts from living donors was consistently superior from those from cadavers. 
The reason why non-domino hearts and hearts from donors who sustained intracranial 
haemorrhage in our study had less MLDL in the first year is not clear.
166
Total ischaemic time.
We found that total ischaemic time was not correlated to MLDL. Hauptman et al150 
using ICUS, Costanzo et al30 using conventional angiography and Rickenbacher et 
al134 using ICUS and conventional angiography found that there was no relationship 
between total ischaemic time and the development of TxCAD. Thus, our study is in 
agreement with these studies.
Echocardiographic ejection fraction and fractional shortening.
The “fractional shortening” was strongly correlated with the “ejection fraction” and so 
the results using any of the two parameters were similar. This strong correlation was 
expected as both parameters are mathematically coupled. The minimum ejection 
fraction/ fractional shortening in the first year was strongly correlated to the long-term 
MLDL in the LV, and tended to occur early after transplant. Low FS obtained in the 
first week after transplant was related to significant MLDL from baseline to Year-1 in 
the LV and SV. Review of literature found that such relationship has not been 
investigated before.
There is nothing in the heart transplant literature relating injury at time of transplant 
and subsequent development of TxCAD. However, experience from kidney transplant 
shows that ischaemia-reperfusion injury is related to subsequent development of 
chronic graft rejection277'280. Myocardial preservation of the cardiac allograft is related 
to endothelial damage281, in addition to subsequent cardiac function282'284. It is thus 
possible that the effect organ preservation which leads to ventricular dysfunction after 
transplant might also have an effect on the development of TxCAD. Thus, patients who 
are found to have a low echocardiographic ejection fraction early after transplantation
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need to be monitored closely for the development of TxCAD, and the cardiovascular 
risk factors well controlled.
Cytomegalovirus
CMV count was not related to MLDL. Hearts from serologically positive CMV donors 
tended to have less MLDL over the first year in both the LV and SV. There was no 
significant evidence of a difference in MLDL between serologically negative CMV 
donors who later develop CMV antigenaemia compared to those who don’t.
Our finding of the lack of association between CMV count and MLDL is in agreement 
with that of Balk et al124 who in their study of 100 patients who survived at least 1 year 
after transplantation, found no significant difference in the incidence of TxCAD 
between patients with and without CMV infection (culture positivity). Radovancevic et 
al127 in a retrospective analysis of 210 cardiac transplant recipients, found no relation 
between TxCAD with CMV infection. However, other investigators found a positive 
relationship. Grattan et al119 in a study of 301 patients, found that 28% of CMV 
infected patients developed severe coronary obstructive lesions, whereas only in 10% 
of patients not infected, did the same degree of TxCAD develop. CMV infection was 
diagnosed on the basis of a positive culture, fourfold increase in CMV serological titre, 
or demonstration of CMV inclusion bodies in the tissues. Koskinen et al120 in a cohort 
of 53 patients demonstrated that CMV infection, as diagnosed by positive culture or 
fourfold rise in specific IgG or specific IgM or CMV antigenaemia, developed 
angiographically detectable TxCAD two years after the diagnosis of the CMV 
infection. Conventional angiography was used. An obvious cause for the discrepancies
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between the different results is the means by which CMV infection and TxCAD were 
diagnosed.
An interesting finding in our study was that hearts from serologically positive CMV 
donors tend to have less MLDL over the first year for both the LV and SV. Thereafter 
this effect tended to disappear. Weimar et al125 assessed the donor/recipient serostatus 
combination in 81 transplant patients and correlated this to the development of TxCAD 
as diagnosed by conventional angiography. They found no difference in the incidence 
of TxCAD between the groups. Conventional angiography, rather than QCA was used.
Haemodynamic data.
Cardiac output, as measured by right heart catheterisation, increased from baseline to 
Year-1 and then stayed fairly constant. There was no association between the CO at 
baseline, or the increase from baseline to Year-1, and the MLDL in either the LV or 
SV. The angiographic EF decreased from baseline to Year-1 and then stayed fairly 
constant. There was no significant relationship between the baseline angiographic EF, 
or the decrease in EF from baseline to Year-1, to the MLDL in either the LV or SV. 
The mean RAP, PAP and PAWP decreased from baseline to Year-1, and then remained 
fairly constant. There was no association between these variables at baseline or the 
decrease to Year-1, with the MLDL in either the LV or SV. The LVEDP decrease from 
baseline to Year-1 and then started to rise again. There was no association between the 
LVEDP at baseline or the decrease from baseline to Year-1, to the MLDL in either the 
LV or SV.
169
Review of literature showed that very little research has been done to investigate the
160haemodynamic aspects of TxCAD. Grocott-Mason et al studied the angiographic EF 
at Year-1 in 111 patients and related it to the development of TxCAD in the first 10 
years post transplant (34 patients). Conventional angiography was used to diagnose 
TxCAD. They found that those who never developed TxCAD in the first 10 years after 
transplant had significandy better cardiac function at Year-1 than those who did (LVEF 
of 70.3 ± 10.4% vs. 63.3 ± 13.4%). Our finding of a negative correlation between the 
baseline angiographic EF and the MLDL in both the LV and SV is in keeping with the 
findings of Grocott-Mason et al182, although our relationship was not statistically 
significant. One reason that might have accounted for this is the shorter follow up 
period in our study (3 years) compared to theirs (10 years). Although baseline 
angiographic EF and echocariographic EF should basically be similar, the difference in 
results that we found in relation to MLDL could well be related to the timing when 
these tests were done.
Grocott-Mason et al182 found a negative relationship between the right atrial pressure 
and the development of TxCAD in the 10 years following transplant. Again, as for the 
angiographic EF, the follow up period and the use of different means to diagnose 
TxCAD might have accounted for the difference in results.
Thus in conclusion, we found that donor male sex was associated with greater MLDL 
in the LV and SV between baseline and Year-1, although the evidence for the SV was 
not as compelling as for the LV. A new finding was that the low initial 
echocardiographic FS during the first week post transplant and minimum fractional 
shortening during the first year were strongly correlated to MLDL in the LV. This
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could be a marker of graft injury and surrogate for the effectiveness of organ 
preservation. The sensitivity of the method used to diagnose TxCAD, in addition to the 
size of the study populations and period of follow up, could account for the difference 
in results between the different investigators.
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CHAPTER 6 
Results in
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This chapter outlines the results of the role of the immunological factors that are 
thought to play a major role in the development of MLDL in the LV and SV. These 
immunological factors were discussed in Chapter 1, section 1.9.
6.1 RATG induction therapy.
We investigated the relationship between RATG induction of immunosuppression and 
MLDL. Patients were divided according to whether or not they had RATG induction or 
RATG rescue (as treatment for severe rejection or temporarily in place of ciclosporin 
because of renal impairment). Table A6.1 shows the results, and table A6.2 shows the 
acute rejection episodes in those who had or did not have RATG in the first 3 and 12 
months. Although the use of induction therapy was associated with a lower incidence of 
acute rejection from baseline to 3-months and 1-year after transplant (p=0.019 and 
0.026 respectively), there was no evidence that its use was associated with a reduction 
in MLDL up to 3 years after heart transplantation (p=0.31 for the LV and 0.27 for the 
SV).
6.2 Prednisolone treatment.
We investigated whether the MLDL was related to those who had prednisolone 
treatment during the whole of the first year post-transplant compared to those who had 
had prednisolone discontinued before the end of the first year. Table A6.3 shows the 
results. There was no evidence of any difference between the two groups in MLDL to 
Year-1 (p=0.14 for the LV, and p=0.17 for the SV) or to Year-3 (p=0.99 for the LV, 
and p=0.1 for the SV).
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6.3 Acute rejection.
As rejection occurs more commonly in the first 3 months after transplant, we 
investigated the rejection data according to whether the rejection occurred in the first 
13 weeks, or in the first year. The following parameters were considered:
1- Average rejection score, each rejection being graded from 1 to 4 with A and B 
subgroups being ignored (ISHLT rejection 1A and 1B=1, 2=2, 3A and 3B=3, 
4=4).
2- Average rejection score according to their grade from 1 to 6 with A and B 
subgroups being considered (ISHLT rejection grade 1A=1, 1B=2, 2=3, 3A=4, 
3B=5,4=6).
3- The number of the rejections, irrespective of whether treated or not.
Table 6.1 shows the basic statistics of the rejection episodes, according to the 3 groups 
mentioned above, and according to whether these episodes occurred in the first 3 
months or in the first year.
Table 6.1: Basic statistics of the rejection episodes.
Period Variable n Mean Standard
deviation
Median
Baseline to 
3-months
"0-4" score 121 0.3430 0.3051 0.3333
"0-6"score 121 0.4201 0.3931 0.4000
Number of rejection 
episodes
121 0.4132 0.6667 0.0000
Baseline to 
Year-1
"0-4"score 121 0.2619 0.2135 0.2353
"0-6"score 121 0.3182 0.2738 0.2667
Number of rejection 
episodes
121 0.4793 0.7648 0.0000
The frequency of occurrence of the rejection episodes is shown in the histograms and 
bar charts in figure 6.1. There was little difference between the 0-4 and 0-6 average 
scoring systems; therefore the average 0-6 score was used. In addition, there was little
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difference when rejection was considered in the first 3 months or in the first 12 months; 
therefore the 12 months data was used in our analysis.
Figure 6.1: Histograms and bar charts of the rejection variables.
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6.4 Mean lumen diameter loss correlated to biopsy score.
Table 6.2 shows the result of the correlation of the 1-6 biopsy score over the first year 
to the MLDL in the LV and SV over the same period. Positive correlations indicate that 
more rejection was associated with greater subsequent loss in diameter. There was no 
significant evidence of any non-zero correlation.
Table 6.2: Correlation of 1-6 biopsy score to the “large” and “small” vessel
mean lumen diameter loss.
Period of decrease Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 -0.023 0.81 0.003 0.98
Year-0 to Year-3 -0.241 0.10 0.015 0.92
6.5 Mean lumen diameter loss correlated to summation ECG voltage.
Table A6.4 shows the basic statistics of the rejection grade correlated to the summation 
ECG voltage (summation of leads 1, 2, 3, VI and V6), and Table A6.5 shows the 
estimated difference from no rejection of each grade of rejection, allowing for patient- 
to-patient differences. The mean ECG voltage tended to decrease with increasing grade 
of rejection.
We looked at (i) average summation ECG voltage over the first year; (ii) standard 
deviation of the summation ECG voltage over the first year; (iii) minimum value of 
summation ECG voltage over the first year. The latter was correlated with average 
rejection score (on "0-6" scale) - smaller minimum values are associated with larger 
rejection scores (p = 0.053).
Table 6.3 correlates the minimum summation ECG voltage in first year and MLDL 
from Year-0 to subsequent years for the LV and SV. There was just one significant
176
result, for a negative correlation for the small vessels. Some of the other estimated 
correlations were positive, however, so no clear picture emerged. Maximum summated 
ECG voltage drop during the first year produced similar results.
Table 6.3: Correlation of the minimum ECG volatage in first year and mean 
lumen diameter loss from baseline to subsequent years in 
the “large” and “small” vessels.
Period of decrease Large vessels Small vessels
Correlation P value Correlation P value
Year-0 to Year-1 0.166 0.074 0.173 0.064
Year-0 to Year-3 -0.106 0.48 -0.339 0.021
6.6 HLA Mismatches.
6.6.1 Total number of mismatches.
The total number of mismatches (MM) is the sum of the A MM, B MM and DR MM. 
Of the 119 patients for whom information was available, 1 had no mismatches, 2 had 
one mismatch, 8 had two mismatches, 27 had three mismatches, 32 had four 
mismatches, 31 had five mismatches and 18 had six mismatches. Details of the MLDL 
are shown in table A6.6 for the LV and SV. The p-values are based on ANOVA tests. 
There was no significant evidence of any association between the number of 
mismatches and MLDL, nor even any significant evidence of any trends.
Correlations of total number of mismatches and MLDL are shown in table A6.7 for the 
LV and SV. Positive correlations would suggest greater diameter loss with greater 
number of mismatches. There was no strong evidence of any significant correlation 
here.
177
6.6.2 Number of “A” mismatches.
Of the 120 patients for whom information was available, 14 had no A MM, 60 had one 
MM and 46 had two MM. Details of the MLDL and the A MM are shown in table A6.8 
for the LV and SV respectively. There was no significant evidence of any association 
between the number of MM and MLDL; if anything, for the LV, there seemed to be a 
smaller loss in lumen diameter when there were more MM.
Correlations of the total number of MM at A and diameter loss are shown in table A6.9 
for the LV and SV. As indicated by the analysis, there was no strong evidence of any 
correlation here.
6.6.3 Number of “B” mismatches.
Of the 119 patients for whom information was available, 8 had no MM, 35 had one 
MM and 76 had two MM. Details of the MLDL are shown in table A6.10 for the LV 
and SV. There was no significant evidence of any association between the number of 
MM and MLDL.
Correlation of the total number of MM at B and MLDL are summarised in table A6.11 
for the LV and SV. There was no strong evidence of any correlation here.
6.6.4 Number of “DR” mismatches.
Of the 120 patients for whom information was available, 11 had no MM, 64 had one 
MM and 45 had two MM. Details of the MLDL are shown in table A6.12 for the LV 
and SV. There was no significant evidence of any association between the number of
178
MM and MLDL; however, there was a trend towards a greater diameter loss with 
increasing number of MM, especially if the small sample size rows are discounted.
Correlations of total number of MM at DR and MLDL are shown in table A6.13 for the 
LV and SV. There was no strong evidence of any correlation here.
6.7 Pre-transplant lymphocytic crossmatch & PRA.
Of the 116 patients for whom information was available, 114 were B cell negative, 2 
were B cell positive. Since there were so few positives, no meaningful comparison 
could be made. Details of the MLDL are shown in Table A6.14 for the LV and SV.
Of the 121 patients studied, 118 were negative for pre-transplant PRA, 2 were positive
11-50%, and 1 was positive 51-100%. Because of the small numbers, we have pooled 
the last two groups. Details of the MLDL are shown in table A6.15 for the LV and SV. 
Due to the number of positives, no meaningful comparison could be made.
6.8 Antivimentin Antibodies.
Table A6.16 shows the basic statistics of our antivimentin antibodies data, and table 6.4 
shows the summary of the data. We used a mean level of >120 units in the first year to 
investigate the relationship of antivimentin antibodies to the development of significant 
MLDL. This level was based on research conducted by Jurcevic et al233, who found out 
that a first-year mean titre of >120 units produced a test with a sensitivity of 63% and a 
specificity of 76% to diagnose TxCAD. Table 6.5 shows the MLDL from baseline (in 
mm) for patients whose 1-year mean antivimentin titre was <120 and >120 units.
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There was no significant evidence of a difference in MLDL between the groups, 
although in the LV there was more narrowing in the positive group.
Table 6.4: Summary statistics of the antivimentin antibodies data.
Statistic n Mean Standard
deviation
Median Minimum
value
Maximum
value
Quartiles 
1st 3rd
1-yr mean 59 94.90 57.42 71.00 50.00 275.0 50.00 118.00
3-yr mean 107 118.5 103.9 85.9 50.0 743. 56.3 144.5
5-yr mean 118 117.29 83.28 89.25 50.00 540.0 64.67 139.25
1-yr max 59 109.47 69.69 83.00 50.00 300.0 50.00 150.00
3-yr max 107 144.0 127.1 106.0 50.0 890. 65.0 193.0
Table 6.5: First year mean antivimentin antibodies level related to the 
mean lumen diameter loss in the “large” and “small” vessels.
Year First 
year 
mean 
titre > 
120 unit
n Large Vessels Small Vessels
Mean
decrease
Standard
deviation
p-value Mean
decrease
Standard
deviation
p-value
Oto 1 No 44 0.191 0.281 0.34 0.073 0.192 0.92
Yes 14 0.269 0.252 0.069 0.105
0 to 3 No 5 0.473 0.243 - 0.1625 0.1703 -
Yes 1 0.70000 0.28889
6.9 Discussion.
The main findings were that RATG induction therapy did not affect the MLDL in either 
LV or SV, although it was associated with reduction in acute rejection. Prednisolone 
treatment during the whole of the first year was not associated with a reduction in the 
MLDL compared to those who did not have it for the whole year. A high 
endomyocardial biopsy score or rejection episodes were not associated with a higher 
incidence of MLDL in either the LV or SV. The mean summation ECG voltage tended 
to decrease with increasing grade of rejection and the minimum value of ECG voltage 
was associated with a larger 0-6 rejection score. However, the association of the 
minimum ECG voltage and TxCAD is not clear. Considering the HLA MM separately
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or together, there was no association between them and the MLDL in either the LV or 
SV.
We also found no association between the pre-transplant lymphocytic crossmatch, PRA 
or the mean 1-year antivimentin antibodies level of >120 units to MLDL, although 
patients with >120 units level had more MLDL in the LV.
Our study found that RATG induction had no effect on MLDL, and hence TxCAD, 1 to
3-years after transplantation. Using conventional angiography, Carrier et al235 and 
Dersdale et al236 showed that RATG induction was associated with reduced incidence 
of TxCAD. Direct comparison between our study and these mentioned studies is not 
possible due to the different sensitivities of the methods used to diagnose TxCAD.
Several investigators studied the association between early prednisolone withdrawal 
from standard triple immunosuppression and the incidence of TxCAD285'288 and found 
that there was no difference in TxCAD incidence between the groups on prednisolone 
and those not on it. All these studies used conventional angiography to diagnose 
TxCAD. Our QCA study is in keeping with results of these investigators, although we 
did not look into other factors which might affect the development of TxCAD, like 
lipid levels and the use of statins, in those who were on steroids compared to those who 
were not.
Our finding of lack of correlation between a high endomyocardial biopsy score to 
increased MLDL, and hence TxCAD, is in agreement with that of Gao et al199; they 
found that the rejection score and other seven parameters of rejection in the first year
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post-transplant were not predictive of TxCAD in a 4 year mean follow-up. Qualitative 
angiography was used to diagnose TxCAD. Stovin et al126 also found no relationship 
between acute rejection and TxCAD; conventional angiography and necropsy were 
used to diagnose TxCAD. Kobashigawa et al200 in a multicentre ICUS study found no 
significant difference in the development of TxCAD between patients in the treated 
endomyocardial biopsy and the treated rejection groups and those who did not reject; 
however, there was a significant correlation between increased average biopsy score at 
0 to 3-months after transplantation and increased intimal thickening, suggesting that 
recurrent mild rejection episodes might have an important role in the development of
137 177TxCAD. Using conventional angiography, Uretsky et al , Radovancevic et al , and 
Narrod et al197 found a correlation between acute rejection and the subsequent 
development of TxCAD. Thus it seems that even by using the same means to diagnose 
TxCAD, researchers are divided in the role acute rejection plays in the development of 
TxCAD, although differences in the factors that might affect TxCAD such as 
immunosuppression protocols, lipid levels and the use of statins might have played a 
role.
It is well recognised that the summation ECG voltage decreases with acute rejection289. 
Our finding that it was not related to the development of TxCAD is not surprising. 
Golshayan et al290 studied different aspects of the post-transplant ECG, such as RBBB 
and SVT, and found no correlation with the development of TxCAD. The fact that the 
ECG voltage is influenced by lots of factors, such as myocardial and pulmonary 
oedema and pericardial effusion, makes it an unreliable tool to correlate with disease 
aspects without worrying that the results might have been contaminated by these 
factors. Intramyocardial ECG amplitudes, which involves direct implantation of
epicardial leads and hence eliminates lots of the factors which influence the ECG 
amplitude, have been successfully used previously to diagnose acute rejection and
291-294momtor rejection treatment
Our finding of no correlation between the total number of MM and the MLDL for 
either the LV and SV agrees with the work of Homick et al210 who studied 550 post 
transplant patients and found no association between the mean number of MM for 
Class I or Class II antigens and TxCAD as diagnosed by qualitative angiography, and 
of Zerbe et al198 who studied of 146 allografts obtained either at re-transplantation or 
autopsy and found no association between the degree of HLA MM and the severity of 
coronary artery luminal narrowing as measured by planimetry of photographs of
coronary artery sections with use of a digitising tablet. On the other hand,
010Radovancevic et al found that patients with four to six MM had a significantly lower 
incidence of TxCAD (p <0.05) than the patients with three or fewer MM.
Radovancevic et al212 in their study of 167 patients who had cardiac transplantation
found that at the HLA-A locus, there was significantly higher incidence of TxCAD
(p<0.01) in the group of patients with zero MM (10 of 17, 58%). This interesting
finding was also reflected in our study; although there was no evidence of any
association between the number of A MM and MLDL, there seemed to be a smaller
reduction in the LV-MLDL when there were more MM. This inverse relationship was
211also reported by Kerman et al .
Our finding of absence of association between B MM and MLDL is in keeping with the 
findings of Radovancevic et al212; however, Kerman et al211 found an inverse
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relationship. Considering the DR MM, our finding of absence of any association 
between them and MLDL is in keeping with the findings of Kerman et al211 and 
Radovancevic et al212.
On review of the literature, we found that there is lack of research in the association 
between the pre-transplant lymphocytic crossmatch and PRA and the MLDL. Our 
ability to investigate this relationship was limited by the very small number of patients 
who were PRA positive or who had a positive crossmatch.
Jurcevic et al233 found that a 1-year antivimentin mean titre of >120 units predicts the 
development of TxCAD up to 5 years post-transplant with a sensitivity of 63% and 
specificity of 76%. This contradicts our finding of no association. Although the use of 
immunosuppression and the numbers of the two populations of patients were 
comparable (109 patients in their study), we had half the number of antivimentin 
samples in our study (440 vs. 880 samples). In addition, their use of conventional 
qualitative angiography to diagnose TxCAD, and the differences in the periods of 
follow up might have played a role. Hosenpud et al found no relationship between 
the IgM antiendothelial cells antibodies obtained 6-8 weeks(early) and Year-1 (late) 
from recipients and donor specific human aortic endothelial cells of those with and 
without TxCAD at 1 year after transplantation. Thus the role of antiendothelial 
endothelial cells antibodies as a predictor of TxCAD needs further investigation.
Thus in conclusion, although the pathogensis of TxCAD is thought to be mainly 
immunological, our research and that of others show that the association between the 
different immunological factors and TxCAD pathogensis in patients receiving
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pharmacological immunosuppression including ciclosporin, azathioprine and 
corticosteroids with or without induction is far from clear. Acute rejection is diagnosed 
and treated early, which might have masked its effect on TxCAD. Further research with 
standardisation of the methods used to detect TxCAD and investigate the different 
immunological factors is needed.
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CHAPTER 7
MULTIVARIATE ANALYSIS.
7.1 Variables considered for multivariate analysis.
7.2 Multivariate analysis of the “large” vessel variables.
7.3 Multivariate analysis of the “small” vessel variables.
7.4 Comparison of the factors affecting the “large” and “small” vessels.
7.5 Discussion.
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In order to learn more about the relationship between the several independent or 
predictor variables and MLDL (dependent or criterion variable), we performed 
multivariate analysis using standard multiple linear regression. The multivariate model 
was obtained using stepwise regression by the backward removal method in which we 
eliminated non-significant variables one-by-one, using a nominal 5% significance level.
To obtain a regression equation (model), the general computational problem that needs 
to be solved in multiple regression analysis, is to fit a straight line (regression line) to a 
set of data (variables)295. A line in a two dimensional or two-variable space is defined 
by the equation Y=a+b*X; on other words, the Y variable can be expressed in terms of 
a constant (or intercept - a) and a slope (regression or B coefficient - b) times the X  
variable. In general, multiple regression procedures will estimate a linear equation of 
the form:
Y = a + bj*Xi + b2*X2 +... + bp*Xp
The regression line expresses the best prediction (model) of the dependent variable (Y), 
given the independent variables (X). However, usually there is variation of the observed 
points around the fitted regression line. The deviation of a particular point from the 
regression line (its predicted value) is called the residual value. The smaller the 
magnitude of the residual values around the regression line relative to the overall 
variability, the better the model fits the observed data. If there is no relationship 
between the X  and Y variables, then the ratio of the residual variability of the Y variable 
to the original variance is equal to 1.0. If X  and Y are perfectly related then there is no 
residual variance and the ratio of variance would be 0. In all cases, the ratio must fall 
somewhere between these 0 and 1.0. 1.0 minus this ratio is referred to as R-square or
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the coefficient o f determination. The R-square value is an indicator of how well the 
model fits the data (e.g., an R-square close to 1.0 indicates that we have accounted for 
almost all of the variability with the variables specified in the model).
However, multivariate analysis has its limitations295. Only associations between 
variables can be ascertained, and one can never be sure about the underlying casual 
mechanism. In linear regression analysis, it is assumed that the relationship between 
variables is linear, although in practice this assumption usually can not be confirmed. 
Fortunately, multiple regression procedures are not greatly affected by minor deviations 
from this assumption. The choice of the number of variables is essential. One would be 
capitalizing on chance when simply including as many variables as can be thought of as 
predictors of a variable of interest, as usually at least a few of them will appear to be 
significant by chance. This problem is compounded when, in addition, the number of 
observations is relatively low. Most authors recommend that one should have at least 
10 to 20 times as many observations (cases, respondents) as one has variables, 
otherwise the estimates of the regression line are probably very unstable and unlikely to 
replicate if one were to do the study over again with another set of data. In addition, 
instability can occur when a model is constructed using independent variables that are 
closely related or highly correlated (e.g. using both FS and EF to assess left ventricular 
function). This problem is described as multicollinearity, and must be avoided by a 
careful selection of predictor variables.
7.1 Variables considered for multivariate analysis.
All the variables that were found to have a significance value of p<0.2 in the univariate 
analysis, and which had completed data of >80% were used as candidate variables for
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the multivariate analysis. The candidate variables considered, together with their codes,
are shown on table 7.1.
Table 7.1: Variables considered in the multivariable analysis, and their codes.
Variable Code
Donor Sex 0= female; l=male
Race O=non-caucasians, l=caucasians
Intracranial Haemorrhage 0=not intracranial haemorrhage, l=intracranial haemorrhage
Initial FS (>36 or <36%) 0= >36%, 1=<36%
Domino Transplant 0=not domino, l=domino
ECG voltage (drop) Maximum fall in ECG summation voltage in Year-1
Prednisolone in first year 0=no, l=yes
Maximum creatinine in first year Maximum serum creatinine in the first year.
7.2 Multivariate analysis of the “large” vessel variables.
Table A7.1 shows a provisional model when all variables were fitted in the analysis of 
the LV- MLDL. Table 7.2 shows the final multivariate model which was obtained after 
dropping non-significant variables one-by-one. The R-square value of the model was 
22.6%. Donor sex, initial fractional shortening <36% and prednisolone treatment 
during the first year were positively correlated with MLDL, whereas intracranial 
haemorrhage was negatively correlated with it. In other words, the use of male donor or 
a donor who died from a cause other than intracranial haemorrhage, an initial 
echocardiographic fractional shortening <36% or prednisolone treatment continuing to 
1-year after transplantation all predicted greater MLDL in the LV.
Table 7.2: “Large” vessel mean lumen diameter loss multivariate model.
Predictor Coeffecient SD p-value
Constant -0.1561 0.1091 0.155
Donor Male Sex 0.15068 0.04925 0.003
Intracranial Haemorrhage -0.09779 0.04753 0.042
Initial FS (>36 or <36%) 0.12849 0.04610 0.006
Prednisolone in first year 0.15234 0.05948 0.012
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7.3 Multivariate analysis of the “small” vessel variables.
A provisional model when all variables were fitted in the analysis of the SV- MLDL is 
shown in Table A7.2. Table 7.3 shows the SV multivariate model, after dropping the 
non-significant variables one-by-one. The R-square value of the model was 22.5%. 
Domino transplants, maximum drop in ECG voltage in Year-1, and maximum 
creatinine in Year-1 were significantly positively correlated to the MLDL, whereas 
being a Caucasian was significantly negatively correlated.
Table 73: “Small” vessel mean lumen diameter loss multivariate model.
Predictor Coeffecient SD p-value
Constant 0.00445 0.08386 0.958
Caucasians -0.15978 0.06187 0.011
Domino Transplant 0.08406 0.03777 0.029
ECG voltage drop 0.020768 0.008682 0.019
Maximum creatinine in first year 0.0004178 0.0001527 0.008
7.4 Comparison of the factors affecting the “large” and “small” vessels.
We then investigated whether the variables affected the two types of vessels differently, 
by regressing the difference in MLDL between the LV and SV on the 8 variables 
earlier found to be significant. The overall significance for whether the variables were 
non-zero was marginal at p = 0.035. On dropping non-significant terms one by one, we 
ended up with the model shown in table 7.4.
Only the variable “donor male” seemed to significantly affect the LV and SV MLDL 
differently with all other variables seemed to have an equal influence on MLDL of the 
LV and SV. When the donor was male, the MLDL in the LV tended to be relatively 
high (p = 0.01).
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Table 7.4: Multivariate model obtained by the regression analysis of 
the difference between the “large” and “small” vessels mean lumen 
diameter loss on the eight key variables.
Predictor Coeffecient SD p-value
Constant 0.08744 0.02903 0.003
Male Donor 0.09860 0.03748 0.010
7.5 Discussion.
We found out that apart from male donor sex, the factors that caused MLDL in the LV 
were similar to those that caused MLDL in the SV, although they only reached 
statistical significance in only one or the other type of vessels. Male donor sex caused 
significant LV MLDL. Thus, it appears that TxCAD is a homogenous disease affecting 
both the LV and SV to similar extent.
Considering the LV, male donor sex was the strongest predictor for large vessel MLDL 
(p=0.003). In addition, it was the only factor that only affected MLDL in the LV, rather 
than the SV (p=0.01). Our findings are in agreement with that of Costanzo et al30 in 
their multi-institutional study using qualitative angiography and with that of Tuzcu et 
al98 using ICUS. However, Rickenbacher et al296 did not find such a relationship using 
either qualitative angiography or ICUS.
The fact that hearts from patients who sustained intracranial haemorrhage had less LV 
MLDL is perhaps surprising. Although this has not been studied before, one would 
have expected that, this group would do worse, due to the profound physiological
1 0 f i  0Q7  ^ q oderangements ’ such as labile blood pressure, elevated catecholamines , and 
activation of surface molecules in peripheral organs by massive release of macrophages 
and T-cell associated cytokines and adhesion molecules from the injured brain into the
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circulation299. However using qualitative angiography, Luckraz et al300 found that the 2- 
year freedom from TxCAD in brain-dead and non-brain-dead donors is the same.
Although dobutamine stress echocardiography (DSE) early after heart transplantation
OAt
was found to predict development of TxCAD , the role of simple transthoracic 
echocardiography has not been studied before. We found that an initial 
echocardiographic fractional shortening of <36% was a predictor of LV-MLDL. Thus, 
this very early parameter can guide us to intensify our efforts to control risk factors that 
might lead to TxCAD. It is quite conceivable that organ preservation methods 
immediately after harvesting the heart, and which affect the immediate post-transplant 
cardiac function, are implicated in the development of TxCAD. DSE has also been
'lryyfound to predict the progression of TxCAD and the development of cardiovascular 
events301. Further studies are needed to evaluate the role of early left ventricular 
function as a risk factor for subsequent TxCAD.
Using conventional angiography, several investigators285'288 found that there was no 
difference in the incidence of TxCAD between patients on prednisolone compared to 
those not on it. We have now shown that using QCA steroid therapy during the first 
year cause more LV-MLDL. Our findings are in keeping with those of Ratkovec et 
al287. Using qualitative angiography up to 3 years in a study of 102 patients, they found 
that TxCAD was not increased in patients withdrawn from maintenance corticosteroids 
when compared with their corticosteroid-requiring counterparts; in fact, with each 1 gm 
increment in cumulative corticosteroid use, there was a slightly increased risk of 
TxCAD was noted.
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Domino transplant, high ECG voltage drop during Year-1, and high maximum 
creatinine in Year-1 were associated with larger MLDL in the SV, whereas Caucasian 
recipients had smaller SV-MLDL. It is not possible for us to compare our findings with 
those of others as the factors that affect SV disease have not been studied by other 
investigators.
Thus TxCAD is a homogenous disease with factors that affect both LV and SV 
similarly, but to different extent. As regards the LV, our findings were compatible with 
those of previous studies. However the association between left ventricular systolic 
function early after transplantation and the subsequent development of TxCAD has not 
been reported previously.
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In this study, we found that QCA could be reliably used to assess TxCAD and to 
investigate the pattern of MLDL in the LV and SV in the first few years after 
transplant. We then used QCA to investigate the relationship of the MLDL to the 
different potential aetiological factors. In this chapter, I will briefly review our findings.
8.1 Change in vessel diameter and tone with time.
Although there was MLDL in both the LV and SV, the loss was greater in the LV 
rather than the SV. Thus the earliest changes of TxCAD occur predominantly in the 
larger epicardial vessels. We also found that subsequent progression of the disease was 
related to the MLDL in the first year. Vessel tone immediately after transplant was not 
a predictor of development of TxCAD at Year-lor Year-3
8.2 Factors causing “large” vessel mean lumen diameter loss.
An important finding of our study that was not reported or investigated before was that 
a low initial echocardiographic fractional shortening during the first week post- 
transplant and a low minimum fractional shortening during the first year were strongly 
related to MLDL in the LV. Donor male sex and hearts from domino transplants were 
associated with greater MLDL from baseline to Year-1. Donors who died from 
intracranial haemorrhage and donors who were serologically CMV positive, had less 
lumen diameter loss in the first year.
8.3 Factors causing “small” vessel mean lumen diameter loss.
Significant SV-MLDL was related to male donors, increase in mean blood pressure 
from baseline to one month, domino hearts and those who had high maximum 
creatinine level in the first year. Caucasian recipients, hearts from donors who had
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intra-cranial haemorrhage and donors who were serologically CMV positive had less 
MLDL. Minimum summation ECG voltage in the first year was negatively related to 
SV-MLDL from baseline to Year-3.
8.4 Multivariate analysis.
Donor male sex, echocardiographic fractional shortening <36% and prednisolone 
treatment during the first year were significantly positively related to LV-MLDL, 
whereas intracranial haemorrhage was significantly negatively related. The R2 value 
was 22.6%. Domino transplants, maximum drop in ECG voltage in Year-1, and 
maximum creatinine in Year-1 were significantly positively related to SV-MLDL, 
whereas Caucasians recipients were significantly negatively related. The R2 value was 
22.5%.
Apart from donor male sex which caused greater LV-MLDL, the significant variables 
affected both the LV and SV equally.
8.5 Clinical implications and importance of the study.
We discovered that early graft function as assessed by the echocardiographic fractional 
shortening/ ejection fraction was a predictor of MLDL in the coronary arteries of the 
transplanted heart. This suggests that factors that affect the quality of a donor heart 
such as the process of brain death, medical management of the organ donor and the 
techniques used to protect the heart during transport back to the transplant centre may 
influence the subsequent development of coronary arterial disease in the transplanted 
heart. This hypothesis could be tested in randomized studies comparing different types 
of donor management or of myocardial protection. Early graft function could be used as 
a surrogate measure in pilot studies. A promising strategy could now be tested in a
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larger scale randomized study using QCA and ICUS to determine the impact on 
TxCAD.
Closer monitoring and control of cardiovascular risk factors for the development of 
TxCAD will be needed in patients who have factors that have been associated with 
TxCAD. This could include more frequent QCA to follow up progress of the disease, 
and identify cases where further treatment is required.
8.6 Limitations of the study.
Our study has the following limitations. It was observational, and treatments were 
determined by physician preference and were not randomly allocated. Thus, for 
example, it is impossible to determine whether patients treated with corticosteroids up 
to 1 year had a greater MLDL because of this drug treatment or whether another 
unmeasured factor led both to the need for more prolonged corticosteroid therapy and 
to the MLDL. The sample size decreased with time. This was due to the length of 
follow up available when the study was concluded. Thus effectively, our study was 
limited to 3 years, and thus our conclusions relate only to the early phase of TxCAD. 
The number of patients was small in some subgroups, e.g. non-Caucasians, which 
limited our ability to detect some important relationships. The range of values present 
in the study population was sometimes large and represented the clinical practice 
during the study period (e.g. ischaemia time in which the mean±SD was 155±57 
minutes).
The R-square values of the multivariate model indicate that the majority of the variance 
in MLDL has not been explained by these models. The results of such models should
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be viewed as provisional until they have been validated in another group of patients. 
However, such models play an important role in generating hypotheses, which can be 
tested by further research.
8.7 Future directions.
Most transplant centres follow-up heart transplant recipients by conventional 
qualitative angiography. However, further information could be obtained by the routine 
use of QCA; simple modification of the angiographic technique can allow quantitative 
analysis.
ICUS remains the only method that can directly visualize disease in the arterial wall. 
However, its routine use is limited by its cost and highly invasive nature. ICUS will 
remain the “gold standard” for studies of therapeutic intervention in transplant coronary 
disease. However, since ICUS involves concomitant angiography, QCA techniques can 
be used to provide complementary information about the more distal vessels, and the 
two techniques should be used to assess specific therapeutic interventions in 
randomised clinical trials.
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APPENDIX
Table A4.1A: Absolute “large” vesse mean lumen diameter loss from baseline.
Vessel Year n Mean
(mm)
Standard
deviation
Median
Prox
LAD
1 114 0.2956 0.3867 0.245
3 47 0.5147 0.3909 0.450
5 6 0.720 0.559 0.61
Mid
LAD
1 107 0.1950 0.3222 0.150
3 42 0.4586 0.3530 0.460
5 4 0.410 0.291 0.34
Prox
Cx
1 113 0.2253 0.3592 0.170
3 45 0.3822 0.4211 0.380
5 7 0.476 0.377 0.41
Prox
RCA
1 113 0.2624 0.3493 0.240
3 45 0.4149 0.3553 0.380
5 5 0.416 0.577 0.38
Mid
RCA
1 111 0.1779 0.2811 0.200
3 45 0.3409 0.3404 0.370
5 6 0.4817 0.2303 0.475
Table A4.1B: Absolute “small” vessel mean lumen diameter loss from baseline.
Vessel Year n Mean
(mm)
Standard
deviation
Median
Distal
LAD
1 103 0.072 0.24 0.05
3 45 0.20 0.33 0.16
5 6 0.46 0.73 0.14
D1 1 107 0.06 0.22 0.03
3 41 0.10 0.28 0.07
5 4 0.11 0.14 0.11
D2 1 86 0.02 0.28 -0.01
3 35 0.05 0.27 -0.01
5 2 0.11 0.20 0.11
Distal
Cx
1 105 0.09 0.21 0.06
3 43 0.26 0.75 0.14
5 7 0.09 0.29 0.02
OM1 1 106 0.06 0.22 0.03
3 42 0.06 0.22 0.04
5 5 0.05 0.19 0.02
OM2 1 80 0.04 0.15 0.03
3 38 0.05 0.20 0.04
5 4 -0.04 0.18 -0.02
Distal
RCA
1 111 0.23 0.34 0.20
3 45 0.29 0.33 0.32
5 6 0.44 0.27 0.49
RVBr 1 107 0.05 0.18 0.06
3 45 0.12 0.18 0.12
5 5 0.22 0.23 0.27
PDA 1 103 0.07 0.22 0.05
3 40 0.11 0.20 0.12
5 4 0.26 0.08 0.24
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Table A4.2A:Proportional “large” vessel mean lumen diameter loss from baseline
Vessel Year n Mean
(%)
Standard
deviation
Median
Prox
LAD
1 114 6.365 8.672 5.423
3 47 10.74 8.05 9.43
5 6 14.81 9.51 14.32
Mid
LAD
1 107 5.65 10.79 4.86
3 42 13.42 9.60 12.96
5 4 11.80 4.95 10.48
Prox
Cx
1 113 5.396 9.305 4.457
3 45 9.18 9.50 10.04
5 7 14.61 13.20 13.09
Prox
RCA
1 113 5.633 7.697 5.974
3 45 9.28 7.87 8.96
5 5 9.38 14.21 7.47
Mid
RCA
1 111 4.098 7.400 5.063
3 45 8.26 8.59 9.44
5 6 11.57 6.17 10.74
‘oportiona “smal ” vessel mean lumen diameter los
Vessel Year n Mean
(%)
Standard
deviation
Median
Distal
LAD
1 103 2.90 13.99 3.01
3 45 9.07 14.37 9.09
5 6 15.24 20.18 8.89
D1 1 107 1.95 11.82 1.57
3 41 3.97 11.93 4.27
5 4 7.16 8.16 6.84
D2 1 86 -0.73 22.12 -0.38
3 35 2.15 20.60 -0.83
5 2 6.24 12.09 6.24
Distal Cx 1 105 3.093 9.941 3.243
3 43 9.07 22.85 6.45
5 7 0.70 15.95 1.04
OM1 1 106 2.085 9.562 1.993
3 42 1.68 11.97 1.77
5 5 2.31 10.65 1.08
OM2 1 80 1.82 10.59 2.11
3 38 1.38 13.49 2.08
5 4 -4.54 13.49 -2.33
Distal
RCA
1 111 5.915 10.077 6.531
3 45 7.96 8.67 8.90
5 6 12.53 7.74 12.77
RVBr 1 107 2.24 11.23 3.73
3 45 6.34 10.21 7.78
5 5 10.61 14.55 15.88
PDA 1 103 3.09 11.76 3.51
3 40 4.99 11.13 5.72
5 4 12.95 4.53 13.50
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Table A4.3: Absolute mean lumen diameter loss between successive years in the
“large” and “small” vessels.
Year n
Large Vessels Small Vessels
Mean Standard
deviation
p-value Mean Standard
deviation
p-value
0-1 117 0.229 0.267 <0.0001 0.0812 0.1557 <0.0001
1-3 47 0.1385 0.2337 0.0002 0.0532 0.1572 0.025
3-5 6 0.175 0.2335 0.13 0.045 0.1056 0.34
Table A4.4: Difference between “large” and “small” vessel 
mean lumen diameter loss between successive years.
Year n
Mean
(mm)
Standard
Deviation
p value
0-1 117 0.148 0.201 <0.0001
1-3 47 0.0853 0.2048 0.0064
3-5 6 0.13 0.272 0.29
Table A4.5 A: Relationship of change in the “large” vessels 
diameter in the first year to long-term change.
Change from Year- 
0 to Year-1
n Max, Years 3 
and 5
Standard
deviation
p-value
Increase, >5% 3 -2.241 3.534 <0.001
Increase, <5% 9 7.449 4.221
Decrease, <5% 14 8.369 7.406
Decrease, >5% 18 11.572 5.456
Decrease, >10% 19 15.391 4.945
Table A4.5 B: Relationship of change in the “small” vessels 
diameter in the first year to long-term change.
Change from Year- 
0 to Year-1
n Max, Years 3, 
and 5
Standard
deviation
p-value
Increase, >5% 7 -0.614 7.529 <0.001
Increase, <5% 8 -0.988 6.569
Decrease, <5% 20 5.879 6.301
Decrease, >5% 21 9.775 7.495
Decrease, >10% 7 13.592 12.279
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Table A5.1: Correlation between “large” and “small” vessel mean lumen 
diameter loss and donor age.
Period of diameter loss Large Vessels Small Vessels
Correlation: p-value Correlation p-value
Year-0 to 1 -0.161 0.083 -0.129 0.17
Year-0 to 3 0.115 0.44 0.190 0.20
Year-0 to 5 -0.573 0.14 -0.246 0.56
Table A5.2: Correlation between “large” and “small” vessel mean lumen 
diameter loss to recipient age.
Period of 
diameter loss
Large Vessels Small Vessels
Correlation p-value Correlation p-value
Year-0 to 1 0.008 0.93 0.069 0.46
Year-0 to 3 0.180 0.23 0.384 0.008
Year-0 to 5 0.059 0.89 0.553 0.6
Table A5.3: Comparison between the mean lumen diameter loss in “large” and 
“small” vessel groups and recipient sex.
Year Sex n Large Vessels Small Vessels
Mean
decrease
Standard
deviation
p-value Mean
decrease
Standard
deviation
P value
0 to 1 Female 18 0.240 0.222 0.83 0.119 0.123 0.19
Male 99 0.227 0.275 0.074 0.160
0 to 3 Female 7 0.275 0.359 0.26 0.192 0.419 0.83
Male 40 0.449 0.250 0.156 0.153
0 to 5 Female 3 0.530 0.402 0.94 0.485 0.614 0.44
Male 5 0.507 0.255 0.142 0.091
Table A5.4: Comparison of the mean lumen diameter loss from baseline in the 
“large” and “small” vessels for the three aetiological groups.
Year Aetiology
group
n Large Vessels Small Vessels
Mean loss 
(mm)
Standard
deviation
p-value Mean loss 
(mm)
Standard
deviation
p-value
Oto 1 Ischaemic 71 0.2475 0.2917 0.57 0.0868 0.1653 0.88
Idiopathic 28 0.1843 0.2482 0.0759 0.1620
Other 18 0.2233 0.1837 0.0675 0.1040
0 to 3 Ischaemic 31 0.4560 0.2908 0.50 0.2000 0.2203 0.18
Idiopathic 10 0.3793 0.2491 0.1090 0.1777
Other 6 0.3287 0.1912 0.0503 0.1283
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A5.5A: Pattern of systolic blood pressure over the years.
Time Number of 
values, n
Mean
(mmHg)
Standard
deviation
Median
(mmHg)
Pre 116 109.24 17.40 109.0
1 month 120 133.49 17.18 130.0
6 months 120 141.24 20.40 140.0
1 year 119 139.21 15.80 140.0
18 months 113 137.81 14.53 140.0
2 years 100 137.24 17.76 135.5
30 months 79 139.59 16.71 140.0
3 years 66 142.21 17.27 140.0
4 years 31 141.65 16.81 140.0
5 years 10 132.20 10.81 130.0
A5.5B: Pattern of diastolic blood pressure over the years.
Time Number of 
values, n
Mean
(mmHg)
Standard
deviation
Median
(mmHg)
Pre 116 67.83 12.08 70
1 month 120 84.28 11.50 84
6 months 120 90.24 12.52 90
1 year 119 90.210 10.678 90
18 months 113 89.097 9.894 90
2 years 100 89.83 10.62 90
30 months 79 90.46 9.51 90
3 years 66 90.09 12.85 90
4 years 31 90.19 8.64 90
5 years 10 91.40 6.33 90
A5.5C: Pattern of mean blood pressure over the years.
Time Number of 
values, n
Mean
(mmHg)
Standard
deviation
Median
(mmHg)
Pre 116 81.63 12.84 80.00
1 month 120 100.69 12.48 100.00
6 months 120 107.24 14.44 107.00
1 year 119 106.54 11.33 106.67
18 months 113 105.34 10.23 104.00
2 years 100 105.63 12.09 103.67
30 months 79 106.84 10.64 106.67
3 years 66 107.46 11.61 106.67
4 years 31 107.34 10.02 106.67
5 years 10 105.00 7.09 103.33
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A5.5D: Pattern of pulse pressure over the years.
Time Number of 
values, n
Mean
(mmHg)
Standard
deviation
Median
(mmHg)
Pre 116 41.41 12.24 40
1 month 120 49.21 11.75 50
6 months 120 51.00 12.50 50
1 year 119 49.00 11.78 50
18 months 113 48.72 11.83 48
2 years 100 47.41 12.38 48
30 months 79 49.14 13.43 50
3 years 66 52.12 18.34 50
4 years 31 51.45 14.01 50
5 years 10 40.80 8.34 40
Table A5.6: Comparison of patients who are not on statins post-transplant
to those who are on statins.
Variable Group n Mean Standard
deviation
p-value
Diameter loss in mm, 
Year-0 to 1, large vessels
No statins 31 0.220 0.264 0.84
Statins 86 0.232 0.270
Diameter loss in mm, 
Year-0 to 1, small vessels
No statins 31 0.066 0.136 0.49
Statins 86 0.087 0.163
TC at Year-l(mmol/L) No statins 30 5.013 0.928 <0.0001
Statins 85 6.08 1.30
TG at Year-l(mmol/L) No statins 30 1.637 0.892 0.0054
Statins 83 2.25 1.27
LDL at Year-l(mmol/L) No statins 30 3.017 0.831 <0.0001
Statins 73 3.89 1.08
HDL at Year-l(mmol/L) No statins 30 1.258 0.336 0.97
Statins 80 1.255 0.479
Table A5.7: Diameter loss in the “large” and “small” vessels from baseline 
to Year-1, and the correlation with the lipid profiles.
Lipid Fraction Vessels Correlation p-value
Total Cholesterol Large 0.008 0.94
Small -0.001 0.99
Triglycerides Large -0.068 0.48
Small 0.077 0.42
LDL Cholesterol Large 0.042 0.68
Small -0.027 0.79
HDL Cholesterol Large 0.050 0.61
Small -0.022 0.82
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Table A5.8: Underlying disease in the domino donor patients.
Underlying Donor Disease Number of 
Patients
%of
Patients
Cystic fibrosis 20 84
Eisenmenger PDA 2 8
Bronchiectasis 1 4
Primary Pulmonary Hypertension 1 4
Total 24 100
Table A5.9: Causes of donor death grouped into 5 groups.
Cause Number % of total Number of 
women
% women
1= intra-cranial haemorrhage 56 46 30 53
2= head injury 24 20 4 17
A = 3,4, 6,7. 12 10 5 42
B = 5, 8 ,9 5 4 3 6
Domino = XXXX 24 20 5 83
Total 121 100.00 47 39
NB- Cause of death numbers correspond to those mentioned in table 5.6.
Table A5.10: Summary statistics of the total ischaemic time in minutes.
n Mean
In
minutes
Standard
deviation
Minimum
value
Maximum
value
95% conf. int. 
From To
120 155.06 56.59 17 279 144.83 165.29
Table A5.ll: Correlation of the ischaemic time to the ‘large” and “small” vessel 
mean lumen diameter loss from baseline to subsequent years.
Period Large Vessels Small Vessels
Correlation p-value Correlation p-value
Year-0 to Year-1 -0.043 0.65 -0.035 0.70
Year-0 to Year-3 -0.090 0.55 -0.050 0.59
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Table A5.12: Correlation of recipient creatinine level and mean lumen diameter
loss.
Creatinine variable Vessel Type Decrease to Year-1 
or Year-3?
Correlation p-value
Pre-transplant Large 1 0.189 0.13
Pre-transplant Small 1 0.125 0.31
Pre-transplant Large 3 0.087 0.67
Pre-transplant Small 3 0.072 0.73
Max value in Year-1 Large 1 0.001 0.99
Max value in Year-1 Small 1 0.231 0.024
Max value in Year-1 Large 3 -0.053 0.76
Max value in Year-1 Small 3 0.333 0.044
Value at Year-1 Large 1 -0.136 0.19
Value at Year-1 Small 1 -0.057 0.58
Value at Year-1 Large 3 -0.092 0.59
Value at Year-1 Small 3 0.041 0.81
Table A5.13: Correlation of recipient glucose level and mean lumen diameter loss.
Glucose variable Vessel Type Year of Lumen 
Diameter Loss
Correlation p-value
Pre-transplant Large 1 0.105 0.51
Pre-transplant Small 1 0.110 0.49
Pre-transplant Large 3 -0.105 0.71
Pre-transplant Small 3 0.506 0.054
Max value in Year-1 Large 1 0.020 0.85
Max value in Year-1 Small 1 -0.008 0.94
Max value in Year-1 Large 3 -0.056 0.74
Max value in Year-1 Small 3 0.144 0.39
Value at Year-1 Large 1 -0.059 0.59
Value at Year-1 Small 1 -0.110 0.30
Value at Year-1 Large 3 -0.221 0.22
Value at Year-1 Small 3 0.182 0.32
Table A5.14: Correlation of the mean ln(CMV count +1) in the first year to mean 
lumen diameter loss from Year-0 to subsequent years in 
the “large” and “small” vessels.
Period of decrease Large vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 -0.079 0.40 -0.071 0.45
Year-0 to Year-3 -0.007 0.97 -0.099 0.51
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Table A5.15: Comparison of the mean lumen diameter loss in the “large” and 
“small” vessels for patients with zero CMV count throughout the first year and 
patients with at least one non-zero count in the first year.
Year CMV 
count 
greater 
than zero?
n Large Vessels Small Vessels
Mean loss Standard
deviation
p-value Mean loss Standard
deviation
p-value
Oto 1 No 65 0.230 0.246 0.97 0.084 0.149 0.86
Yes 52 0.228 0.294 0.078 0.165
Oto 3 No 26 0.378 0.290 0.20 0.170 0.231 0.76
Yes 21 0.479 0.241 0.151 0.177
Table A5.16: Basic statistics of the cardiac output
Year n Mean Standard
deviation
Median
0 117 4.626 1.166 4.500
1 111 4.960 1.186 4.880
3 38 4.839 1.175 4.755
5 5 5.010 0.858 4.600
Table A5.17: Correlation of cardiac output at baseline to subsequent 
mean lumen diameter loss.
Period of MLDL Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 -0.081 0.39 -0.113 0.23
Year-0 to Year-3 0.123 0.41 -0.113 0.41
Table A5.18: Correlation of increase in cardiac output from baseline to 
Year-1, to subsequent mean lumen diameter loss 
in the “large” and “small” vessels.
Period of diameter 
loss
Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 0.039 0.69 0.078 0.42
Year-0 to Year-3 0.005 0.97 0.218 0.17
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Table A5.19: Basic statistics of angiographic ejection fraction.
Year n Mean Standard
deviation
Median
0 114 71.70 10.73 75.0
1 108 68.03 11.65 70.0
3 . 40 69.28. 10.74 69.0
5 8 69.37 5.93 68.5
Table A5.20: Correlation of angiographic ejection fraction at baseline 
to subsequent mean lumen diameter loss.
Period of diameter 
loss
Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 -0.140 0.14 -0.154 0.11
Year-0 to Year-3 -0.280 0.062 -0.008 0.96
Table A5.21: Correlation between decrease in angiographic ejection fraction from 
baseline to Year-1 and the subsequent mean lumen diameter loss.
Period of decrease Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 -0.064 0.53 0.090 0.37
Year-0 to Year-3 0.084 0.60 -0.030 0.85
Table A5.22: Basic statistics of the mean right atrial pressure over time.
Year n Mean Standard
deviation
Median Minimum
value
Maximum
value
0 117 8.068 3.562 8. 0. 17.
1 113 4.823 2.977 4. 0. 14.
3 38 5.658 3.419 5. 1. 16.
5 4 5.75 2.22 6 3 8
Table A5.23: Basic statistics of the pulmonary artery mean pressure over time.
Year n Mean Standard
deviation
Median Minimum
value
Maximum
value
0 119 22.630 6.055 22. 11. 45.
1 114 17.921 5.241 17. 8. 46.
3 38 18.263 4.791 17. 11. 31.
5 5 19.40 4.39 18 16 27
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Table A5.24: Basic statistics of the mean pulmonary artery wedge
Pressure over time.
Year n Mean Standard
deviation
Median Minimum
value
Maximum
value
0 119 14.218 4.484 14.0 3. 30.
1 114 10.886 4.238 10.0 1. 28.
3 38 11.316 4.114 11.5 3. 20.
5 5 13.00 3.81 12. 9 19
Table A5.25: Basic statistics of the left ventricular end diastolic 
pressure over time.
Year n Mean Standard
deviation
Median Minimum
value
Maximum
value
0 118 12.297 4.854 12.00 2. 28
1 115 9.974 4.518 10.00 2. 25
3 48 12.333 5.774 11.50 4. 33
5 10 13.90 5.28 14.5 6 26
Table A5.26: Decrease in right atrial pressure from baseline to Year-1.
n Mean
decrease
Standard
deviation
Median Minimum
value
Maximum
value
p-value
109 3.257 4.334 3 -12 17 <0.0001
Table A5.27: Decrease in pulmonary artery mean pressure from
baseline to Year-1.
n Mean
decrease
Standard
deviation
Median Minimum
value
Maximum
value
p-value
112 4.75 6.871 5 -22 24 <0.0001
Table A5.28: Decrease in left ventricular end diastolic pressure 
from baseline to Year-1.
n Mean
increase
Standard
deviation
Median Minimum
value
Maximum
value
p-value
112 -2.366 6.214 -3 -17 16 0.0001
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Table A5.29: Correlation of the mean right atrial pressure at baseline 
to subsequent mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 0.051 0.59 0.047 0.62
Year-0 to Year-3 0.092 0.54 0.036 0.81
Table A5.30: Correlation of the decrease in mean right atrial pressure from 
baseline to Year-1, to subsequent mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation P value Correlation p value
Year-0 to Year-1 0.081 0.40 -0.055 0.57
Year-0 to Year-3 -0.025 0.87 -0.001 0.996
Table A5.31: Correlation of the pulmonary artery mean pressure at 
Baseline, to subsequent mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 0.079 0.40 0.029 0.76
Year-0 to Year-3 0.234 0.11 -0.022 0.89
Table A5.32: Correlation of decrease in pulmonary artery mean pressure 
from baseline to Year-1, to subsequent mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 0.102 0.28 -0.014 0.89
Year-0 to Year-3 0.043 0.78 -0.064 0.67
Table A5.33: Correlation of the left ventricular end diastolic pressure at baseline, 
to subsequent mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 -0.135 0.15 -0.114 0.22
Year-0 to Year-3 -0.050 0.74 -0.085 0.57
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Table A5.34: Correlation of the decrease in left ventricular end 
diastolic pressure from baseline to Year-1, to subsequent 
mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation p value Correlation p value
Year-0 to Year-1 0.078 0.42 0.102 0.29
Year-0 to Year-3 0.224 0.14 0.016 0.92
Table A6.1: Relationship between the use of RATG induction therapy 
and mean lumen diameter loss.
Year RATG n Large Vessels Small Vessels
Mean loss 
(mm)
Standard
error
p-value Mean loss 
(mm)
Standard
error
p-value
Oto 1 No 35 0.208 0.045 0.80 0.0532 0.019 0.49
Induction 68 0.244 0.034 0.0869 0.021
Rescue 7 0.208 0.089 0.1101 0.046
0 to 3 No 22 0.468 0.050 0.31 0.206 0.053 0.27
Induction 14 0.476 0.068 0.114 0.038
Rescue 6 0.286 0.168 0.072 0.079
Table A6.2: Acute rejection episodes in those who had and 
did not have RATG therapy.
Period RATG
treatment
n Mean Standard
error
p-value
Baseline to 3 month No 42 1.19 0.16 0.019
Yes 68 0.82 0.14
Baseline to 1 year No 42 1.45 0.19 0.026
Yes 68 1.04 0.17
Table A6.3: Mean lumen diameter loss in those who were and were not on 
prednisolone treatment during the first year.
Year Prednislone? n Large Vessels Small Vessels
Mean
diameter
loss
Standard
deviation
P-
value
Mean
diameter
loss
Standard
deviation
P-
value
0 to 1 No 21 0.141 0.288 0.14 0.042 0.130 0.17
Yes 93 0.245 0.263 0.088 0.161
0 to 3 No 12 0.435 0.214 0.99 0.106 0.108 0.10
Yes 32 0.434 0.265 0.191 0.229
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Table A6.4: Basic statistics of the rejection grades 
and summation ECG voltage.
Rejection grade n Mean Standard
deviation
Median
NR 602 5.3212 1.5694 5.1000
1A 303 5,2650 1.6721 5.1000
IB 53 4.455 1.528 4.100
2 4 3.687 1.149 4.000
3A 62 4.672 1.510 4.250
3B 2 5.875 0.460 5.875
4 1 3.2000 * 3.2000
NR = no rejection.
Table A6.5: Estimated difference in summation ECG voltage 
from no rejection of each grade of rejection.
Rejection grade Mean difference 
from no rejection
Standard error of 
difference
1A -0.014 0.05865
IB -0.349 0.11703
2 -0.230 0.40232
3A -0.522 0.10806
3B -0.529 0.56447
4 -1.364 0.79679
Table A6.6: Total number of mismatches related to “large”and “small” 
vessel mean lumen diameter loss.
Year Total 
number of 
mismatches
n Large Vessels Small Vessels
Mean Standard
deviation
p-value Mean Standard
deviation
p-value
0 to 1 0 1 0.0460 0.0000 0.98 -0.0186 0.0000 0.90
1 2 0.3040 0.3055 0.1258 0.0200
2 8 0.2352 0.2348 0.1120 0.1212
3 25 0.2412 0.2804 0.0592 0.1344
4 31 0.1967 0.2968 0.0798 0.1989
5 30 0.2397 0.2497 0.1057 0.1175
6 18 0.2398 0.2807 0.0682 0.1854
Oto 3 0 0 0.38 0.11
1 2 0.5140 0.1131 0.1169 0.0302
2 3 0.3420 0.2612 0.3574 0.2330
3 10 0.5262 0.2420 0.1558 0.1251
4 12 0.3027 0.2186 0.0797 0.1039
5 12 0.3903 0.3339 0.1107 0.1628
6 7 0.5264 0.2962 0.3099 0.3900
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Table A6.7: Correlation of total number of mismatches to “large”and “small
vessel mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 0.015 0.87 0.019 0.84
Year-0 to Year-3 -0.002 0.99 0.050 0.74
Table A6.8: Number of A mismatches related to “Iarge”and “small” 
vessel mean lumen diameter loss.
Year Number of 
mismatches 
at A locus
n Large Vessels Small Vessels
Mean Standard
deviation
p-value Mean Standard
deviation
p-value
0 to 1 0 14 0.2580 0.2828 0.85 0.0309 0.1417 0.35
1 57 0.2312 0.2795 0.0973 0.1709
2 45 0.2124 0.2525 0.0750 0.1397
Oto 3 0 7 0.4465 0.2746 0.79 0.1676 0.1232 0.81
1 19 0.4444 0.2333 0.1352 0.1713
2 20 0.3874 0.3153 0.1789 0.2635
Table A6.9: Correlation of total number of A mismatches to “large”and “small”
vessel mean lumen diameter loss.
Period of decrease Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 -0.054 0.57 0.037 0.69
Year-0 to Year-3 -0.094 0.53 0.050 0.74
Table A6.10: Number of B mismatches related to “large”and “small” 
vessel mean lumen diameter loss.
Year Number of 
mismatches 
at B locus
n Large Vessels Small Vessels
Mean Standard
deviation
p-value Mean Standard
deviation
p-value
0 to 1 0 8 0.3628 0.2103 0.31 0.1468 0.1130 0.47
1 32 0.2010 0.2457 0.0727 0.1322
2 75 0.2245 0.2821 0.0797 0.1683
0 to 3 0 2 0.5300 0.1358 0.72 0.1744 0.1116 0.94
1 14 0.3795 0.2605 0.1430 0.1795
2 30 0.4315 0.2881 0.1656 0.2290
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Table A 6.ll: Correlation of total number of B mismatches to “large”and “small”
vessel mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 -0.069 0.46 -0.065 0.49
Year-0 to Year-3 0.018 0.91 0.030 0.84
Table A6.12: Number of DR mismatches related to “large”and “small” 
vessel mean lumen diameter loss.
Year Number of 
mismatches 
at DR locus
n Large Vessels Small Vessels
Mean Standard
deviation
p-value Mean Standard
deviation
p-value
Oto 1 0 11 0.1413 0.2915 0.26 0.0540 0.1196 0.81
1 61 0.2091 0.2559 0.0801 0.1504
2 44 0.2737 0.2757 0.0880 0.1736
0 to 3 0 6 0.4170 0.1844 0.74 0.2262 0.1981 0.41
1 25 0.3939 0.2927 0.1218 0.1303
2 15 0.4645 0.2784 0.1945 0.3016
Table A6.13: Correlation of total number of DR mismatches to “large”and 
“small” vessel mean lumen diameter loss.
Period of loss Large Vessels Small Vessels
Correlation P value Correlation P value
Year-0 to Year-1 0.154 0.10 0.054 0.56
Year-0 to Year-3 0.085 0.57 0.021 0.89
Table A6.14: Pre-transplant cross-match related to “Iarge”and “small” 
vessel mean lumen diameter loss.
Year Crossmatch
positive?
n Large Vessels Small Vessels
Mean loss Standard
deviation
p-value Mean loss Standard
deviation
p-value
0 to 1 No 110 0.215 0.025 0.95 0.076 0.156 0.61
Yes 2 0.230 0.19 0.217 0.279
Oto 3 No 44 0.4075 0.2729 0.1535 0.2086 -
Yes 0
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Table A6.15: Pre-transplant PRA correlated to “large”and “small”
vessel mean lumen diameter loss.
Year Pre-transplant 
PRA positive?
n Large Vessels Small Vessels
Mean
loss
Standard
deviation
p-value Mean
loss
Standard
deviation
p-value
Oto 1 No 114 0.225 0.265 0.56 0.077 0.152 0.37
Yes 3 0.377 0.382 0.247 0.252
Oto 3 No 47 0.4234 0.2713 0.1615 0.207
Yes 0
Table A6.16: Basic statistics of the antivimentin antibodies data.
Month/
Year
n Mean Standard
deviation
Median Minimum
value
Maximum
value
Quartiles 
1st 3rd
PreTx 121 113.09 94.41 86.00 49.00 648. 56.50 130.00
1 month 10 63.00 21.08 50.00 50.00 112 50.00 77.7
3months 25 95.6 59.4 68.0 50.0 237 50.0 117.5
6months 23 85.6 58.2 59.0 50.0 289 50.0 92.0
1 year 51 95.31 66.21 68.00 50.00 300 50.00 106.0
3 years 66 135.7 147.5 92.0 50.0 890 50.0 154.0
5 years 23 104.0 68.3 95.0 50.0 353 52.0 127.0
Table A7.1: “Large” vessel mean lumen diameter loss provisional model.
Predictor Coeffecient SD p-value
Constant 0.0120 0.1789 0.947
Donor Sex 0.11786 0.06654 0.080
Caucasians -0.0875 0.1158 0.452
Intracranial Haemorrhage -0.11392 0.06521 0.084
Initial FS (>36 or <36%) 0.11900 0.06067 0.053
Domino Transplant -0.00746 0.08316 0.929
ECG voltage (drop) 0.00559 0.01764 0.752
Prednisolone in first year 0.12438 0.07165 0.086
Maximum creatinine in first year -0.0001118 0.0002729 0.683
Table A7.2: “Small” vessel mean lumen diameter loss provisional model.
Predictor Coeffecient SD p-value
Constant -0.0065 0.1039 0.951
Donor Sex 0.02989 0.03864 0.441
Caucasians -0.03298 0.03787 0.386
Intracranial Haemorrhage 0.01681 0.03523 0.634
Initial FS (>36 or <36%) 0.02299 0.04161 0.582
Domino Transplant -0.16155 0.06727 0.019
ECG voltage (drop) 0.05208 0.04829 0.284
Prednisolone in first year 0.01534 0.01024 0.138
Maximum creatinine in first year 0.0003711 0.0001585 0.022
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PRESENTATION IN INTERNATIONAL MEETINGS
The following abstracts of material from this thesis were presented in the following 
international meetings:
1. RATG induction does not attenuate cardiac allograft vasculopathy. IA Bolad, D 
Robinson, NR Banner. International Conference of Immunosuppression annual 
scientific meeting, California, USA. December 2001. Selected for the Young 
Investigators Excellence Award presentation.
2. Left ventricular systolic function early after heart transplantation predicts 
cardiac allograft vasculopathy. IA Bolad, D Robinson, NR Banner. American 
College of Cardiology 51st annual scientific meeting in Atlanta, USA. March 
2002.
3. Loss of coronary lumen diameter early after Heart Transplantation is greatest in 
the larger epicardial vessels. IA Bolad, D Robinson, NR Banner. International 
Society of Heart and Lung Transplantation annual scientific meeting. 
Washington DC, USA. April 2002.
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